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Pulmonary arterial hypertension (PAH) is a rare but fatal lung disease with a high 
mortality. Pathologically, PAH is characterised by progressive pulmonary vascular 
remodelling and it is well known that pulmonary arterial smooth muscle cell (PA-
SMC) proliferation and migration is a key driver of this remodelling. Recently, the 
secreted glycoprotein, osteoprotegerin (OPG) has been implicated as an important 
pathogenic mediator in PAH. OPG is elevated within the serum and pulmonary 
vascular lesions from patients with PAH and OPG induces PA-SMC proliferation and 
migration in vitro. Furthermore, genetic deletion or antibody blockade of OPG can 
prevent and reverse established disease in pre-clinical animal models of PAH. 
However, it remains unclear how OPG signals to induce PA-SMC proliferation. 
Therefore, the work undertaken in this thesis aimed to characterise the OPG signalling 
cascade in PA-SMCs and identify the receptor through which this is mediated. 
 
OPG was found to induce significant expression of CDK5, phospho-CDK4, phospho-
ERK1/2, phospho-HSP27 and significantly altered expression of phospho-mTOR in 
PA-SMCs. OPG significantly altered the expression of 57 PAH-associated genes in 
PA-SMCs. Investigations into identifying an OPG binding partner revealed four novel 
interactions between OPG and Fas, IL1RAcP, GAP43 and TMPRSS11D. The 
interaction between OPG and Fas was confirmed in PA-SMCs. Fas expression was 
elevated in PA-SMCs, the pulmonary artery and right ventricle from idiopathic PAH 
patients. Fas blockade significantly inhibited OPG-induced gene expression in PA-
SMCs and significantly inhibited OPG-induced PA-SMC proliferation by 34%, which 
was further reduced by simultaneous TRAIL blockade. 
 
These data begin to reveal the receptor and novel intracellular signalling mechanisms 
through which OPG induces PA-SMC proliferation. As well as further highlighting 
OPG as a potential therapeutic target in PAH, these data also suggest a more diverse 




1.1 The Normal Pulmonary Circulation and Right Ventricle 
The pulmonary circulation delivers deoxygenated blood from the body to the lungs, 
via the heart, where it is replenished with oxygen (Boron 2005). From the right atria, 
blood is pumped into the right ventricle, where it is then pumped out through the 
pulmonary artery (PA), which branches and divides to form smaller pulmonary 
arterioles and capillaries within the lungs. The pulmonary vascular bed branches 
throughout the lungs to enable gaseous exchange to occur between each of the 
millions of alveoli and the capillaries surrounding them (Boron 2005).  
 
As such, the pulmonary vasculature is a high flow, low-pressure system with a low 
resistance to blood flow to allow gaseous exchange (Naeije 2013). Under normal 
physiological conditions, the pulmonary artery exhibits a mean pulmonary arterial 
pressure (mPAP) of ~7-19 mmHg (Naeije & Westerhof 2011). The right ventricle is a 
crescent-shaped, thin-walled structure that pumps this low-pressure system. The right 
ventricle is naturally adaptive to the demands of exercise by producing an elevation in 
mPAP of up to 40 mmHg (Pokreisz et al. 2007). However, because of its thin-walled 
structure, the right ventricle cannot acutely generate an mPAP of >40 mmHg.  
 
1.2 Pulmonary Hypertension 
The accumulation of vascular changes, sustained pulmonary vascular vasoconstriction 
and progressive pulmonary vascular remodelling leads to a persistent and prolonged 
elevation in mPAP. This once low pressure, low resistance network of vessels 
becomes a fatally diseased system where a devastating lung disease, known as 
pulmonary hypertension, manifests. Pulmonary hypertension (PH) is a progressive 
lung disease that is diagnosed at right heart catheterisation as an mPAP of >25 mmHg 
at rest. Pre-capillary PH, pulmonary arterial hypertension, is diagnosed by a 
pulmonary arterial wedge pressure (PAWP) of <15 mmHg and post-capillary PH is 
diagnosed by a PAWP of >15 mmHg (Hoeper, Bogaard, et al. 2013). PH was first 
described over a century ago and since then, major developments in our understanding 
of the disease have led to a better characterisation and diagnosis of the disease. 
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1.2.1 Historical Classification of Pulmonary Hypertension 
In 1865, the German physician, Klob, reported on the case of a 59-year-old man who 
suffered cyanosis, oedema and dyspnoea prior to his death and post-mortem revealed 
pulmonary arterial narrowing and arteriosclerosis (van Wolferen et al. 2007). Later in 
1891, another German physician, Ernst Von Romberg, described a 24-year-old patient 
with abnormalities in the pulmonary artery and right ventricular hypertrophy. 
Pulmonary hypertension was later coined “Ayerza’s disease” following several reports 
made by Arrillaga, a physician who was first alerted to the condition by his professor, 
Ayerza (van Wolferen et al. 2007).  
 
Heath and Whitaker later described the clinical and histologic features of PH after 
discussing six case studies of patients admitted to the cardiovascular unit in Sheffield 
(United Kingdom). All cases presented with cyanosis and classical symptoms of PH. 
Autopsy revealed enlargement of the heart, right ventricular hypertrophy and atrial 
dilation (Heath & Whitaker 1956). Histologic analysis also revealed muscularisation 
of previously non-muscular pulmonary arteries (<100 µm diameter) and larger 
pulmonary arteries (100-1000 µm diameter), with medial necrosis and luminal 
occlusion. Patients also presented with adventitial fibrosis and pulmonary arterial 
dilation (Heath & Whitaker 1956). This work described, for the first time, the specific 
pulmonary arterial remodelling that occurs in PH patients. 
 
The first attempt at classifying pulmonary hypertension was made by Brenner (1957), 
where pulmonary hypertension patients were divided into 5 groups: 1) chronic 
bronchitis and emphysema, 2) left to right heart shunt, 3) primary pulmonary 
hypertension, 4) primary pulmonary arteriosclerosis and 5) pulmonary embolism 
(Brenner 1957). However, in 1973, the World Health Organisation (WHO) held the 
first conference on pulmonary hypertension to review the scientific information, 
discuss the pathogenesis and clinical presentation of primary pulmonary hypertension 
(Hatano et al. 1975). This meeting resulted in a classification based on aetiology 
consisting of two groups: secondary PH, which was described as PH of known cause, 
such as pulmonary hypertension due to pulmonary thromboembolism, pulmonary 
veno-occlusive disease, or left-to-right shunt (Group 2) and primary PH, which was 
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described as PH of unknown cause and cases were only assigned to this category once 
all possible known causes had been excluded (Group 1) (Hatano et al. 1975).  
 
However, at the second WHO symposium held in Evian, a clinical classification was 
introduced. This resulted in five groups being established: 1) Pulmonary arterial 
hypertension (PAH) (including primary pulmonary hypertension), 2) pulmonary 
vascular hypertension, 3) PH associated with disorders of the respiratory system or 
hypoxia, 4) PH caused by thrombotic or embolic disease and 5) PH caused by disease 
affecting the pulmonary vasculature (Simonneau et al. 2004). The “Evian 
classification” abandoned the term “secondary pulmonary hypertension” because it 
was deemed confusing. The term “primary pulmonary hypertension” was later 
discontinued at the third WHO symposium in 2003 and instead, PAH was split into 
the subgroups IPAH, familial PAH (FPAH) and PAH related to risk factors or 
associated conditions (Simonneau et al. 2004).  
 
In 2008, the decision was made at the fourth WHO symposium, held at Dana Point, to 
include genetic causes of PH, pulmonary veno-occlusive disease and/or pulmonary 
capillary hemangiomatosis (Group 1’), chronic thromboembolic pulmonary 
hypertension (Group 4) and PH with unclear multifactorial mechanisms (Group 5) 
(Simonneau et al. 2009). Finally, in 2013, the fifth most recent WHO symposium was 
held in Nice, France and the classification was further updated still. The most recent 
classification of PH established at the symposium in Nice symposium is shown in 





Figure 1.1- Updated Clinical Classification of Pulmonary Hypertension, Nice, 
France  2013 (Fifth WHO symposium). 
BMPR2 = bone morphogenetic protein receptor type II, Alk-1 = activin receptor-like 
kinase 1, ENG = endoglin, SMAD9 = mothers against decapentaplegic homolog 9, 
CAV1 = caveolin 1, KCNK3 = potassium channel, subfamily K, member 3. 
Modifications to Dana Point classification (2008) are shown in bold (Simonneau et al. 
2013)1. 
                                                 
1 Reprinted from Journal of the American College of Cardiology, Vol 62, Gerald Simonneau, 
Michael A. Gatzoulis, Ian Adatia, David Celermajer, Chris Denton, MD, Ardeschir Ghofrani, 
Miguel Angel Gomez Sanchez, R. Krishna Kumar, Michael Landzberg, Roberto F. Machado, 
Horst Olschewski, Ivan M. Robbins, Rogiero Souza, Updated Clinical Classification of 




The updated classification of PH consists of five groups, 1) pulmonary arterial 
hypertension, 2) pulmonary hypertension due to left heart disease, 3) pulmonary 
hypertension due to lung disease and/or hypoxia, 4) chronic thromboembolic 
pulmonary hypertension (CTEPH) and 5) pulmonary hypertension with unclear 
multifactorial mechanisms (Figure 1.1). Pre-capillary PH includes Group 1, Group 3, 
Group 4 and Group 5 of the updated clinical classification of PH and post-capillary 
PH consists of only Group 2. However, the work described throughout this thesis 
focuses on PAH, in particular, idiopathic PAH.  
 
1.3 Pulmonary Arterial Hypertension 
PAH, or Group 1, is defined as pre-capillary PH and is diagnosed as an mPAP of >25 
mmHg and a pulmonary capillary wedge pressure of <15 mmHg (Hoeper, Bogaard, et 
al. 2013). PAH can be further divided into four subgroups (Figure 1.1, Group 1). The 
first subgroup, IPAH, refers to those patients who present with sporadic disease, with 
no known aetiology, no family history of the disease and no identified risk factor 
(Simonneau et al. 2013). The second group describes heritable PAH. In these families 
where there are multiple cases of PAH, 80% present with mutations in the 
transforming growth factor-beta (TGF-β) super family member, bone morphogenetic 
protein receptor 2 (BMPR2) mutations and 5% present with mutations in the other 
TGF-β superfamily members activin receptor-like kinase 1 (ALK-1, ACVRL1), 
endoglin (ENG) and Mothers Against Decapentaplegic Homolog 9 (SMAD9) (Figure 
1.1, Group 1.2). Mutations in caveolin-1 (CAV1) and potassium channel, subfamily K, 
member 3 (KCNK3) have also been identified and all of these mutations are discussed 
in further detail in Chapter 1.4.7. However, in 20% of families presenting with PAH, 
the mutation is currently unknown (Simonneau et al. 2013). Group 1.3 describes PAH 
that is induced by drug and toxins, such as the anorexigen aminorex (Kay et al. 1971). 
Finally, Group 1.4 describes PAH associated with other disorders, including 
connective tissue disease (Group 1.4.1), HIV infection (Group 1.4.2), portal 
hypertension (Group 1.4.3), congenital heart disease (Group 1.4.4) and 
schistosomiasis (Group 1.4.5). 
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PAH currently effects 3482 patients in the UK and 44.9% of patients diagnosed with 
PH have PAH. Collectively, IPAH, HPAH and anorexigen-assocaited PAH have an 
incidence rate of 1.1 cases per million in the United Kingdom (McGoon et al. 2013). 
PAH is more common in women than men, with a ratio of 1.8:1. Those affected have 
a median age of 62 years in the UK (http://www.hscic.gov.uk/catalogue/PUB13318, 
Health and Social Care Information Centre, 2013). Of these cases, 34.6% have 
idiopathic PAH, 32.1% congenital heart disease, 25.7% connective tissue disease, 
3.9% portal hypertension, 1.4% familial PAH, 0.8% HIV and 0.4% drug-induced 
PAH (http://www.hscic.gov.uk/catalogue/PUB13318, Health and Social Care 
Information Centre, 2013). Patients with PAH have a one-year survival rate of 88% 
and a three-year survival rate of 68% (http://www.hscic.gov.uk/catalogue/PUB13318, 
Health and Social Care Information Centre, 2013). 
 
1.3.1 Clinical Presentation and Diagnosis 
Symptoms of PAH typically present when the mPAP reaches 30-40 mmHg (Eddahibi 
et al., 2002). In a study of 187 patients with pulmonary arterial hypertension, the most 
common symptom reported was breathlessness (60%) with the second most common 
symptom being fatigue (19%). Patients also reported chest pain, fainting, oedema and 
palpitations (Rich et al. 1987). However, during this study, the time between the onset 
of the first symptom and diagnosis was reported to be 2.03 years ± 4.9 years and 
although 90% patients were diagnosed within 3 years, some patients reported 
symptom onset 20 years before diagnosis (Rich et al. 1987).  
 
Diagnosis can made by non-invasive methods such as chest x-ray, electrocardiogram, 
vasodilator challenge and 6-minute walk test, however these methods often require 
confirmation by right heart catheterization (Elliot & Kiely 2006; Kiely et al. 2013). 
Both electrocardiogram and x-ray can appear normal in PAH patients, hence PAH 
may be overlooked or misdiagnosed. Unfortunately, due to the extent of vascular 
remodelling that has already developed during the asymptomatic stage of disease and 
the obstacles that sometimes arise during diagnosis, median survival without therapy 
is 2.8 years (Elliot and Kiely, 2006), with right heart failure being the major cause of 
mortality (Pokreisz et al., 2007). Because symptoms often present late, it is imperative 
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that diagnosis is made early to ensure patients can be treated as soon as possible to 
prolong patient life as much as possible. 
1.3.2 PAH and the Right Heart 
As discussed in Chapter 1.1, the pulmonary vascular system is low in pressure, and 
the right ventricle can naturally adapt to acute elevations in pressure (Pokreisz et al., 
2007). During prolonged periods of elevated pressure, the right ventricle employs 
compensatory mechanisms to tolerate chronic hypertension. Cardiomyocytes undergo 
hypertrophy to reduce cardiac wall stress and maintain cardiac output. However, 
without improved pressure or afterload, there is a decline in blood flow to the right 
myocardium. Ischemia and apoptosis of right ventricle cardiomyocytes results in right 
ventricular dilation, stiffening and impaired stroke volume, poor ventricular filling, 
reduced cardiac function, inadequate organ perfusion and eventual right heart failure 
(RHF) in PAH patients (Davies & Morrell 2008; Pokreisz et al. 2007). 
 
1.4 The Pathogenesis of Pulmonary Arterial Hypertension 
The pathogenesis of PAH is an incredibly complex process that affects all layers, 
intima, media and adventitia, of the pulmonary arteries (Humbert et al. 2004). PAH 
typically affects the smaller, more distally located arterioles of the pulmonary 
circulation (Rabinovitch 2008). Endothelial cell (EC) apoptosis, EC and smooth 
muscle cell (SMC) proliferation, sustained pulmonary arterial vasoconstriction, 
inflammation and the immune system all play an important role in PAH and 
contribute to loss of lumen diameter and increased pulmonary pressure. Although the 
initial stimulus preceding the sustained pulmonary vasoconstriction and cell 
proliferation is currently unknown, there is a hypothesis that injury to the endothelium 
causes EC apoptosis, which is believed to be the early initial insult (Budhiraja et al. 
2004; Voelkel et al. 2012). Proliferation of apoptosis-resistance ECs, and then PA-
SMCs is then thought to follow EC injury and apoptosis (Voelkel et al. 2012). 
Dysfunctional endothelial cells are also thought to underlie the imbalance between 
vasodilators and vasoconstrictors that leads to pulmonary vasoconstriction in PAH 
(Rabinovitch 2008). Muscularisation of previously non-muscular pulmonary arterioles 
is thought to occur through the proliferation and migration of pulmonary arterial 
smooth muscle cells (PA-SMCs). Although it is currently unclear whether 
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inflammation is causal or a consequence of disease pathogenesis, it is probable that 
the inflammation that occurs in PAH may be a result of inflammation that has not 
been resolved following pulmonary vascular injury (Voelkel et al. 2012). 
 
Although the initial cause of remodelling and abnormal cell growth remains unknown, 
the identification of mutations in the TGF-β superfamily member, BMPR2, identified 
the cause of some cases of heritable PAH (Thomson et al. 2000; Atkinson et al. 2002). 
However, the literature suggests that only 20% of BMPR2 mutation carriers will 
actually develop disease (Newman et al. 2004).. This that there is a need for “multiple 
hits” in the development of PAH, such as genetic mutations in other genes, for 
example the serotonin receptor (HTR2B), in addition to BMPR2 mutations (Yuan & 
Rubin 2005). 
 
1.4.1 Endothelial Cell Apoptosis 
As discussed above in Chapter 1.4, endothelial cell apoptosis is thought be the initial 
early insult in PAH. Endothelial cell apoptosis is thought to occur as a result of 
endothelium injury caused by a number of factors including shear stress from 
increased pulmonary blood flow, infection, such as HIV, hypoxia, genetic 
susceptibility, such as BMPR2 mutations and epigenetic factors such as microRNAs 
(Budhiraja et al. 2004; Voelkel et al. 2012).  
 
In 1974, Meyrick et al reported on the case of a 41 year-old male with pulmonary 
hypertension who displayed a reduction in the number and size of vessels and slightly 
reduced filling at the apices of the lung (Meyrick et al. 1974). However, there has 
been controversy as to whether the apparent loss of vessels was actually caused by 
inadequate perfusion of distally located vessels due to the luminal narrowing and 
increased vasoconstriction, rather than an actual loss of vessels (Michelakis et al. 
2008). However, there is now evidence that loss of distal vessels occurs in PAH and 
the underlying cause of this loss is likely to be endothelial cell apoptosis (Zhao et al. 
2005). Recent evidence suggesting that loss of functional BMPR2 signalling actually 
induces EC apoptosis further supports the idea that EC apoptosis may indeed 
contribute to the pathogenesis of PAH (Teichert-Kuliszewska 2006). In animal 
models, pulmonary EC apoptosis is observed prior to and accompanying disease 
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development, in addition to EC proliferation (Taraseviciene-Stewart et al. 2001). This 
further supports the idea that EC apoptosis is an early event in the pathogenesis of 
PAH and underpins the loss of distally located pulmonary arterioles. 
1.4.2 Endothelial Cell Proliferation 
Endothelial cell proliferation has been hypothesised to occur either as a result of 
endothelium injury or following endothelial cell apoptosis (Tuder & Graham 2010; 
Voelkel et al. 2012; Humbert et al. 2008). The mechanisms that lead to EC 
proliferation are currently unclear, however, endothelium injury may be a stimulus for 
EC proliferation (Humbert et al. 2008). EC proliferation may also occur after EC 
apoptosis causes a population of apoptosis-resistant ECs to emerge, which then 
proliferate, perhaps to compensate for the preceding EC death, and form plexiform 
lesions (Tuder & Graham 2010; Voelkel et al. 2012). It is thought that the 
proliferation of the endothelial cells and matrix deposition, which contributes to the 
formation of concentric and constrictive lesions within the intimal layer cause the 
greatest reduction in pulmonary artery lumen size (Stenmark & Frid 2011). 
  
The proliferation of dysfunctional apoptosis-resistant ECs causes the formation of 
plexiform lesions, the hallmark of end-stage disease that occludes the lumen and 
narrows the pulmonary artery (Tuder & Graham 2010). Plexiform lesions are colonies 
of proliferating ECs lined by SMCs, myofibroblasts and connective tissue matrix that 
frequently form where the pulmonary artery branches (Pietra et al. 2004). The 
vigorous EC growth that contributes to lesion formation was first reported by Tuder et 
al (1994) after proliferating cells stained positive for the EC markers factor VIII and 
vimentin and exhibited low immunoreactivity for SMC specific markers. It was later 
identified that the ECs within plexiform lesions were monoclonal (Lee et al. 1998). 
Although plexiform lesions are described in PAH, the contribution of these plexiform 
lesions to the increase in pulmonary vascular resistance observed in PAH still remains 
unclear (Tuder & Graham 2010). In fact, there has been some reports of the plexiform 
lesion being a marker for endothelial cell abnormality, rather than being 
haemodynamically relevant (Humbert et al. 2008), however other literature contests 
the claim that plexiform lesions do not contribute to haemodynamic changes (Tuder & 
Graham 2010). However, it is clear from the literature that the exact cause of EC 
dysfunction and subsequent plexiform lesion formation is still ambiguous. 
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1.4.3 Pulmonary Vasoconstriction 
The initial stimulus preceding pulmonary vasoconstriction is unknown, however 
endothelium injury is also thought to alter the effect ECs have on vascular 
homeostasis, as well as causing EC apoptosis and proliferation (Budhiraja et al. 2004; 
Humbert et al. 2008). Endothelium injury is though to cause EC dysfunction and 
subsequently affect the release of vasoactive compounds (Humbert et al. 2008). An 
imbalance of vasoactive mediator release from dysfunctional ECs leads to sustained 
pulmonary vasoconstriction and subsequent reduction in lumen diameter that 
contributes to the increase in pulmonary vascular resistance in PAH (Schermuly et al. 
2011). PAH patients show reduced levels of the vasodilators prostaglandin I2, nitric 
oxide and cyclic guanosine monophosphate (cGMP) and increased levels of the 
vasoconstrictors thromboxane A2, angiotensin II, endothlin-1 and serotonin, which 
cause excessive vasoconstriction (Schermuly et al. 2011). Furthermore, these 
vasoactive mediators also contribute to PA-SMC proliferation, a key pathogenic 
process in PAH, which is discussed in further detail below (Hassoun et al. 1992; Giaid 
et al. 1993; Lee et al. 1994; Hervé et al. 1995; Christman et al. 1992; Giaid & Saleh 
1995; Farber & Loscalzo 2007). 
 
1.4.3.1 Endothelin 1 
Plasma levels of Endothelin-1 (ET-1), a vasoconstrictor produced in ECs are 
increased in patients with PAH (Farber and Loscalzo, 2004, McLaughlin and 
McGoon, 2006). Furthermore, ET-1 protein and mRNA was detected in the 
endothelial cells of pulmonary arteries displaying medial thickening (Giaid et al. 
1993). ET-1 induces PA-SMC contraction by binding to ETA and ETB receptors 
present on PA-SMCs. ETB receptors present on ECs potentiate vasoconstriction by 
inducing the release of thromboxane, another vasoconstrictive compound 
(McLaughlin and McGoon, 2006, Rabinovitch, 2008). ET-1 also acts as a mitogen for 
PA-SMCs and ET-1 induces PA-SMC proliferation via ETA and ETB receptors 
(Hassoun et al. 1992; Davie et al. 2002). Interestingly, Davie et al (2002) also showed 
ET-1 binding sites of a higher number in the distal PAs of primary pulmonary 
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hypertension (PPH) patients compared to control subjects. This could help to explain 
why smaller, distally located arterioles are affected more frequently in PAH.  
 
1.4.3.2 Serotonin 
Serotonin is a vasoconstrictor shown to induce PA-SMC hyperplasia and hypertrophy 
(Lee et al. 1994; Rabinovitch 2008). The involvement of serotonin in PAH 
pathogenesis was proposed in the 1960s after a correlation between increased risk of 
PAH and individuals taking the anorexigen, Aminorex, was observed (Eddahibi et al., 
2002, MacLean, 2007a). Increased plasma levels of serotonin have been reported in 
PAH patients and PAH has been associated with the depletion in serotonin platelet 
content and subsequent increased plasma levels due to reduced uptake of serotonin 
from plasma (Hervé et al. 1995). PA-ECs synthesize serotonin from tryptophan 
through the catalytic actions of tryptophan hydroxylase 1 (tph1), which is 
subsequently secreted from PA-ECs to act on different serotonin receptors (MacLean, 
2007a). TPH1 expression is also increased within the lungs and PA-ECs of idiopathic 
PAH patients (Eddahibi et al. 2006).  
 
1.4.4 Pulmonary Arterial Smooth Muscle Cell Proliferation 
In the normal pulmonary vasculature, PA-SMCs are usually contractile and show low 
levels of proliferation, even though there are growth factors present in the vasculature 
that could potentially exert a mitogenic effect on PA-SMCs. Instead, medial vascular 
smooth muscle cells are embedded within the extracellular matrix consisting of 
proteins, produced by the vascular SMCs, that inhibit SMC proliferation, such as 
collagen I, collagen IV and heparin sulphate (Fritze et al. 1985; Koyama et al. 1996). 
However, in PAH, an increase in mitogenic factors and reduction in these anti-
proliferative factors cause PA-SMCs to acquire a dysfunctional, hyper-proliferative 
phenotype. 
 
The hallmark of all classes of pulmonary hypertension is the increase in pulmonary 
artery wall thickness and all three layers of the pulmonary artery, intima, media and 
adventitia show an increase in thickness (Chazova et al. 1995). Just like many of the 
pathogenic processes in PAH, the underlying cause of PA-SMC proliferation is 
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currently unknown and may be due to an inherent property of PA-SMCs, or may be 
caused by preceding EC dysfunction (Humbert et al. 2008). EC injury may cause the 
leakage of vascular elastase that degrades the vascular matrix to allow proliferative 
mediators to permeate the vascular wall and initiate the growth of smooth muscle cells 
within the medial layer (Budhiraja et al. 2004). The proliferation of smooth muscle 
cells and myofibroblasts cause an increase in medial thickness and the proliferation 
and accumulation of fibroblasts, myofibrobalsts and increased matrix deposition 
underlies adventitial thickening (Stenmark & Frid 2011). 
 
Abnormal proliferation and migration of α-smooth muscle actin positive cells, 
referred to as PA-SMCs from here on, underpin the characteristic pulmonary arterial 
remodelling observed in PAH (Davies and Morrell, 2008, Eddahibi et al., 2002). PA-
SMC hyperplasia and hypertrophy result in the medial muscularisation of distal 
pulmonary arteries (Davies and Morrell, 2008, Eddahibi et al., 2002, Rabinovitch, 
2008). The tunica media was originally believed to be a homogenous population of 
cells, however this view has changed dramatically due to evidence that cells of the 
media actually belong to a heterogeneous population. Different subpopulations of PA-
SMCs are found throughout the pulmonary vasculature and at different sites along the 
vasculature. Frid et al (1994) have shown that the tunic media consists of different cell 
populations, with non-muscular cells located in the sub-endothelial layer of the inner 
media, SMCs within the middle media and both SMCs and non-muscular cells in the 
outer media (Frid et al. 1994). Furthermore, the different populations of cells within 
the media display distinct markers when stimulated with serum: the middle media 
SMCs expressed both the proliferation marker Ki-67 and smooth muscle-myosin, 
however serum stimulation of the outer media SMCs resulted in a reduction in smooth 
muscle-myosin (Frid et al. 1997). This may provide an important clue as to why only 
certain populations of cells, for example cells located in the smaller pulmonary 
arteries, undergo pathogenic changes in disease (Frid et al. 1997). 
 
A number of different factors that are dysfunctional or dysregulated in PAH can 
induce the proliferation of PA-SMCs. Growth factors, such as PDGF, which has been 
shown to be increased in IPAH patients, induce that proliferation of PA-SMCs (Yu et 
al. 2003; Perros et al. 2008). Additionally, the BMP ligands BMP2, BMP4 and BMP7 
that usually bind BMPR2 to inhibit SMC proliferation, no longer inhibit PA-SMC 
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proliferation when BMPR2 is mutated in FPAH and IPAH patients (Atkinson et al. 
2002; Tajsic & Morrell 2011). Instead, this loss of signalling causes the proliferation 
of PA-SMCs. An imbalance between vasoactive compounds, which also act as 
mitogens and inhibitors of PA-SMC proliferation, also contribute to the excessive PA-
SMC proliferation. Endothelin-1, serotonin (5-hydroxytryptamine, 5-HT), 
angiotensin-II and thromboxane A2 are all potent vasoconstrictors that are 
upregulated in PAH and induce the proliferation of PA-SMCs (Hassoun et al. 1992; 
Giaid et al. 1993; Lee et al. 1994; Hervé et al. 1995; Christman et al. 1992).  
 
Coupled with the increase in mitogenic factors, there is also a reduction in the 
vasodilators nitric oxide (NO) and prostacyclin, which usually inhibit PA-SMC 
proliferation (Giaid & Saleh 1995; Farber & Loscalzo 2007). In addition to the growth 
factors and vasoactive compounds, and of direct relevance to this thesis and discussed 
in further detail later, OPG and TRAIL have recently been shown to play an important 
role in PAH pathogenesis and the proliferation and migration of PA-SMCs (Secchiero 
et al. 2003; Hameed et al. 2012; Lawrie et al. 2008; Condliffe et al. 2012). The role of 
these mitogens and dysfunctional signalling pathways in PAH pathogenesis will be 
discussed in more detail below, as their effects are not limited to a single action on a 
single cell type, but rather they exert complex and intertwining effects on a variety of 
cell types in disease. 
 
1.4.5 Fibroblast Activation and Proliferation 
The adventitial layer is thought to be an injury-sensing layer, which contains 
fibroblasts that respond to injury. These fibroblasts are activated by a variety of 
stresses, including inflammatory and environmental stresses, such as hypoxia. Upon 
activation, the fibroblasts acquire a proliferative phenotype, begin to express the 
contractile protein α-smooth muscle actin and extracellular matrix proteins. The 
fibroblasts also increase secretion of chemokines and cytokines, growth factors and 
angiogenic factors (Stenmark et al. 2012). Activated fibroblasts, which have acquired 
this hyper-proliferative phenotype, are observed in the pulmonary artery adventitia of 
PAH patients and animal models of PH (El Kasmi et al. 2014). Fibroblasts derived 
from the hypoxic calf model of PH exhibited a pro-inflammatory phenotype and were 
also found to induce the migration, adhesion and activation of monocytes, a process 
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found to be mediated by paracrine IL-6 signalling (M. Li et al. 2011; El Kasmi et al. 
2014). Interestingly, fibroblasts derived from the hypoxic calf were found to have an 
active form of protein kinase C zeta (PKC-zeta), which instead of repressing 
replication and reducing DNA synthesis as in normal adventitial fibroblasts, actually 
caused an increase in fibroblast proliferation (Das et al. 2008). This suggests that the 
increase in fibroblast proliferation may be due to an activated form of PKC-zeta 
present in the remodelled vascular wall that induces proliferation instead of inhibiting 
DNA synthesis.  
 
1.4.6 Inflammation 
Inflammation is now widely acknowledged as playing an important role in the 
pathogenesis of PAH. Whether inflammation is causal or a consequence of disease is 
currently debated, however, it is probable that PH occurs when inflammation of 
pulmonary vascular injury is not resolved (Voelkel et al. 2012). Inflammation may 
also be caused by the release of chemokines from dysfunctional ECs that cause 
inflammatory cell recruitment. For example, IPAH PA-ECs markedly enhanced 
monocyte migration, a response that was abolished by CC chemokine ligand 2 
inhibition (Sanchez et al. 2007; Humbert et al. 2008;) There have been a number of 
cytokines and chemokines implicated in PAH pathogenesis. Serum levels of the 
inflammatory cytokines, interleukin-1 (IL-1) and interleukin-6 (IL-6) are increased in 
patients with IPAH (Humbert et al. 1995). IL-6 induces the migration of PA-SMCs in 
vitro and IL-6 levels are increased in the chronic hypoxic and monocrotaline (MCT) 
rat model of PAH (Savale et al. 2009; Bhargava et al. 1999). Furthermore, IL-6 has 
also been shown to promote the development and progression of the pathogenic 
pulmonary vascular remodelling in mice overexpressing IL-6 (Steiner et al. 2009). 
Inhibition of IL-6 attenuated disease development in the MCT rat and IL-6 knockout 
also prevented disease development in the chronic hypoxic mouse model of PAH 
(Savale et al. 2009; Bhargava et al. 1999).  
 
IL-1 serum levels are also elevated in IPAH patients and work published by Voelkel 
et al (1994) showed that the naturally occurring IL-1 receptor antagonist IL-1ra 
(anakinra) protected against disease development in the MCT rat model, but did not 
protect against disease development in the chronic hypoxic model. Authors proposed 
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that this was due to the fact that IL-1α stimulates the vasodilator, nitric oxide (NO); 
therefore IL-1ra caused an inhibition in NO production in the chronic hypoxic mouse 
model. Hence, disease was maintained due to the reduction in NO production 
(Voelkel et al. 1994). In the Paigen-fed ApoE-/- mouse model of PAH, animals exhibit 
increased IL-1β and IL-6 levels, however, ApoE-/-IL-1R1-/- mice deficient in the IL1 
receptor surprisingly develop a more severe phenotype and further increased IL-1β 
and IL-6 levels (Lawrie et al. 2011). Consequently, an alternatively spliced, lung 
specific IL-1R1 transcript was identified that actively signals IL-1 in the lung, but is 
still inhibited by IL-1ra (Lawrie et al. 2011). Alongside the IL-1 and IL-6 
inflammatory cytokines, monocyte chemotactic protein 1 (MCP1) and fractalkine 
have also been implicated as potential mediators in PAH pathogenesis (Sanchez et al. 
2007; Perros, Dorfmüller, Souza, Durand-Gasselin, Godot, et al. 2007) and 
inflammatory cells, including T-cells, B-cells and macrophages have been identified 
in plexiform lesions of PAH patients (Tuder et al. 1994a). 
 
Alongside pulmonary vascular remodelling, there is an infiltration of inflammatory 
cells and the formation of lymphoid tissue within the pulmonary artery. Perivascular 
infiltrates occur in pulmonary vascular lesions and comprise of T-lymphocytes, B-
lymphocytes, macrophages, dendritic cells and mast cells (Rabinovitch et al. 2014). 
Studies have also shown that the inflammatory pathology is more advanced in the 
presence of BMPR2 mutations (Rabinovitch et al. 2014). Regulatory T cells have been 
implicated in PAH, with abnormal numbers and function CD4 positive T cells being 
observed in conditions associated with PAH, for example HIV and systemic sclerosis 
(Speich et al. 1991; Radstake et al. 2009). Furthermore, in T cell deficient athymic 
nude rats, Sugen5416 treatment resulted in macrophage, mast cell and B cell 
infiltration in the lung due to vascular injury and endothelial cell apoptosis, which 
immune-restricted rats were protected from (Tamosiuniene et al. 2011). 
 
Macrophages are also found to infiltrate the pulmonary arteries and macrophages have 
been identified as constituents of obliterative plexiform lesions in both PAH patients 
and animal models of PH (Tuder et al. 1994b; Savai et al. 2012; Frid et al. 2006; 
Vergadi et al. 2011). Alongside macrophage recruitment, macrophages were found to 
secrete leukotriene B4 (LTB4), which induced PA-EC injury and apoptosis, along with 
PA-SMC proliferation and hypertrophy in athymic nude rats. Interestingly, blockade 
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of macrophage-derived LTB4 reversed experimental PH (Tian et al. 2013), implicating 
macrophages and the macrophage-derived leukotriene LTB4 in the pathogenesis of 
PAH. 
 
Natural killer cells, which usually have a beneficial effect on PH, can also acquire a 
pathogenic phenotype and in doing so, increase their matrix metalloprotease (MMP) 
production and reduce the amount of interferon-γ production (Rabinovitch et al. 
2014). PAH patients also show an increase in the number of functionally deficient, 
CD56-/CD16+ natural killer cell subset (Ormiston et al. 2012). Dendritic cells have 
also been found to accumulate in the remodelled pulmonary arteries of both patients 
and animal models of PH (Perros, Dorfmüller, Souza, Durand-Gasselin, Mussot, et al. 
2007) and aggregates of ectopic lymphoid tissue have been observed in the pulmonary 
vasculature of IPAH lungs, some of which were structurally similar to lymph nodes 
(Carragher et al. 2008). Studies now suggest, at least in animal models, that 
inflammation precedes vascular remodelling, indicating that inflammation may be 
causal, rather than consequential, in disease development (Rabinovitch et al. 2014; 
Tamosiuniene et al. 2011).  
 
1.4.7 Genetics of Pulmonary Arterial Hypertension 
In 2004, the decision was made at the fourth WHO symposium held at Dana Point, to 
include genetic causes of PH after the identification of genetic causes in a number of 
cases of PAH (Simonneau et al. 2009). Mutations in a number of genes, including a 
number of genes belonging to the TGF-β superfamily, have been identified in patients 
with both FPAH and IPAH. 
 
1.4.7.1 Bone Morphogenetic Protein Receptor 2 Mutations  
As mentioned previously, BMPR2 mutations which lead to dysfunctional BMP 
signalling, can induce the proliferation of PA-SMCs and induce EC apoptosis (Tajsic 
& Morrell 2011; Teichert-Kuliszewska 2006). In non-diseased cells, BMPR2 has been 
shown to protect ECs from apoptosis and conversely induce PA-SMC apoptosis 
(Majka et al. 2011; Teichert-Kuliszewska 2006; Zhang et al. 2003). Mutations in 
BMPR2 have been identified in familial PAH (Lane et al. 2000; Deng et al. 2000) and 
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IPAH (Thomson et al. 2000) and these mutations were predicted to effect ligand 
binding, kinase activity and dimer formation (Lane et al. 2000). Mutations in BMPR2 
underpin heritable forms of PAH and reduced expression is associated with 
dysfunctional SMAD1/5/8 signalling and PA-SMC proliferation (Nishihara et al. 
2002; Rudarakanchana et al. 2002). Additionally, in IPAH PA-SMCs, BMP ligands 
did not inhibit PA-SMC proliferation, and instead of inducing apoptosis, TGFβ 
actually stimulated PA-SMC proliferation (Morrell et al. 2001). Mouse EC studies 
also revealed that a reduction in BMPR2 cell surface expression may further increase 
p38 MAPK phosphorylation and thus activate proliferative pathways which may also 
contribute to PA-SMC proliferation (Eddahibi et al. 2002). This disruption in BMPR2 
signalling caused by the BMPR2 mutations is now believed to underlie the 
dysfunctional EC apoptosis and exuberant PA-SMC proliferation observed in PAH. 
 
Over 300 mutations in the BMPR2 gene have now been identified and BMPR2 
mutations have been identified in 75% of FPAH and 25% of IPAH patients (Soubrier 
et al. 2013). However, as the literature suggests, only 20% of BMPR2 mutation 
carriers will actually develop disease, and these statistics suggest that “multiple hits” 
may be required for the onset of PAH pathogenesis (Newman et al. 2004). These 
“hits” may include mutations and polymorphisms in modifier genes or exposure to 
environmental influences such as HIV infection that trigger disease development in 
these patients (Geraci et al. 2010). 
 
1.4.7.2 Activin Receptor-Like Kinase 1 and Endoglin Mutations 
Interestingly, mutations in the TGF-β receptor superfamily type 1 receptor, ACVRL1 
(also known as ALK-1, activin receptor-like kinase 1) and type III receptor, Endoglin 
(ENG), have been identified in hereditary haemorrhagic telangiectasia (HHT)-
associated PAH (Harrison et al. 2003; McAllister et al. 1994). Mutations in ACVRL1 
and ENG were identified in patients with HHT, an autosomal dominant condition in 
which vascular dysplasia gives rise to symptoms including recurrent epistaxis 
(bleeding from the nose), gastro-intestinal haemorrhage and arteriovenous 
malformations in the pulmonary, cerebral and hepatic vessels (Johnson et al. 1996). 
ACVRL1 mutations have been mapped to a second locus linked to HHT type 2 
(Johnson et al. 1996). Harrison et al (2003) then identified mutations in ACVRL1 in 
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patients with HHT that also presented with symptoms of PAH. There is now evidence 
that the mutations in ACVRL1 are also present in FPAH and IPAH patients that do not 
show any symptoms of HHT (Fujiwara et al. 2008). 
 
Mutations in ENG, which is expressed in ECs, were also found to underlie HHT 
(McAllister et al., 1994) and were identified in patients with HHT presenting with 
PAH symptoms (Harrison et al., 2003). More recent work has identified mutations in 
ACVRL1 and ENG in Chinese patients with HHT-associated pulmonary hypertension 
(Eyries et al. 2012; Chen et al. 2013).  
 
1.4.7.3 SMAD9 
Mutations in the TGF-β signal transducer, SMAD9 have also been identified in PAH 
patients. The SMAD9 gene encodes the protein SMAD8 which forms a complex with 
SMADmad4 after being phosphorylated, along with SMAD1 and SMAD5, by the 
activated type 1 BMP receptor (Majka et al. 2011). Shintani et al (2009) identified a 
mutation in SMAD9 in an IPAH patient that did not have mutations in BMPR2 or 
ACVRL1. This mutation was also identified in the father of this patient (Shintani et al. 
2009). Variants in SMAD1, SMAD4 and SMAD9 have also been identified in a 
cohort of 324 PAH cases (Nasim et al. 2011). 
 
1.4.7.4 Caveolin-1 
In addition to the mutations in the TGF-β superfamily, mutations in the CAV1 gene 
have also been identified in a family of PAH patients (Austin et al. 2012). CAV1 
encodes the protein caveolin-1, an important component of plasma membrane 
invaginations called caveolae. Caveolae are abundant in cell surface receptors, which 
are critical for cellular signalling cascades, including the TGF-β signalling cascade 
(Soubrier et al. 2013). Austin et al (2012) used whole genome sequencing to identify a 
mutation in a family with multiple sufferers of PAH but who lacked mutations in 
other PAH-associated genes, such as BMPR2. The CAV1 mutation was identified in 
both the family members who had PAH, and those who did not have PAH. Hence, the 
CAV1 mutation also has variable penetrance like the other PAH-associated genes 




KCNK3 (TASK-1) is a mammalian potassium channel whose subunits consist of four 
transmembrane domains and two pore domains (Reyes et al. 1998). Mutations in 
KCNK3 were recently identified by whole exome sequencing in members of the same 
family who were diagnosed with PAH (Ma et al. 2013). Whole-cell patch-clamp 
studies also revealed that the mutations were all loss-of-function mutations (Ma et al. 
2013). Potassium channels open to allow potassium to enter the cell, causing 
membrane hyperpolarisation. This hyperpolarisation then causes voltage-gated 
calcium channels to close, reducing the intracellular calcium and hence cause 
vasodilation (Olschewski et al. 2006). Conversely, the inhibition of potassium 
channels leads to membrane depolarisation, calcium entry, cell contraction and 
vasodilation (Olschewski et al. 2006). Knocking down KCNK3 caused PA-SMC 
depolarisation and hypoxia has also been reported to inhibit KCNK3 function 
(Olschewski et al. 2006). It is therefore speculated that these loss-of-function 
mutations contribute to membrane depolarisation and cause subsequent smooth 
muscle cell contraction and pulmonary vasoconstriction.   
 
1.4.7.6 Serotonin Transporter 
The serotonin transporter allows the reuptake of serotonin into cells. SERT is encoded 
by a single gene located on chromosome 17q11.2 (MacLean 2007). The L-allelic 
variant of the SERT gene promoter present in 65% of IPAH patients potentiates SERT 
activity (MacLean 2007; McLaughlin & McGoon 2006). Activation of SERT is 
hypothesized to contribute to PAH pathogenesis by increasing serotonin reuptake in 
PA-SMCs, thus inducing PA-SMC proliferation through the induction of cyclin and c-
Fos, production of calcium binding proteins, MAPK and ERK1/2 phosphorylation 
(Rabinovitch, 2008).  Overexpression of SERT in mice has been reported to worsen 
hypoxia induced PAH (Rabinovitch, 2008). Mutations in BMPR2 are suspected to 
increase SERT activity, exasperating the effects of both mutated BMPR2 and SERT on 
PASMC proliferation. However, the involvement of SERT in pathogenesis remains 
ambiguous, with other research groups suggesting this variant is not a sufficient risk 




1.5 TRAIL in Pulmonary Arterial Hypertension 
TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) belongs to the 
tumour necrosis factor (TNF) receptor family and induces apoptosis of tumour cell 
lines, both in vivo and in vitro, through activation of death receptors at the cell surface 
(Spierings et al., 2004). TRAIL acts on 4 receptors: TRAIL R1 (Death receptor (DR) 
4), TRAIL R2 (DR5), TRAIL R3 (decoy receptor (DCR) 1) and TRAIL R4 (DCR2), 
and also binds a fifth decoy receptor, osteoprotegerin (OPG) (Spierings et al., 2004; 
Vitovski et al., 2007). TRAIL R1 and TRAIL R2 each contain a death receptor in their 
cytoplasmic domain, thus induce tumour cell apoptosis, a process not observed in 
normal cells (Spierings et al., 2004; Vitovski et al., 2007). TRAIL R3 and R4 are 
termed “decoy receptors”. R3 lacks a complete death domain and R4 possesses only a 
partial death receptor in the cytoplasmic domain, hence both fail to induce apoptosis 
(Spierings 2004; Vitovski et al. 2007). However, TRAIL has also been found to 
induce the proliferation and migration of both rat and human vascular SMCs 
(VSMCs) through TRAIL R1 and R3 interaction and subsequent ERK1/2 
phosphorylation rather than inducing cell apoptosis as expected (Secchiero et al., 
2004) and plays an important role in PAH (Hameed et al. 2012; Dawson et al. 2014). 
 
TRAIL RNA expression is elevated in IPAH PA-SMCs and TRAIL has been shown 
to induce the proliferation and migration of PA-SMCs in vitro, an effect mediated 
through the TRAIL R1 and TRAIL R3 receptors, which are also elevated in IPAH 
PA-SMCs, and ERK1/2 phosphorylation (Hameed et al. 2012). TRAIL expression 
was found to correlate with disease development in the MCT rat model of PAH, with 
an increase in TRAIL expression in the pulmonary arterioles, epithelial and 
endothelial cells observed in animals with disease (Hameed et al. 2012). Interestingly, 
TRAIL expression in the pulmonary vascular tissue is responsible for driving disease 
pathogenesis (Hameed et al. 2012).  
 
Blockade of TRAIL by either antibody blockade or genetic deletion prevents and 
reverses disease in animal models of PAH. Administration of an anti-TRAIL antibody 
from the start of disease induction prevented MCT injected developing disease and 
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even reversed established disease in the Paigen diet-fed ApoE-/- mouse model 
(Hameed et al. 2012). Disease reversal in the Paigen diet-fed ApoE-/- mouse was 
accompanied by an increase in apoptosis and a reduction in proliferating cells, medial 
thickness and vessel muscularisation (Hameed et al. 2012). Genetic deletion of 
TRAIL was also found to prevent disease development in the chronic hypoxia and 
sugen-hypoxia model and the paigen-diet fed ApoE-/- mouse model of PAH (Hameed 
et al. 2012; Dawson et al. 2014). This therefore makes TRAIL an attractive target for 
future PAH therapies.  
 
1.6 Current Treatments for PAH 
There is currently no curative treatment for PAH apart from lung transplantation 
(McLaughlin and McGoon, 2006). However, transplants are very limited and so this is 
not a feasible option for many patients. In the most recent National Audit of 
Pulmonary Hypertension, less than 1% of all PAH patients underwent transplantation. 
Left untreated, the median life expectancy for IPAH patients was 2.8 years, however 
in some patients, we now see a median life expectancy of up to and over 5 years 
(D’Alonzo et al. 1991; Hurdman et al. 2012).  
 
Treatments for PAH include anti-coagulants and calcium channel blockers, as well as 
diuretics and long-term oxygen therapy, all treatments that are used for heart failure. 
Specific therapies approved for PAH target the underlying vasoconstriction and can 
offer successful relief from symptoms. Specific PAH treatments target the three main 
vasoactive pathways that are important in the pathogenesis of PAH and induce 
vasodilation. Endothelin receptor antagonists, such as Bosentan and Macitentan, dual 
endothelin (ET) receptor antagonists that block both the ETA and ETB receptors, and 
Ambrisentan, a selective ETA receptor antagonist, all block the effects of endothelin 
and induce vasodilation (Galiè et al. 2013). Prostanoids, such as Baraprost, 
Epoprostanol, Iloprost and Trepostinil are active analogues of the vasodilator, 
prostacyclin, and hence induce vasodilation. Selexipeg is a selective prostacyclin IP-
receptor agonist and induces vasodilation through binding the prostacyclin IP receptor 
(Galiè et al. 2013). Riociguat stimulates nitric oxide-soluble guanylate cyclase and 
enhances cGMP production to promote vasodilation. Sildenafil, Tadalafil and 
vardenafil are all phosphodiesterase-5 (PDE-5) inhibitors that prevent cGMP 
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degradation via PDE-5 and hence induce vasodilation of pulmonary arterioles (Galiè 
et al. 2013). 
 
It is clear from the literature that research is now aimed at increasing our 
understanding of the pathogensis of PAH in order to identify novel therapeutic targets. 
As mentioned briefly in Chapter 1.4.4, and of direct relevance to this thesis, 
osteoprotgerin has recently been identified as an important mediator in PAH 
pathogenesis. Osteoprotegerin will now be discussed in detail. 
 
1.7 Osteoprotegerin 
OPG, meaning “to protect bone”, was first unknowingly described as the 
osteoclastogenesis inhibitory factor (OCIF), originally purified from human fibroblast 
conditioned media (Tsuda et al. 1997). OCIF was known to be a cytokine that 
inhibited bone reabsorption (Tsuda et al., 1997). Within the same year, Simonet et al 
(1997) identified OPG as an important regulator of bone density after transgenic mice 
overexpressing OPG developed osteopetrosis, an increase in bone density, and a 
decrease in the bone resorbing cells, osteoclasts. Analysis of a foetal rat intestinal 
library revealed a 401 amino acid-long, secreted cytokine with an N-terminus 
analogous to TNF receptor superfamily members (Simonet et al. 1997). We now 
know OPG to be a heparin-binding secreted glycoprotein belonging to the TNF 
receptor superfamily that exists as a 55-62 kDa monomer or a 110-120 kDa 
disulphide-linked homodimer (Simonet et al. 1997; Zauli et al. 2009). 
 
OPG is a 401 amino acid-long protein that contains a 21 amino-acid long signal 
peptide that is cleaved to generate the mature, 380 amino-acid long form (Zauli et al. 
2009). OPG consists of seven structural domains. Domains 1-4 are cysteine rich 
domains that share structural similarities with the TNF receptor extracellular domains 
(Yamaguchi et al. 1998). Domains 1-4 were found to be sufficient to abolish 
osteoclastogenesis, a process that OPG is involved in and this will be discussed below. 
Domains 5 and 6 contain death domains, which share similarities with the Fas and 
TRAIL death receptors and domain 7 consists of 50 amino acids and the cys-400 
residue that is essential for disulphide bond formation and the dimerisation of OPG 
(Yamaguchi et al. 1998). Domain 7 may also play an important role in regulating the 
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release and activity of OPG (Zauli et al. 2009). The structure of full length OPG is 
shown in Figure 1.2. To enhance the activity of OPG, an OPG-Fc protein has also 
been synthesised, in which the cysteine-rich domains are fused to the Fc domain of 
human IgG1 and the signal peptide, death domains and heparin binding domains have 
been removed (Zauli et al. 2009). The structure of the OPG-Fc protein is also shown 




Figure 1.2- The structure of full length OPG and the synthesised OPG-Fc protein.  
OPG consists of four cysteine-rich domains (domains 1-4), two death domain 
homologous regions (domains 5 and 6) and a heparin-binding domain (domain 7), 
containing at cysteine residue at amino acid position 400, which is required for 
dimerization. The synthesised OPG-Fc protein however consists only of the four 
cyctein-rich domains and is fused to the Fc domain of human IgG12.  
 
                                                 
2 Springer and Cellular and Molecular Life Sciences, 66, 2009, 841-851, Role of full-length 
osteoprotegerin in tumor cell biology, Zauli. G, Melloni. E, Capitani. S and Secchiero. P, 
Figure 1, original copyright notice is given to Cellular and Molecular Life Sciences, with kind 
permission from Springer Science and Business Media. 
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OPG is expressed in a variety of tissues, including the human heart, kidney, placenta 
and lung (Simonet et al. 1997). A variety of cells express and secrete OPG, including 
bone marrow stromal cells and cells belonging to the osteoblastic cell lineage, B cells, 
megakaryocytes, platelets, vascular endothelial cells and smooth muscle cells, 
including PA-SMCs (Zauli et al. 2009; Li et al. 2007; Collin-Osdoby et al. 2001; 
Condliffe et al. 2012; Olesen et al. 2005). OPG was first identified, and is probably 
best known, for its role in bone biology as a soluble decoy receptor for RANKL 
(receptor activator of nuclear factor-kappa B ligand). OPG has also been shown to be 
a decoy receptor for TRAIL and since its discovery in 1997, OPG has been implicated 
in a variety of processes and diseases, including vascular calcification, angiogenesis, 
atherosclerosis and hypertension.  
 
1.7.1 The OPG/RANKL/RANK Axis in Bone Biology 
As discussed briefly above, OPG was first identified as an inhibitor of 
osteoclastogenesis and an important regulator of bone reabsorption. Yasuda et al 
(1998) identified RANKL as a ligand for OPG and reported that RANKL also played 
an important role in bone biology, with RANKL-induced osteoclast-like cell 
formation being inhibited by OPG (Yasuda et al. 1998). We now know that the 
interactions between OPG, RANKL and RANK (receptor activator of nuclear factor-
kappa B), the receptor of RANKL, to be very important in the regulation of bone 
density.  
 
The OPG/RANKL/RANK axis is important in bone remodelling with OPG playing a 
central role in regulating osteoclast production and function (Vitovski et al., 2007). 
Bone is continuously renewed through the removal of bone at trabeculae by 
osteoclasts; multinucleated bone reabsorbing cells, and is then laid down by bone 
forming cells, termed osteoblasts (Boyce & Xing 2007; Hofbauer & Schoppet 2004). 
Osteoclasts form from the cytoplasmic fusion of myeloid haematopoietic precursors 
(Boyce and Xing, 2007). Osteoclastogenesis requires binding of RANKL, a type 2 
homotrimeric transmembrane protein expressed on mature osteoblasts, to its receptor, 
RANK, a type 1 homotrimeric transmembrane protein expressed on osteoclast 
precursor cells (Boyce & Xing 2007; Hofbauer & Schoppet 2004; Vitovski et al. 
2007). Upon formation, this receptor ligand complex induces osteoclast formation, 
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activation and survival to prevent precursor differentiation into macrophages (Boyce 
and Xing, 2007; Hofbauer and Schoppet, 2004; Vitovski et al., 2007) by activating 
NF-kB through recruitment of adaptor protein, TRAF6 (Boyce and Xing, 2007). NF-
kB then translocates to the nucleus to induce c-Fos expression, which subsequently 
results in osteoclastogenic gene transcription. OPG, secreted from osteoblasts, acts as 
a decoy receptor for RANKL, preventing the RANKL/RANK interaction, osteoclast 
activation and subsequent bone reabsorption (Hofbauer and Schoppet, 2004, Vitovski 
et al., 2007).  
 
Post-natal OPG is critical for the maintenance of bone density and disrupted OPG 
expression in vivo results in the development of bone disorders (Bucay et al. 1998). 
OPG knockout mice exhibit osteoporosis, a reduction in bone density due to excessive 
bone reabsorption (Bucay et al., 1998). Conversely, elevated OPG levels or inactive 
RANKL result in osteopetrosis, elevated bone density due to reduced bone 
reabsorption (Simonet et al. 1997; Vitovski et al. 2007). In order to protect against 
excessive bone reabsorption, OPG mRNA is upregulated during bone formation 
(Tanaka et al. 2011). Mutations in OPG have also been associated with idiopathic 
hyperphosphatasia, an autosomal recessive bone disease that results in long bone 
deformation (Whyte et al. 2002). Although OPG was first identified and studied for its 
role in bone biology as a decoy receptor for RANKL, OPG interaction with TRAIL 
and the ability of OPG to block TRAIL-induced apoptosis of cancer cell lines has 
been known and studied for over a decade.  
 
1.7.2 OPG in Tumour Cell Biology 
Emery et al (1998) discovered that OPG acts as a decoy receptor for TRAIL. 
Immunoprecipitation revealed OPG to be a binding partner for membrane-bound or 
secreted TRAIL (Emery et al., 1998). OPG and TRAIL interaction was confirmed in 
vitro after OPG was reported to inhibit TRAIL-induced apoptosis of Jurkat cells and 
TRAIL repressed OPG inhibition of osteoclastogenesis (Emery et al., 1998). A role 
for OPG in tumour cell biology was identified by the ability of OPG to inhibit 
TRAIL-induced apoptosis of cancer cells (Cross et al., 2006). OPG has been reported 
to prevent TRAIL-induced apoptosis of ovarian cancer cell lines, in an αvβ3 integrin 
and αvβ5 integrin-dependant manner (Lane et al. 2012; Lane et al. 2013). OPG has 
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also been reported to prevent TRAIL-induced apoptosis of human microvascular 
endothelial cells (HMVECs), a process also requiring αvβ3 (Pritzker et al. 2004). 
Taken together, these findings support a role for OPG in the survival of cancer cells, a 
process that appears to be mediated through the αvβ3 and αvβ5 integrin. 
 
Along with cancer cell survival, OPG has also been implicated in angiogenesis, the 
formation of new blood vessels, which is required for the development and 
progression of tumours (Cross et al. 2006). OPG expression was identified in the 
endothelium of malignant colorectal, breast and metastatic cancer tumours, but not in 
the endothelium of benign tumours or normal tissue. OPG induces human dermal 
microvascular cells (HuDMECs) to form cord-like capillary structures (Cross et al. 
2006). Furthermore, OPG was also found to induce vessel-formation in vivo via 
heparin binding, which suggests a role for the heparin-binding domain in OPG 
signalling (McGonigle et al. 2008). More recently, work undertaken by Benslimane-
Ahmim and colleagues has shown that OPG induces the migration and differentiation 
of endothelial colony-forming cells into cord-like structures, promotes fibroblast 
growth factor-2 (FGF2)-induced neoangiogenesis in vivo and increases endothelial 
colony-forming cell adhesion to fibronectin in vitro (Benslimane-Ahmim et al. 2011).  
 
1.7.3 OPG and Calcification 
The development of calcified arteries alongside osteoporosis in OPG-/- mice first 
revealed a role for OPG in vascular biology and accumulating evidence supports a 
protective role for OPG against calcification (Bucay et al., 1998). Administration of 
recombinant OPG or restoring OPG expression reverses experimental calcification 
and VSMC calcification is reduced with OPG treatment in vitro (Schoppet et al., 
2011). High concentrations of calcium, previously shown to induce VSMC 
calcification, were found to induce OPG mRNA expression in healthy VSMCs 
(Schoppet et al., 2011). Active NF-kB induced OPG mRNA expression through αvβ3 
integrin in ECs, with OPG protecting against apoptosis of cells hosting inactive NF-
kB (Malyankar et al. 2000). However, the transcriptional regulators controlling OPG 
expression remain unknown (Zhang et al. 2002).   
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Extracellular calcific stimuli induce the release of nanoparticles containing OPG 
protein from viable and apoptotic VSMCs (Schoppet et al., 2011). A study conducted 
recently reported that OPG reduced VSMC calcification in rat VSMCs. These data 
suggest an inhibitory role of OPG against calcification (Zhou et al. 2013). However, 
concentrations of OPG equivalent to those in coronary artery disease (CAD) and 
chronic kidney disease (CKD) patient serum appear to have no experimental effect 
against calcification (Schoppet et al., 2011). Olesen et al (2012) reported that OPG 
had no effect on VSMC calcification, however this may be due to the variation 
between the different donors used for this study (Olesen et al. 2012).  Evidently, the 
role of OPG against calcification in disease still remains elusive.  
 
1.7.4 OPG and Vascular Cell Proliferation 
Interestingly, there is now accumulating evidence showing the ability of OPG to 
induce the proliferation of vascular endothelial cells. OPG increases HuDMEC and 
HUVEC proliferation and both cell types were found to secrete OPG (Cross et al., 
2006). Authors state that both HuDMECs and HUVECs were insensitive to TRAIL, 
suggesting that the OPG-induced EC proliferation may be through TRAIL-
independent signalling mechanisms (Cross et al., 2006). However, there have been 
reports in the literature that show TRAIL can alter HUVEC and HuDMEC phenotype 
(Pritzker et al. 2004; Secchiero et al. 2004). Evidently, due to the contradictions in the 
literature, it cannot be concluded whether OPG-induced EC proliferation is due to a 
TRAIL-independent signalling mechanism. OPG was also reported to induce human 
microvascular endothelial cell proliferation and migration through αvβ3 and αvβ5 
integrins (Kobayashi-Sakamoto et al. 2008) and induce the survival of serum-deprived 
aortic SMCs (Bennett et al. 2006). 
 
1.7.5 OPG in Cardiovascular Disease 
OPG has been implicated as a potential mediator in cardiovascular disease and a 
patient study conducted by Stepien et al (2011) revealed elevated OPG in 
hypertensive patients compared to control patients. Elevated OPG levels have also 
been observed within pericardium of malignant and non-malignant pericardial 
effusion compared to pericardial fluid from coronary artery disease patients 
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(Karatolios et al. 2012). Ziegler et al (2005) reported a positive correlation between 
the severity of peripheral artery disease (PAD) and plasma values of OPG; however, 
this study does not determine whether OPG is causative of disease. 
 (Ziegler et al. 2005; Stępień et al. 2011) 
OPG and RANKL expression have been observed within the failing myocardium and 
OPG, RANKL and RANK are all upregulated in experimental and clinical heart 
failure. Elevated levels of OPG, RANKL and RANK mRNA within ischemic areas of 
the left ventricle and increased systemic OPG expression in patients with severe aortic 
stenosis also support the involvement of OPG, alongside RANKL and RANK, in heart 
failure (Ueland et al. 2012). Furthermore, OPG plasma levels are also a predictor of 
asymptomatic coronary artery disease in type-2 diabetic patients and OPG plasma 
levels are also significantly higher in patients with systemic hypertension, decreased 
kidney function and type-1 diabetic patients with nephropathy and signs of 
cardiovascular disease (Avignon et al. 2005; Rasmussen et al. 2006). 
 
OPG has also been implicated as playing an important atheroprotective role. OPG is 
considered to be a negative regulator of atherosclerotic lesion development after 
studies revealed that the absence of OPG causes an increase in lesion area and 
calcification in the innominate artery of older (40 week and 60 week old) OPG-/-
ApoE-/- mice (Bennett et al. 2006). Furthermore, bone marrow transplantation data 
published recently by the same group has implicated both vessel wall-derived and 
bone marrow-derived OPG as being sufficient to reduce lesion size and calcification 
in the innominate artery of mice (Callegari et al. 2013).  
 
However, there are conflicting reports regarding the role of OPG in atherosclerosis. 
High-fat diet fed LDLR-/- mice show a reduction in calcification after treatment with 
the recombinant OPG-Fc protein; however, this has no effect on atherosclerotic lesion 
size (Morony et al. 2008). This may be due to a calcification-induced inflammatory 
response already activated in the vessels, one that OPG can no longer modulate. OPG 
has been identified as a potential marker of atherosclerosis in patients with 
atherosclerosis, as plasma levels of OPG increase with increasing severity of 
atherosclerosis (Hosbond et al. 2012; Jinkwon Kim et al. 2013). LDLR-/- mice have 
increased OPG levels upon disease onset, which did not increase with disease 
progression, suggesting that OPG may be a marker disease onset (Morony et al. 
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2008), however, this may not be the case in atherosclerosis patients. It is clear from 
the literature that the role of OPG in atherosclerosis still requires investigation. 
 
1.7.6 Osteoprotegerin in Pulmonary Arterial Hypertension 
Data published by Lawrie et al (2008) implicates OPG as a potential mediator in the 
pathogenesis of PAH. OPG is regulated by BMP signalling, serotonin and 
interleukins, predominantly IL-1, which have all been implicated in the pathogenesis 
of PAH (Lawrie et al., 2008). Lawrie et al (2008) hypothesised that the signalling 
pathways employed by BMPs, serotonin and the inflammatory cytokine IL-1 all 
converge to dysregulate OPG expression, thus causing the proliferation and migration 
of PA-SMCs. Immunohistochemical analysis of human lungs revealed an increase in 
OPG release from SMCs in patients with IPAH compared to healthy controls. 
Furthermore, immunohistochemical staining for OPG binding partners, TRAIL and 
RANKL, was elevated in ECs and SMCs present within IPAH patient lungs. 
Increased serum levels of OPG in IPAH patients further suggest a role for OPG in 
PAH (Lawrie et al., 2008).  
 
Investigations into the effect of OPG on PA-SMC phenotype and dysfunctional 
signalling on OPG release generated also revealed that recombinant OPG increased 
proliferation and migration of PA-SMCs in a dose dependent manner. Human PA-
SMCs transfected with siRNA (to mimic the heterozygous loss of function BMPR2 
mutation) demonstrated increased OPG release, as did PA-SMCs treated with 5HT 
and IL-1. For the first time, these data demonstrate that OPG is upregulated in patients 
of PAH and furthermore, OPG can influence the proliferation and migration of human 
PA-SMCs (Lawrie et al., 2008). 
 
A recent patient study conducted by Condliffe et al (2012) revealed elevated OPG 
mRNA expression in human PA-SMCs isolated from IPAH patients. Serum levels of 
OPG were increased in IPAH patients and a significant correlation between OPG 
serum and pulmonary arteriole remodelling in rodent models was identified. These 
findings also support the role of OPG as an important biomarker in disease (Condliffe 
et al., 2012). 
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In addition to patient data and the effects of OPG in vitro, unpublished data from the 
Pulmonary Vascular Research Group at the University of Sheffield have shown that 
genetic deletion of OPG can prevent disease development in the Sugen-hypoxic 
(SuHx) mouse model of PH (Figure 1.3A) and blockade of OPG, though 
administration of an anti-OPG antibody, can reverse disease in the Paigen diet fed 
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Figure 1.3- Genetic deletion of OPG prevents disease development in the SuHx 
mouse model and antibody blockade of OPG reverses disease in the Paigen fed 
ApoE-/- mouse model of PH .  
A) Disease was induced in C57Bl/6 and OPG-/- using the Sugen5416/hypoxia method 
by administering weekly injections of Sugen5416 during 3 weeks exposure to 
normoxia or hypoxia, alongside normoxic control mice. Mice exposed to SuHx 
developed disease as shown by a significant increase in RVSP, compared to Sugen 
alone or hypoxia alone. However, OPG-/- mice exposed to Sugen-hypoxia are 
protected against disease development. B) Male ApoE-/- mice fed on a high fat Paigen 
diet (8 weeks) develop elevated RVSP compared to those animals fed on normal chow 
diet (8 weeks). However, 4-week administration of an anti-OPG antibody after 8 
weeks Paigen diet reverses disease in ApoE-/- mice, shown by a reduction in RVSP. 
Error bars represent mean ± SEM, n=3-6. **p<0.01. Data generated by the 
Pulmonary Vascular Research Group, Department of Cardiovascular Science, 
University of Sheffield. Dawson et al manuscript in preparation. 
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These data show that blockade of OPG, through genetic deletion or antibody blockade 
prevents and reverses disease development animal models of PAH. These data 
provide evidence that OPG is an important pathogenic mediator in disease, and 
contributes directly to disease progression in PAH animal models. However, the 
mechanisms by which OPG exerts its effects in order to influence PA-SMC phenotype 
are still unknown. 
 
1.8 Hypothesis and Aims 
I hypothesised that OPG was binding to a previously undescribed cell surface receptor 
to active a previously undescribed signalling pathway in PA-SMCs. I also 
hypothesised that blocking the interaction between OPG and the identified receptor 
would prevent OPG-induced PA-SMC proliferation. 
 
I therefore aimed to identify the receptor to which OPG was binding on PA-SMCs and 
the intracellular signalling mechanism through which OPG was inducing PA-SMC 
proliferation.  
 
In order to identify a mechanism through which OPG signals in PA-SMCs, there were 
four aims to be addressed in this thesis:  
1) To determine which receptor(s) OPG is binding on PA-SMCs in order to initiate a 
signalling cascade. 
2) To determine which intermediate proteins OPG is signalling through in order to 
induce downstream mRNA transcription and PA-SMC proliferation.  
3) To identify which genes are transcribed as a result of OPG signalling in PA-SMCs.  
4) To determine whether blocking the interaction between OPG and the identified 
receptor(s) can modulate PA-SMC phenotype. 
 
These aims are represented in the schematic below (Figure 1.4) and I will be aiming to 

























Figure 1.4- Aims to be addressed in this thesis. 
 In order to identify the mechanism through which OPG induces PA-SMC 
proliferation, 1) the receptor to which OPG is binding on PA-SMCs must be 
identified, 2) the changes in protein expression and activation and 3) the changes 
gene expression that OPG induces in PA-SMCs must be investigated. Finally, the 
effect on blocking the interaction between OPG and its binding partner on PA-SMC 
proliferation must also be assessed to determine the importance of the interaction in 




2. GENERAL METHODS 
2.1 Cell Culture 
All cell culture was performed in a Class II laminar flow hood in a sterile 
environment, using aseptic techniques. Cells were cultured in sterile, disposable T75 
cm2 cell culture flasks, until ready for experimentation, in incubators at 37°C in 95% 
room air with 5% carbon dioxide (CO2). All experiments were then carried out using 
disposable, sterile consumables, sterile reagents and media.  
 
2.1.1 Human Pulmonary Arterial Smooth Muscle Cells (HPA-SMC) 
2.1.1.1 HPA-SMC Culture and Passage 
HPA-SMCs were purchased from Lonza (Basel, Switzerland) and grown in T75 cm2 
cell culture flasks, prior to experimentation, in sterile SmBM (Smooth Muscle Basal 
Medium), containing the SmGm-2 SingleQuots: 5% v/v foetal bovine serum (FBS) 
(CC-4102D, SmGM-2 SingleQuots, Lonza, Basal, Switzerland), 0.1% v/v insulin, 
0.2% v/v hFGF-β, gentamicin (30 μg/ml) and amphotericin (15 ng/ml) (full growth 
media) (Lonza, Basel, Switzerland) at 37°C (5% CO2). 
 
Once HPA-SMCs reached ~80% confluence, the cells were then passaged and 
transferred into T75 cm2 cell culture flasks to continue growth, or T25 cm2 cell culture 
flasks or 96 well plates for experimentation. SmBM growth media was removed from 
the T75 cm2 cell culture flasks and cells were washed three times in 1xPBS. All traces 
of PBS were removed and 5 ml 1x Trypsin/EDTA was added to each T75 cm2 cell 
culture flask. Flasks were then incubated at 37˚C for 5 minutes. Flasks were then 
removed from the incubator and cells displaced from the bottom of the flask by gentle 
tapping. To ensure cells were fully trypsinized, cells were observed using a 
microscope. Once fully trypsinized, 5 ml trypsin neutralisation solution was added to 
flask. Cells were then transferred to a 15 ml tube and cells were pelleted by 
centrifuging for 5 minutes at 1,200 xg. The cell pellet was then resuspended in 9 ml 
SmBm full growth media and the cells were split 1:3 (one T75 cm2 cell culture flask 
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split into three T75 cm2 cell culture flasks or nine T25 cm2 cell culture flasks) or 
plated into flat bottom 96 well plates at a specific seeding density. 
2.1.1.2 HPA-SMC Haemocytometer Counts 
HPA-SMCs were removed from the T75 cm2 cell culture flasks by trypsinisation as 
detailed in Chapter 2, Section 2.1.1.1. 1 ml trypsinized cells were then transferred into 
10 ml SmBm-2 full growth media and mixed gently. 10 μl cell suspension was then 
pipetted onto each side of a haemocytometer. Cells were then counted under the 
microscope at a 10x magnification, by counting cells in the centre square and only 
counting cells overlapping the boundary of the centre square on the left and top 
boundaries. Cells in the centre square of each side of the haemocytometer were 
counted and an average of both sides were taken. An estimate of cell number was the 
calculated as follows: 
 
Cell number (cells/ml)= ((Cell No centre square side 1 + Cell No centre square side 2) 
/ 2) x 104 
 
2.1.1.3 HPA-SMC Synchronization 
Prior to stimulation of cells for all following experiments detailed in this Chapter, 
HPA-SMCs were synchronized for 48 hours with growth arrest media (DMEM, 0.2% 
v/v FBS, 0.5% v/v penicillin and streptomycin), unless stated otherwise. 
Synchronization of HPA-SMC cell cycles was performed to ensure all HPA-SMC cell 
cycles were halted between the G1 and S-Phase of the cell cycle prior to stimulation. 
This was to ensure that any changes in proliferation, protein or RNA expression were 
due to the stimulation of the cells and not due to the completion of cell cycles in a 
sub-population of cells. Cells were synchronized by removing all traces of SmBm-2 
full growth media and washing the cells twice in 10 ml 1 x PBS. 10 ml growth arrest 
media was then pipetted into T75 cm2 cell culture flasks, 4 ml into T25 cm2 cell 








2.2 Pierce™ 660 nm Protein Assay 
Protein concentration of cell lysates was measured using the Pierce 660 nm protein 
assay. The Pierce 660 nm protein assay is a dye-based assay that uses an acidic buffer 
reagent containing a proprietary dye-metal complex. Upon dye-metal complex 
binding to the protein in the acid environment of the buffer, the dyes maximum 
absorption is shifted. The reddish-brown colour of the buffer changes to green when 
protein binds to the dye-metal complex. The maximum absorption of the dye is then 
measured at 660 nm, with the colour change produced being proportional to the 
amount of protein. The colour change is due to the binding of positively charged basic 
proteins to the de-protonated dye at low pH. The Pierce 660 nm protein assay was 
used to measure protein concentration because, unlike other protein assays, it is 
compatible with most detergents that are used in the preparation of protein lysates. 
 
2.2.1 Preparation of Bovine Serum Albumin (BSA) Standards 
Bovine serum albumin (BSA) standards were prepared at 2000 μg/ml, 1500 μg/ml, 
1000 μg/ml, 750 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 25 μg/ml and 0 μg/ml by 
diluting one 2000 μg/ml bovine serum albumin standard ampule (stock) (Pierce) as 
follows: 
 
Vial BSA Standard 
Concentration (μg/ml) 
Volume and Source 
of BSA (μl) 
Volume of distilled 
water 
A 2000 300 of stock 0 
B 1500 375 of stock 125 
C 1000 325 of stock 325 
D 750 175 of vial B 
dilution 
175 
E 500 325 of vial C 
dilution 
325 
F 250 325 of vial E 
dilution 
325 
G 125 325 of vial F 
dilution 
325 
H 25 100 of vial G 
dilution 
400 




2.2.2 Microplate Procedure for Protein Assay 
Lysates were defrosted on ice and 1 g Ionic Detergent Compatibility Reagent added to 
20 ml Pierce 660 nm Protein Assay Reagent and mixed well. Following the 
microplate procedure, 10 μl of each BSA standard or lysate was then added in 
duplicate to a separate well of a 96 well plate. 150 μl Protein Assay Reagent was then 
added to each well containing the BSA standards and samples. The 96 well plate was 
then covered, mixed for 1 minute on a plate shaker and incubated at room temperature 
for 5 minutes. The plate was then scanned at 700 nm using the LiCOR Odyssey Sa 
system. 
 
2.3 Western Blotting 
2.3.1 General Protocol 
Western blotting is an analytical technique used to detect proteins within a protein 
lysate using gel electrophoresis and antibodies against specific proteins. Western 
blotting uses gel electrophoresis to separate proteins within the lysate based on the 
length of polypeptides (denatured gel) or based on the structure of proteins (native 
gel). Following electrophoresis, proteins are then transferred onto a membrane to 
allow easier manipulation during staining with specific antibodies. For all western blot 
protein analysis discussed throughout this thesis, the following protocol was 
performed prior to staining the membranes with specific antibodies. Gel 
electrophoresis was performed on denatured proteins using the XCell SureLock™ 
Mini-Cell Electrophoresis system (Life Technologies, Paisley, UK) and NuPAGE 
Novex 4-12% Bis-Tris 1.0 mm 10 well precast mini-gels (NP0321BOX, Life 
Technologies, Paisley, UK). Protein samples were prepared as discussed later in this 
chapter for each specific experiment.  
 
2.3.1.1 Sample Preparation 
Prior to electrophoresis, 30 μl protein lysate aliquots were defrosted on ice and protein 
loading buffer (928-4004, Licor, Bad Homberg, Germany) added to the eppendorf 
containing the lysate (1 μl per 3 μl lysate). NuPAGE reducing agent (NP0009, Life 
Technologies, Paisley, UK) was then added to the eppendorf (1 μl per 10 μl lysate and 
protein loading buffer). Eppendorfs containing the protein lysate, loading buffer and 
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reducing agent were then mixed by vortexing for 15 seconds and heated at 70°C for 
10 minutes to ensure the proteins were denatured. 
 
2.3.1.2 Electrophoresis System Set-up and Sample Loading 
Prior to sample loading, the gels were inserted into the XCell SureLock™ Mini-Cell 
Electrophoresis system by removing the gels from the pouch and peeling off the tape 
at the bottom of the gel. The Upper Chamber was then filled with 200 ml NuPAGE 
MOPS SDS 1x running buffer (Life Technologies, Paisley, UK) to check the tightness 
of the seal and ensure the Upper Chamber was not leaking. Once the seal was tight, 
additional NuPAGE MOPS SDS 1x running buffer was added to the Upper Chamber 
to ensure the buffer level exceeded the tops of the wells and 500 μl NuPAGE 
antioxidant (NP0005, Life Technologies, Paisley, UK) was added to the running 
buffer in the Upper Chamber. 30 μl of the denatured protein lysates was then added to 
the appropriate wells, along with 5 μl Novex Sharp™ pre-stained protein standard 
(LC5800, Life Technologies, Paisley, UK). The Lower Buffer Chamber was the filled 
with 400 ml running buffer. 
 
2.3.1.3 Gel Electrophoresis 
The gels were exposed to electrophoresis for 45 minutes at 200 V. When running only 
one gel, a second, blank gel with the tape still intact was used to form the Upper 
Chamber. 
 
2.3.1.4 Protein Wet Transfer 
Once electrophoresis was complete, the gels were removed from the XCell 
SureLock™ Mini-Cell Electrophoresis system. The gel plates were then separated 
using a Gel Knife and the gel foot and wells removed using the Gel Knife. The 
proteins were then transferred onto Whatman nitrocellulose membrane (10401196, 
GE Healthcare Life Sciences, Amersham, UK) using wet transfer. Prior to transfer, 1x 
NuPAGE transfer buffer (NP0001, Life Technologies, Paisley, UK) containing 10% 
v/v methanol (when transferring one gel) or 20% v/v methanol (when transferring two 
gels) (VWR Chemicals) and 1 ml antioxidant was prepared and sponges, filter paper 
and nitrocellulose membrane were pre-soaked before transferring the gels using the 
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XCell II™ Blot Module, as shown in Figure 2.1. Gels were transferred facing the 
cathode core and any air bubbles were rolled out before inserting the blot module into 
the Lower Buffer Chamber. The Upper Chamber was then filled with 1x NuPage 
transfer buffer until the gel/membrane assembly was covered and the Lower Chamber 
was filled with 300 ml transfer buffer. The gels were then transferred for 60 minutes 
at 30 V. 
 
 
Figure 2.1- Wet transfer set-up.  
After electrophoresis, proteins were transferred from the gel onto nitrocellulose 
membrane to allow easier manipulation during blocking and staining with specific 
antibodies. Proteins were transferred onto nitrocellulose membrane using wet 
transfer, where all components of the transfer system shown in A and B were pre-
soaked in transfer buffer. When transferring one gel, the transfer set-up in A was used 
and when transferring two gels, the transfer set-up in B was used. 
 
2.3.1.5 Membrane Blockade 
Once the proteins were transferred, membranes were placed in blocking buffer (5% 
w/v low fat milk in 1x PBS or 30% v/v Odyssey blocking buffer (927-4000, Licor, 
Bad Homberg, Germany) in 1x PBS) for 1.5 hours at room temperature, with gentle 
rocking. 
 
2.3.1.6 Primary Antibody Incubation 
Membranes were incubated with desired primary antibodies, diluted as appropriate (as 
discussed throughout the chapter for each specific experiment) in 30% v/v Odyssey Sa 




2.3.1.7 Secondary Antibody Incubation 
After primary antibody incubation, membranes were washed for 3 x 10 minute washes 
in 0.1% v/v Tween-20 (in 1X PBS) before incubating with desired secondary 
antibodies. All IRDye 680LT and 800CW secondary antibodies were diluted 1:15000 
in 30 % Odyssey blocking buffer containing 0.1% v/v SDS or 5% w/v low fat milk. 
Membranes were incubated with secondary antibodies for 1 hour at room temperature, 
protected from light, with gentle rocking. Membranes were then washed for 3 x 10 
minute washes in 0.1% v/v Tween-20 in 1 x PBS. 
 
2.3.1.8 Membrane Scanning 
Following primary and secondary antibody incubation, membranes were scanned on 
the Licor Odyssey Sa system using the following parameters shown in Table 2.1. 
 
Table 2.1 Licor Odyssey Sa System Scanning Parameters 
 Channel 
 700 nm 800 nm 
Resolution 200 μm 200 μm 
Intensity 7.0 7.0 
Focus Offset 3.0 mm 3.0 mm 
 
 
Membranes were analysed using the Western Analysis tool. The amount of protein 
was proportional to the number of pixels detected (“total”). Amount of protein in each 
lane was then analysed by using the “Add Band” tool, subtracting lane background 
from each lane and expressing protein as a percentage of the control sample, 
normalised to the loading control. Protein expression was calculated as follows: 
 




Protein expression (% control)= Protein expression / Control sample protein 
expression 
 
2.3.1.9 Membrane Stripping 
When required, antibodies were stripped from the membranes using 1X Re-blot Plus 
mild antibody stripping solution (2502, Millipore, Massachusetts, USA). Membranes 
were incubated in 20 ml 1X Re-blot Plus mild antibody stripping solution for 15 
minutes at room temperature, with gentle rocking. Membranes were then washed two 
times 5 minutes in 30% v/v Odyssey blocking buffer. If required, membranes were re-
probed with the appropriate secondary antibody using the methods described in 
Chapter 2, Section 2.3.1.7 and scanned using the methods described in Chapter 2, 
Section 2.3.1.8 to ensure all traces of primary antibody was removed. The membranes 
were then incubated with primary and secondary antibodies using the methods 
described in Chapter 2, Section 2.3.1.6 through to 2.3.1.7. 
 
2.4 Retrogenix Cell Microarray 
In order to identify OPG binding partners, a Retrogenix Cell microarray was carried 
out by Retrogenix (Sheffield, UK). In this Retogenix cell microarray, binding between 
OPG and 2505 human plasma membrane proteins was determined by expressing each 
membrane protein in HEK293 cells. Retrogenix, Sheffield, UK, carried out all 
experimental methods outlined in Chapter 2.4.1 to Chapter 2.4.3 below. 
 
2.4.1 Pre-Screen 
Firstly, a pre-screen was conducted to determine optimal OPG and antibody 
concentrations to use in the primary screen. OPG was screened against HEK cells 
expressing syndecan-1 (positive control) and pIRES-hEGFR-IRES-ZsGreen1 or the 
membrane protein TREM1 (negative control) and pIRES-hEGFR-IRES-ZsGreen1 
with varying concentrations of rhOPG (2 μg/ml and 0.5 μg/ml) and the anti-OPG 
antibody (2 μg/ml and 0.5 μg/ml). Secondary antibody, Alexafluor 647 rabbit anti-
goat, was then added to the cells to determine levels of OPG binding to syndecan-1 
and TREM1 membrane proteins and determine any background binding. 
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2.4.2 Primary Screen 
Following the pre-screen, human embryonic kidney 293 (HEK293) cells were grown 
on top of duplicate expression vectors consisting of green fluorescent protein (GFP) 
and one full-length human plasma membrane protein. The expression vector pIRES-
hEGFR-IRES-ZsGreen1 was spotted onto every slide to ensure minimum threshold of 
transfection was achieved. Cells were reverse transfected, fixed and the slides were 
treated with 0.5 g/ml rhOPG (Peprotech, London, UK), 0.5 g/ml anti-OPG 
(Peprotech, London, UK) followed by Alexafluor647 anti-goat antibody. Two 
replicate screens were performed and fluorescent images were analysed and quantified 
using ImageQuant software. A hit was then defined as a duplicate spot showing a 
raised signal compared to background levels. Hits were classified as weak, medium or 
strong depending on the spot intensity. 
 
2.4.3 Confirmation Screen 
Hits identified in one or both primary screens were then confirmed and analysed 
following the same methodology as for the primary screen. Vectors encoding hits 
were then sequenced to confirm protein identity. OPG plus anti-OPG plus secondary 
antibody, anti-OPG plus secondary antibody or OPG plus secondary antibody were 
used as controls in the conformation screen. (http://www.retrogenix.com/default.asp).  
 
2.5 Co-Immunoprecipitation 
Immunoprecipitation is a technique that uses an antibody against a specific protein to 
purify the protein antigen from a solution. Co-immunoprecipitation (Co-IP) uses this 
principle to isolate protein complexes from a solution, by using an antibody against a 
known protein within the complex to precipitate the protein complex and thus allow 
identification of unknown protein components within the complex. Co-IP was 
therefore used to pull down unknown OPG binding partners using an antibody against 
OPG and confirm OPG interaction with identified OPG binding partners. 
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2.5.1 Preparation of CHAPS Lysis Buffer 
Prior to cell stimulation, a 1% v/v CHAPS cell lysis buffer was prepared in 30 mM 
TRIS-HCl (pH 7.5), 150 mM NaCl. Immediately before use, HALT™ protease 
inhibitor (10 μl/ml) (87786, Pierce Thermo Scientific) and EDTA (10 μl/ml) were 
added. 
 
2.5.2 Preparation of HPA-SMC lysate 
HPA-SMCs (P5) were grown T75 cell culture flasks in fully supplemented SmBm 
growth media until 80% confluent. Cells were then stimulated with rhOPG (500 
ng/ml) in SmBm full growth media for 30 minutes at 37C, without synchronization 
of cell cycles. After stimulation, cell culture flasks were placed on ice and washed 
twice with ice-cold PBS, ensuring all trace of PBS was removed. Cells were lysed in 1 
ml CHAPS lysis buffer and incubated on ice for 15 minutes with occasional rocking. 
Following cell lysis, cells were scraped using a 25 mm cell scraper, transferred to a 
fresh 1.5 ml Eppendorf and disrupted by passing through a 21 gauge needle 5 times. 
The HPA-SMC lysate was clarified by centrifugation at 12,000 x g for 10 minutes at 
4C. The protein concentration of the HPA-SMC lysate was then measured by Pierce 
660 nm protein assay and kept on ice until use after concentration quantification. 
 
2.5.3 Preparation of Co-IP Reactions 
Co-IP reactions were then prepared in 1.5 ml Eppendorfs by adding the reagents as 













Table 2.2 Fas IP reactions 
Eppendorf Antibody 
(Ab) 
Lysate rhOPG rhFas CHAPS 
buffer 
1.1 Fas Ab (2 
μg) 
250 μl (50 μ 
g) lysate 
- - - 
1.2 No Ab 250 μl (50 μ 
g) lysate 
- - - 
1.3 Fas Ab (2 
μg) 
- rhOPG 0.1 
μg 
rhFas 0.1 μg 250 μl 
CHAPS 
1.4 No Ab - rhOPG 0.1 
μg 
rhFas 0.1 μg 250 μl 
CHAPS 
1.5 Fas Ab (2 
μg) 
- rhOPG 1 μg rhFas 1 μg 250 μl 
CHAPS 
1.6 No Ab - rhOPG 1 μg rhFas 1 μg 250 μl 
CHAPS 
1.7 Fas Ab (2 
μg) 
- - rhFas 1 μg 250 μl 
CHAPS 





Table 2.3 IL1RAcP IP Reactions 
Eppendorf Antibody Lysate rhOPG rhIL1RAcP CHAPS 
buffer 
2.1 IL1RAcP 
Ab (2 μg) 
250 μl (50 μ 
g) lysate 
- - - 
2.2 No Ab 250 μl (50 μ 
g) lysate 
- - - 
2.3 IL1RAcP 
Ab (2 μg) 
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The 1.5 ml Eppendorfs containing the Co-IP reactions were then incubated at 4°C, 
overnight, with end-over-end mixing to allow immune complexes to form. 
 
2.5.4 Precipitation of Immune Complexes 
Following overnight incubation, 50 μl nProteinG sepharose 4 Fast Flow beads (50% 
slurry) were added to each Co-IP reaction and precipitated for 1 hour at 4°C with end-
over-end mixing. Each Co-IP reaction was then centrifuged at 12,000 x g for 20 
seconds and the pellet washed 3 times with 1 ml CHAPS lysis buffer and once with 
wash buffer (50 mM TRIS, pH 8.0).  
 
2.5.5 Dissociation of Immune Complexes 
The pellet was re-suspended in one times NuPAGE sample reducing agent and 5% v/v 
SDS. The pellet was then heated at 95°C for 5 minutes and centrifuged at 12,000 x g 
for 20 seconds. The supernatant was then transferred to a new Eppendorf and one 
times LiCOR lane marker added to each Eppendorf. 
 
2.5.6 Analysis of Immune Complexes 
The supernatants were then analysed by Western Blotting using the protocol described 
in Chapter 2, Section 2.3 to 2.3.1.9. Following membrane blockade in 30% v/v 
odyssey blocking buffer, membranes were incubated with goat polyclonal anti-OPG 
antibody (SC8468, Santa Cruz Biotechnology), for 3 hours at room temperature. OPG 
antibody was added at a 1:1000 dilution in 30% v/v odyssey blocking buffer. After 
incubation with the primary antibody, the membranes were washed 3 times 10 
minutes in one times PBS plus 0.1% v/v tween-20. Membranes were then incubated 
with secondary antibody IRDye 680LT Donkey anti-goat (926-32214, LiCOR, Bad 
Homberg, Germany) at a 1:15,000 dilution in 30% v/v Odyssey blocking buffer for 1 
hour at room temperature. The membranes were then washed 3 times 10 minutes in 
one times PBS plus 0.1% v/v Tween-20. The membranes were then scanned using the 





Histological slides of the pulmonary artery and right ventricle from donors with 
idiopathic PAH and control subjects undergoing lung resection for cancer or from 
donor lung were obtained from the Papworth Hospital NHS Trust tissue bank. All 
subjects gave informed written consent, and the study was approved by the Local 
Research Ethics Committee. Immunohistochemical analysis of the sections was then 
performed by Ms Nadine Arnold, Pulmonary Vascular Research Group, Department 
of Cardiovascular Science, University of Sheffield.  
 
Briefly, tissue sections were de-waxed and rehydrated through graded alcohols to 
water. Endogenous peroxidases were blocked by incubation in 3% v/v hydrogen 
peroxide in water for 10 minutes. Slides were rinsed in tap water and antigen retrieval 
was performed by incubating the slides in citrate buffer (10 mMol/L, pH 6.0) for 20 
minutes at 95°C. Slides were cooled for 20 minutes at room temperature before 
permeabilisation in 0.5% v/v Triton X-100 in PBS for 10 minutes and non-specific 
binding sites were blocked with 1% w/v low fat milk in 1 x PBS for 30 minutes at 
room temperature. Excess milk was then blotted away and primary antibodies, Fas 
monoclonal antibody (Mouse, Enzo Life Sciences, ADI-AMM-227-E) (1:100 
dilution) or IL1RAcP polyclonal antibody (Rabbit, Abcam, Ab8110) (1:1000 
dilution), were added and incubated overnight at 4°C. Primary antibodies were then 
washed off in 3 changes of PBS, incubating slides for 5 minutes between each wash. 
Slides were incubated with biotinylated anti-rabbit (1:200) biotinylated anti-mouse 
(1:200) secondary antibodies for 30 minutes at room temperature. All primary and 
secondary antibodies were diluted in 1 x PBS. Slides were washed in 3 changes of 1 x 
PBS, 5 minutes each. Slides were incubated with ABC complex for 30 minutes at 
room temperature and then washed in 3 changes of 1 x PBS, incubating slides for 5 
minutes in each change of 1 x PBS. DAB substrate was then added for 10 minutes and 
slides were then rinsed in tap water. Slides were counterstained with Carazzi’s 
haemotoxylin for 1 minute, washed in tap water and dehydrated through graded 
alcohols to xylene. Slides were mounted using DPX mountant and left to dry 




2.7 Kinex Antibody Microarray 
In order to identify OPG-induced changes in protein phosphorylation and expression, 
Kinexus, Canada, performed a Kinex Antibody Microarray. Following cell 
synchronization and stimulation, Kinexus, Canada, performed all experimental 
methods outlined in Chapter 2, Section 2.7. HPA-SMCs were synchronized with 0.2% 
v/v FBS in growth arrest media for 48 hours and stimulated with 0.2% v/v FBS, 
rhOPG (50 ng/ml) and PDGF (20 ng/ml) for 10 and 60 minutes. Phosphorylation 
targets were identified from protein lysates by Kinex antibody microarray (Kinexus, 
Canada). Briefly, 50 μg lysate protein was covalently tagged with fluorescent dye and 
untagged protein removed by gel filtration. Non-specific binding sites were blocked 
and the samples were loaded side by side (control vs. stimulated) onto incubation 
chambers mounted on the microarray. The microarray consisted of 812 polyclonal and 
monoclonal antibodies (262 phospho-specific and 550 pan-specific), in duplicate. 
Samples were incubated and unbound protein washed away. Binding of proteins to 
their corresponding antibodies was detected in the form of 16-bit images captured by 
Perkin-Elmer ScanArray Reader laser array scanner (Waltham, MA). Signal 
quantification was performed by ImaGene 8.0 (Biodiscovery, El Sergundo, CA) and 
Z-ratios calculated. A Z-ratio of ±1.5 was deemed significant.  
 
2.8 DAVID (The Database for Annotation, Visualization and 
Integrated Discovery) Analysis of Kinex Antibody 
Microarray Results 
Uniprot accession codes of proteins deemed significantly regulated by OPG (z-ratio of 
± 1.5) were then analysed using DAVID functional annotation to generate fold 
enrichment pathway analysis through the Kegg Pathway Database. An intersection of 
≥2 fold change and p≤0.05 was used for the pathway fold enrichment analysis. Protein 
targets identified by the Kinex antibody microarray were then selected for validation 






2.9 Kinex Antibody Microarray Validation 
2.9.1 In-Cell Western Assay 
2.9.1.1 HPA-SMC Stimulation 
HPA-SMCs (P4-P7) were grown as described in Chapter 2, Section 2.1.1.1 and 
transferred into 96 well plates (Corning Costar, Sigma, Dorset, UK) at a seeding 
density of 5x103 cells/well. Cells were synchronized as described in Chapter 2, 
Section 2.1.1.3 and then stimulated with rhOPG (50 ng/ml) for 10 and 60 minutes 
alongside quiesced cells (negative control).  
 
2.9.1.2 HPA-SMC Fixing and Permeabilization 
Cells were then fixed with fixing solution (PBS containing 3.7% v/v formaldehyde), 
by removing the cell culture media and adding 150 μl fixing solution to each well by 
pipetting the fixing solution down the sides of the wells. Cells were fixed for 20 
minutes at room temperature. Fixing solution was then removed removed by pipetting 
and 200 μl 0.1% v/v Triton X-100 in 1 x PBS was added to each well, by pipetting the 
solution down the sides of the wells to prevent cell detachment. Three times 10-
minute washes in Triton X-100 were performed at room temperature, with gentle 
shaking.  
 
2.9.1.3 Cell Blockade 
Cells were blocked in 150 μl blocking solution (5% w/v low-fat milk in PBS) for 1.5 
hours at room temperature, with gentle shaking.  
 
2.9.1.4 Primary Antibody Incubation 
Intracellular phospho-proteins were detected by incubating each column of wells of 
the 96 well plate with blocking solution containing one of the following antibodies: 
phospho-CDK2, phospho-CDK4, phospho-HSP27 (S15), phospho-p38, phospho-
p44/p42 MAPK, phospho-PLCγ2 or phospho-AKT. All primary antibodies were 
diluted 1:200, in blocking buffer. Cells were incubated with 50 μl of each of the 
primary antibodies, overnight at 4°C, with gentle shaking. Following overnight 
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incubation, cells were washed in wash solution (PBS, 0.1% Tween), for 5 times 5 
minutes with gentle shaking. 
 
2.9.1.5 Secondary Antibody and Nuclear Staining 
Following primary antibody incubation and washing, cells were incubated with anti-
Rabbit IRDye 800 and anti-Mouse IRDye 800 (1:15,000 dilutions) in blocking 
solution containing 0.1% v/v Tween. Nuclear stains DRAC5 (1: 10,000 dilution) and 
Sapphire 700 (1:1000 dilution) were also added to secondary antibody solutions. 
Background wells were prepared by incubating cells with blocking buffer (containing 
0.1% v/v Tween-20) containing only secondary antibody to determine non-specific 
antibody binding. Cells were incubated with secondary antibodies, nuclear stains and 
blocking buffer for 1 hour at room temperature, with gentle rocking. Cells were then 
washed with wash solution for 5 times 5 minutes. 
 
2.9.1.6 Plate Analysis 
Plates were analyzed using the Licor Odyssey Sa system, using the paramters 
described in Table 2.1. Cell number (nuclear stain) was detected in the 700 nm 
channel and phospho-proteins detected in the 800 nm channel. Signal quantification 
was calculated by subtracting background, normalizing the 800 channel (protein 
phosphorylation) to 700 channel (cell number) and calculating percentage response in 






Figure 2.2- ICW Assay Protocol. 
HPA-SMCs plated into 96 well plates were quiesced for 48 hours and stimulated with 
rhOPG (50 ng/ml) and 0.2% FBS for 10 and 60 minutes. Cells were then fixed and 
permeabilsed, blocked and probed with primary antibodies against intracellular 
phospho-proteins, overnight. Cells were then washed and probed with secondary 
antibodies and nuclear stains to quantify cell number. Cells were then washed and 
scanned using the LiCOR Odyssey Sa System. Phospho-proteins were then detected in 
the 800 nm channel and cell number detected in the 700 nm channel. 
 
2.9.2 Western Blotting 
2.9.2.1 HPA-SMC Stimulation 
HPA-SMCs (P4-P7) were grown as described in Chapter 2, Section 2.1.1.1 and 
passaged into 9x T25 cell culture flasks (1:3 split). Cells were then grown until cells 
reached ~80% confluence. Cells were then synchronised as described in Chapter 2 
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section 2.1.1.3. Growth arrest media was then removed after 48 h and cells were 
stimulated with 0.2% FBS (starve media) or rhOPG (50 ng/ml) diluted in starve 
media) for 10 minutes and 60 minutes. 
 
2.9.2.2 HPA-SMC Lysis 
2.9.2.2.1  Sodium Orthovanadate Lysis 
Immediately before lysing, cell lysis buffer (78% v/v ddH2O, 1% v/v 1M Tris HCl, 
1% v/v 100 mM SDS, 100 mM sodium orthovanadate, 10% v/v protease inhibitor 
cocktail) was prepared and boiled for 5 minutes. After stimulation, cell culture media 
was removed and cells were washed three times in cold PBS. All trace of PBS was 
removed with a pipette and 300 μl of lysis buffer heated to 95°C was added to each 
flask and incubated for 5 minutes. Cells were then scraped using a cell scraper and the 
lysate was transferred to a fresh 1.5 ml Eppendorf. Lysates were boiled for 5 minutes 
at 100°C and then centrifuged at 4°C, 14,000 rpm for 10 minutes to clarify the cell 
lysate. Following centrifugation, the supernatant was then transferred into fresh 0.5 ml 
Eppendorfs in 30 μl aliquots and immediately frozen at -80°C until required. Sodium 
orthovanadate lysis buffer was used to lyse cells prior to performing western blotting 
to detect phospho-proteins. 
 
2.9.2.2.2  Triton X-100 Lysis 
Immediately before lysing, cell lysis buffer (150 mM NaCl, 20 mM Tris, 1% v/v 
Triton X-100, 0.1% v/v SDS in 1 x PBS) was prepared. Immediately before use, 
HALT Protease Inhibitor cocktail (100X) was added to the cell lysis buffer. After cell 
stimulation, cell culture media was removed from the T25 cm2 cell culture flask and 
the cells were washed three times in cold PBS. All trace of PBS was removed using a 
pipette and 300 μl cell lysis buffer was added per T25 cm2 cell culture flask. Flasks 
were then immediately frozen at -80°C, ensuring an even layer of lysis buffer was 
spread over the bottom of the cell culture flask. Immediately before western blotting, 
T25 cm2 cell flasks were defrosted on ice, and aliquotted into 30 μl aliquots before 
freezing at -80°C. 
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2.9.2.3 Primary Antibody Incubation 
Western blotting was performed on cell lysates according to the protocol described in 
Chapter 2 section 2.3. After gel electrophoresis and blocking as described in Chapter 
2, Section 2.3, the blot was incubated with blocking buffer (5% w/v low fat milk 
(Marvel) in 1xPBS) containing phospho-CDK4, phospho-ERK1/2 phospho-p44/p42 
MAPK or phospho-HSP27 primary antibodies (1:1000 dilutions), or mTOR, phospho-
mTOR, CDK5, FADD, Atg7, Atg13 or Daxx primary antibodies in 30% v/v Odyssey 
blocking buffer, overnight at 4°C. β-actin and p44/p42 primary antibodies (1:1000 
dilutions) were also added and used for loading controls. Following primary antibody 
incubation, membranes were washed in 0.1% v/v Tween-20, for 3 times 10 minutes 
washes. 
 
2.9.2.4 Secondary Antibody Incubation 
Secondary antibodies Donkey anti-Rabbit IRDye 800 and Goat anti-Mouse IRDye 
800 were diluted 1:15000 in blocking buffer and incubated for 1 hour at room 
temperature, protected from light. Following secondary antibody incubation, 
membranes were washed in 0.1% v/v Tween-20, for 3 times 10 minutes washes. 
 
2.9.2.5 Membrane Scanning 
Each blot membrane was then scanned and signal detected using the Licor Odyssey Sa 
system. Band density was quantified by subtracting background and counting the 
number of pixels in each band (number of pixels proportional to density). Band 
density of phospho-proteins was then normalised to the band density of loading 
controls. 
 
2.10 Agilent RNA Microarray 
A microarray consists of thousands of genes spotted onto a slide that are used to look 
at gene expression in samples, for example healthy cells versus cancer cells, in order 
to gain insight into the causes and development of disease. An Agilent RNA 
microarray was performed in order to investigate changes in gene expression in HPA-
SMCs stimulated with rhOPG compared to unstimulated cells. 
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When a gene is activated in cells, mRNA is transcribed. RNA is then isolated from the 
cells and reverse transcribed into cDNA. Fluorescently labelled cRNA is then 
synthesised from the cDNA using fluorescent nucleotides. In a two-colour microarray, 
a different fluorescent nucleotide is used for the stimulated, for example Cy3, and 
unstimulated control, for example Cy5. The fluorescently labelled cRNA from both 
samples is then combined and added to the microarray slide consisting of thousands of 
oligonucleotides. In a one-colour microarray, each sample is labelled with the same 
fluorescent nucleotide, for example Cy3, and each sample is run on a different sub-
array on the microarray slide. If the mRNA is expressed in the samples, the cRNA 
then hybridizes to the complementary oligonucleotide on the slide. The more mRNA 
is expressed in the sample, the more cRNA hybridises to the oligonucleotides. The 
colour of fluorescence detected provides information on whether the mRNA is 
expressed in the stimulated or unstimulated samples. 
 
 
2.10.1 HPA-SMC Stimulation 
HPA-SMCs (P7) were grown as previously described in Chapter 2, Section 2.1.1.1, 
and synchronized in T25 cm2 cell culture flasks as previously described in Chapter 2, 
Section 2.1.1.3. After 48 hours, growth arrest media was removed and HPA-SMCs 
were stimulated with rhOPG (50ng/ml) or growth arrest media (0.2% FBS, negative 
control). Nine T25 cm2 cell culture flasks per condition were stimulated. Cells were 
stimulated for 6 hours, before cell culture media was removed and 500 μl TRIzol 
reagent was added to each T25 cm2 cell culture flask. Flasks were then frozen at -
80°C, ensuring an even layer of TRIzol was spread over the bottom of the cell culture 
flask. 
 
2.10.2 HPA-SMC RNA Isolation 
T25 cm2 cell culture flasks previously stimulated and frozen at -80°C (described in 
Chapter 2.10.1) were defrosted on ice and RNA was extracted by J. Iremonger 
(Pulmonary Vascular Research Group, Department of Cardiovascular Science, 
University of Sheffield) using the DirectZol RNA extraction kit. 
 
 65 
2.10.3 Bioanalyzer Analysis of RNA Quality 
The quality of extracted RNA was then assessed using Agilent 2100 Bioanalyzer. 
RNA quality analysis was carried out by J. Iremonger (Pulmonary Vascular Research 
Group, Department of Cardiovascular Science, University of Sheffield), according to 
the Agilent RNA 6000 Nano Kit Guide. 
 
2.10.4 Agilent RNA Microarray 
Agilent 8-plex, single colour human gene expression microarrays were then 
performed to analyse gene expression in HPA-SMCs stimulated with rhOPG (50 
ng/ml) or 0.2% FBS (growth arrest media). RNA was pooled from 3 individual 
samples per sub-array, with three sub-arrays being run for each condition (rhOPG or 
0.2% FBS). Microarray analysis was performed, as described in the Agilent One-
Colour Microarray-Based Gene Expression Analysis Protocol Low input Quick Amp 
Labeling protocol (version 6.6, September 2012 Agilent technologies, G4140-90040). 
Successful hybridization of the RNA to sixty thousand complimentary probes was 
detected by scanning the microarrays using the Agilent G2565BA microarray scanner 
by J. Iremonger (Pulmonary Vascular Research Group, Department of Cardiovascular 
Science, University of Sheffield). 
 
2.10.5 Agilent RNA Microarray Analysis 
Dr Alex Rothman (Pulmonary Vascular Research, Department of Cardiovascular 
Science, University of Sheffield) performed the microarray data handling. The data 
were background corrected and Log2 transformed using Bioconductor and Lima 
programs in the programming language R. Log2 fold change was calculated by 
subtracting the raw data of unstimulated control samples from the raw data of OPG-
stimulated PA-SMCs. Output files were then organised by removing duplicate probes 
and using the intersection of Log2 fold change >0.3 and p<0.05 for further analysis 
and heat map generation. 
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2.10.6 Heat Map Generation 
A heat map was generated using R, with the help of Dr Alex Rothman, Department of 
Cardiovascular Science, University of Sheffield. PAH associated genes were 
identified using the search term “pulmonary hypertension” in Medline (Pubmed). A 
heat map was then generated to show mean ± SD (standard deviation) of OPG-
regulated genes that are associated with PAH. Mean ± SD was calculated for each 
data value by: 1) calculating the mean of all 6 arrays (3x OPG and 3x unstimulated). 
2) Standard deviation of all 6 arrays was calculated and finally 3) the mean of all 6 
arrays was subtracted from each data value before dividing by the SD of all 6 arrays 
((Data value-mean of all 6 arrays)/SD of all 6 arrays). 
 
2.10.7 DAVID (The Database for Annotation, Visualization and 
Integrated Discovery) Analysis of Agilent RNA Microarray 
Agilent Oligo IDs of genes regulated by OPG (Log2 Fold change >0.3 and p<0.05) 
were then analysed using DAVID functional annotation to generate fold enrichment 
pathway analysis through the Kegg Pathway Database. Intersections of ≥2 fold change 
and p≤0.05 were used for the pathway fold enrichment analysis. 
 
2.11 TaqMan® Real-time Quantitative Polymerase Chain 
Reaction 
In order to validate the RNA microarray and measure the RNA expression levels of 
identified targets in HPA-SMC lysates, real-time quantitative polymerase chain 
reaction (RT-qPCR) was performed. PCR is a technique that allows sequences within 
DNA, generated from a cDNA template, to be amplified thousands of times. The PCR 
product (amplicon) is then detected and quantified, often by post-PCR electrophoresis, 
after the last PCR cycle has been completed. RT-PCR however, allows the PCR 
product to be detected and quantified after the completion of each individual PCR 
cycle has been completed, in real time. RT-PCR therefore allows the starting amount 
of DNA to be theoretically calculated. Theoretically, there is a doubling of DNA with 
each PCR cycle and the DNA is amplified exponentially. However, the reaction 
eventually plateaus. In RT-PCR, fluorescent markers are incorporated into the DNA 
during each cycle; hence the fluorescence is proportional to the amount of amplicon 
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produced. Fluorescence is then plotted against cycle number to generate an 
amplification plot representing accumulation of amplicons over PCR duration. If a 
DNA sequence expression is abundant, amplification is detected in earlier cycles. 
However, if expression is low, amplification is detected in later cycles. 
 
Taqman RT-qPCR uses fluorescent probes as the fluorescent detection system. The 
Taqman probe contains a 5’ reporter dye, usually a FAM™ or VIC™ dye, covalently 
linked to a quencher dye, usually TAMRA™ or a non-fluorescent dye at the 3’ end. 
The proximity of the quencher dye to the report dye suppresses the fluorescence of the 
reporter dye. If the specific DNA target sequence is present, the probe anneals to the 
DNA between the forward and reverse primer sites. The AmpliTaq Gold® DNA 
polymerase, which exhibits 5’ to 3’ activity, then cleaves the probe between the report 
and quencher dye. The probe then displaces from the DNA target sequence, the 
cleaved reporter dye fluoresces and polymerization of the DNA sequence continues. 
The 3’ end of the probe is blocked and thus is not extended during the reaction. The 
fluorescence then accumulates exponentially as each PCR cycle is completed 
repeating the process above. 
 
2.11.1 HPA-SMC stimulation 
HPA-SMCs (P4-P7) were passaged into T25 cell culture flasks and grown until cells 
reached ~80% confluence. Cells were then synchronised as described in Chapter 2 
section 1.1.1.3. Growth arrest media was removed after 48 h and cells were stimulated 
with 0.2% v/v FBS (starve media) or rhOPG (50 ng/ml diluted in starve media) for 6 
hours at 37°C. Following stimulation, the media was removed and 500 μl TRIzol 
reagent was added directly to the T25 cell culture flasks. Flasks were then frozen at -
80°C until RNA was extracted. 
 
 
2.11.2 DirectZol RNA Extraction 
2.11.2.1  Preparation of DNase I Cocktail 
Before RNA extraction, all areas and equipment were cleaned with RNaseZap®. 
Immediately before RNA extraction, a DNase I cocktail was prepared by 
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reconstituting 250 units lyophilized DNase I in 250 μl DNase/RNase-free water. 5 μl 
(5 units) DNase I were then added to 8 μl 10X DNase I reaction buffer, 3 μl 
DNase/RNase-free Water and 64 μl RNA wash buffer in an RNase-free tube and 
mixed gently. 
 
2.11.2.2  RNA Extraction 
Immediately before RNA extraction, T25 cm2 cell culture flasks were defrosted on 
ice. 500 μl ethanol (96-100%) was then added directly to the cell homogenate and 
mixed well by pipetting. The mixture was the loaded into a Zymo-Spin™ IIC Column 
placed in a collection tube and centrifuged for 1 minute at 10,000 xg. The flow 
through was discarded and the Zymo-Spin™ IIC Column was transferred into a new 
collection tube. 400 μl RNA wash buffer was then added to the Zymo-Spin™ IIC 
Column, placed in a collection tube, and centrifuged for 1 minute at 10,000 xg. The 
Flow through was discarded. 80 μl of the DNase I cocktail was then added directly to 
the matrix of the Zymo-Spin™ IIC Column in a collection tube. The column was then 
incubated at 37°C for 15 minutes, then centrifuged at 10,000 xg for 30 seconds. 
 
400 μl Direct-Zol™ RNA pre-wash was then added to the column and centrifuged for 
1 minute at 10,000 xg and the flow through was discarded. 700 μl RNA wash buffer 
was then added to the column and centrifuged for 1 minute and the flow through 
discarded. The column wash the centrifuged for a further 2 minutes in an empty 
collection tube to ensure complete removal of the wash buffer. The column was then 
transferred carefully into an RNase-free tube. 50 μl of DNase/RNase water was the 
added directly to the column matrix and centrifuged at 14,000 xg for 1 minute. The 
concentration of the eluted RNA was then measured using the Nanodrop 1000 and 
then frozen immediately at -80°C until required. 
 
2.11.2.3 Nanodrop 1000 Spectrophotometer 
The concentration of RNA isolated from samples as described for each experiment 
was measured using the Nanodrop 1000 Spectrophotometer (ThermoScientific, United 
Kingdom). Prior to RNA measurement, all areas and equipment were cleaned with 
RNaseZap® and RNA samples were defrosted on ice. The pedestals of the Nanodrop 
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1000 were cleaned with a clean, lint-free tissue. The “Nucleic Acids” program on the 
Nanodrop software was launched and a 1 μl RNase-free water sample was loaded on 
the pedestal. Once the machine was calibrated, the machine was then blanked to 
RNase-free water that the RNA samples were suspended in. Once blanked, the 
pedestals were cleaned with a clean, lint-free tissue. 1 μl sample was then pipetted 
onto the pedestal and the RNA concentration was measured. The pedestals were then 
cleaned with a clean, lint-free tissue. This process was repeated for each sample, with 
the machine being re-blanked after every 15 samples. 
 
2.11.3 Reverse Transcription of Isolated RNA 
Before reverse transcription, all areas and equipment were cleaned with RNaseZap®. 
Complementary DNA (cDNA) was synthesized from RNA by reverse transcription 
using the Applied Biosystems High Capacity RNA-to-cDNA™ kit (4387406, 
Invitrogen, Life Technologies, Paisley, UK). In order to yield 2000 ng cDNA output, 
1000 ng RNA was added to each reaction. A total of 9 μl RNA was added to 10 μl 2X 
RT buffer and 1 μl 20X enzyme to ensure a total of 20 μl for each reaction. A control 
reaction containing no RNA and no enzyme was also prepared. The volume of RNA 
and RNase free-water required was calculated as follows: 
 
Volume RNA sample required (μl) = RNA sample concentration (μg/μl) / RNA input 
required (ng) 
 
Volume of RNase-free water required (μl) = 20 – (volume RNA sample required (μl) 
+ volume 2X RT buffer (μl) + volume 20X enzyme (μl). 
 
cDNA was then synthesized using the Applied Biosystems Verti 96 well thermocycler 
at 37°C for 60 minutes and 95°C for 5 minutes followed by incubation at 4°C. The 
cDNA was then stored at -20°C until required. 
 
2.11.4 TaqMan RT-qPCR Reaction Set-up 
Before Taqman RT-qPCR reactions were set up, all areas and equipment were cleaned 
with RNaseZap®. Taqman RT-qPCR reactions were set up in triplicate wells of a 
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384-well clear bottom plate. 50 ng cDNA was added to each appropriate well by 
diluting 20 μl cDNA previously synthesised in 180 μl RNase-free water and pipetting 
5 μl diluted cDNA into each well. 0.5 μl of 20x probe, 18S, ACVRL1, BMPR1A, 
CAV1, FAS, GAP43, IL1RAcP, PDGFRA, TGFBR1, TGFBR2, TMPRSS11D, TNC, 
TRAIL, VEGFA and VIPR1 (Appendix 7.1.11), was then added to each appropriate 
well. 4.5 μl Taqman Universal Mastermix was then added to each well. 
 
2.11.5 TaqMan 7900HT Fast Real Time PCR System Set-up 
The Taqman RT-qPCR was performed using the 7900HT Fast Real Time PCR 
System (Life Techologies), using the 9600 Emulation setting and 45 cycles. The 
thermal profile was used as follows for each cycle: 2 minutes at 50°C, 10 minutes at 
95°C, 15 seconds at 95°C and 1 minute at 60°C. 
 
Taqman validation was performed using cDNA generated from the nine individual 
unstimulated (0.2% v/v FBS) and OPG-stimulated samples used for the microarray 
and a further four unstimulated (0.2% v/v FBS) and OPG-stimulated HPA-SMC 
samples generated separately from the microarray samples. 
 
 
2.11.6 TaqMan data analysis 




2.12 Fas and TRAIL neutralisation to assess OPG-induced 
proliferation of HPA-SMC 
2.12.1 HPA-SMC Pre-Incubation with Antibodies 
HPA-SMCs were grown in fully supplemented media as described in Chapter 2 
Section 2.1.1.1, until ~80% confluent. Cells were then trypsinized and seeded into 96 
well plates at 5x104 cells/ml (200 µl/well). Three wells were left empty without any 
cells added to the wells, however media was added to the wells. Cells were left to 
adhere for 24 hours at 37°C (5% CO2) before cell cycles were synchronized for 48 h 
in growth arrest media as described in Chapter 2 Section 2.1.1.3. Cells were then 
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washed 3 times in PBS and incubated with Fas neutralising antibody (Mouse 
Monoclonal Fas Antibody (human, neutralising), clone ZB4, Millipore, Darmstadt, 
Germany)  (1500 ng/ml), TRAIL neutralising antibody (1500 ng/ml) or both Fas and 
TRAIL antibody (1500 ng/ml) diluted in growth arrest media, for 30 minutes (37°C, 
5% CO2).  
 
2.12.2 HPA-SMC Stimulation 
Following pre-incubation with antibodies, cells were stimulated with OPG (30 ng/ml), 
PDGF (20 ng/ml) or 0.2% v/v FBS in the presence or absence of Fas, TRAIL or both 
Fas and TRAIL antibodies for 72 h (37°C, 5% CO2). All stimulants and antibodies 
were added in triplicate wells and to a final volume of 200 µl in each well, diluted in 
growth arrest media. 
 
2.12.3 CellTiter-Glo® Measurement of HPA-SMC Proliferation 
The CellTiter Glo® assay is a luminescent cell viability assay that was used to 
perform a high-throughput cell proliferation assay. The assay principally uses the 
Luciferase enzyme to catalyse the oxidation of its chemical substrate, luciferin, using 
ATP as a co-substrate. After cell lysis, ATP is released from the cells, which the 
luciferase enzyme uses to catalyse luciferin oxidation to generate light. Therefore, the 
luminescence generated by luciferase is proportional to the amount of ATP, which is 
proportional to the number of cells. 
 
2.12.3.1  CellTiter-Glo® Assay 
Prior to performing the CellTiter-Glo® assay, the CellTiter-Glo® Buffer and 
CellTiter-Glo® substrate were equilibrated to room temperature before use. 10 ml 
CellTiter-Glo® buffer was added to CellTiter-Glo® substrate and mixed to form the 
CellTiter-Glo® Reagent. 100 µl of the CellTiter-Glo® reagent was then added 
directly to the 96 wells containing the stimulations, including the wells containing 
media only (background wells). The plate was then mixed for 2 minutes on a plate 
shaker to lyse the cells. The plate was then incubated for 10 minutes to allow the 
luminescence signal to stabilize, before reading the luminescent signal on a VarioSkan 
Flash (Thermo Scientific) plate reader. 
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2.13 Fas neutralisation to assess RNA expression in HPA-
SMCs 
HPA-SMCs were grown and synchronised in T25 cm2 cell culture flasks as previously 
described in Chapter 2, section 2.1.1. Cells were then incubated for 30 minutes with 
Fas neutralising antibody (Mouse Monoclonal Fas Antibody (human, neutralising), 
clone ZB4, Millipore, Darmstadt, Germany) (1500 ng/ml) in growth arrest media. 
Following pre-incubation with the Fas antibody, cells were stimulated with rhOPG 
(50 ng/ml) for 6 hours in the presence or absence of Fas neutralising antibody. The 
media was then removed and 500 µl Trizol solution was immediately added to each 
T25 cm2 cell culture flask. Flasks were then frozen at -80°C before extracting the 
RNA using the DirectZol RNA extraction kit (Chapter 2.11.2). Expression of TRAIL, 










As discussed in the introduction to this thesis (Chapter 1.7), OPG is a secreted 
glycoprotein that can exist as a 55-62 kDa monomer or a 110-120 kDa homodimer 
(Simonet et al. 1997; Zauli et al. 2009). Trimers of OPG have also been detected in 
nanoparticles at a molecular weight of 180 kDa (Schoppet et al. 2011). Interactions 
between OPG and several proteins have already been reported in the literature. OPG is 
perhaps best known for its role as a decoy receptor for RANKL and as a decoy 
receptor for TRAIL. By binding to TRAIL, OPG can prevent TRAIL-induced 
apoptosis of tumour cell lines (Cross et al., 2006) and by binding to RANKL, can 
block osteoclastogenesis (Yasuda et al. 1998; Hsu et al. 1999). However, in both 
cases, OPG has simply been shown to bind and prevent the interaction of RANKL and 
TRAIL with their receptors, to block signalling, rather than signalling itself.  
 
The ability of OPG to form homodimers has been found to influence the ability of 
OPG to bind to RANKL. OPG homodimers have been identified as having a higher 
affinity for binding RANKL than OPG monomers (Schneeweis et al. 2005) and 
although TRAIL trimers have been identified to bind to TRAIL receptor trimers, 
TRAIL trimers have been found to bind to only one OPG receptor molecule (Bosman 
et al. 2014). Therefore, the ratio to which OPG binds TRAIL and RANKL is different 
and the formation of OPG dimers and trimers may also influence the affinity to which 
OPG binds to different ligands. 
 
Although OPG is known to bind RANKL and TRAIL, it is possible that OPG may be 
binding to a different binding partner to induce the pathogenic phenotype in PA-
SMCs. Although both RANKL and TRAIL are expressed in patient lesions (Lawrie et 
al., 2008), current literature would suggest that OPG is binding to TRAIL and 
RANKL to block their respective signalling, rather than signalling through the OPG 
ligands, TRAIL and RANKL. 
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OPG also binds to syndecan-1 (SDC-1) (Standal et al. 2002; Mosheimer et al. 2005) 
and the OPG-SDC-1 interaction has been found to be important in monocyte 
migration (Mosheimer et al. 2005). However, SDC-1 was not detected within PAH 
patient lesions (Lawrie et al., 2008) suggesting that SDC-1 is not likely to be the 
receptor through which OPG induces the PA-SMC phenotype to contribute to disease 
pathology and induce disease in patients. 
 
OPG binding to von Willebrand Factor (vWF) and thrombospondin-1 (vWF 
reductase) has also been reported (Zannettino et al., 2005). vWF is a protein localised 
to Weibel Palade bodies (WPB) found exclusively in ECs (Zannettino et al. 2005), 
therefore, it seemed unlikely that the interaction with vWF would mediate an OPG 
response in PA-SMCs. Finally, Kobayashi-Sakamoto et al (2008) suggested an 
interaction between OPG and αvβ3 and αvβ5, after blockade of αvβ3 and αvβ5 was 
reported to reduce OPG-induced human microvascular EC (HMVEC) migration. 
However, the interaction between OPG and αvβ3 and αvβ5 was not confirmed and 
therefore remains to be determined.  
 
Interestingly, work by Yamaguchi et al (1998) has shown that domains 5 and 6 of 
OPG can induce cell apoptosis when included in a chimeric OPG-Fas protein 
consisting of the Fas transmembrane domain. OPG does not have a transmembrane 
domain and although domains 5 and 6 are structurally similar to the death domains 
belonging to Fas, overexpression of OPG did not induce cell apoptosis (Yamaguchi et 
al. 1998). These findings suggest that domains 5 and 6 of OPG have the potential to 
signal and induce apoptosis but may not in normal cell biology due to the absence o a 
transmembrane domain. However, these findings show the ability of OPG to induce 
phenotypic changes in cells when expressed as a chimeric protein with Fas. Fas, like 
TRAIL, belongs to the TNF superfamily and it would therefore be interesting to 
determine whether there may be an interaction between OPG and Fas that allows OPG 
to signal in PA-SMCs. 
 
After examining the reported OPG interactions, it seems that OPG may induce 
changes in PA-SMC phenotype by binding to different proteins than those mentioned 
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above. Therefore, I used an unbiased screening approach to identify potential OPG 
binding partners.  
 
3.2 Aims 
In order to gain more insight into how OPG induces changes in PA-SMC phenotype, I 
sought to identify human plasma membrane proteins expressed on PA-SMCs to which 
OPG binds to cause the proliferation of PA-SMCs. The three main aims of this 
chapter were to: 
 
1. Identify human plasma membrane proteins to which OPG binds by Retrogenix 
cell microarray. 
2. Confirm selected interactions between OPG and human membrane proteins in 
PA-SMC lysates using co-immunoprecipitation. 
3. Determine the expression of receptors in IPAH patient tissue (right ventricle 
and pulmonary artery) using immunohistochemical staining. 
 
3.3 Methods 
3.3.1 Retrogenix Cell Microarray 
The identification of OPG human protein binding partners was performed for OPG 
using the Retrogenix Cell Microarray (Sheffield, UK). Optimal binding conditions 
were first established using syndecan-1 (positive control) and TREM-1 (negative 
control).  HEK293 cells were reverse transfected with expression vectors consisting of 
one of 2505 (~60% of all known) human plasma membrane proteins and OPG binding 
was assessed (http://www.retrogenix.com/default.asp) (Chapter 2.4).  
 
3.3.2 TaqMan RT-qPCR 
RNA was extracted from 0.2% FBS-stimulated or OPG-stimulated (50 ng/ml) PA-
SMCs after 6-hour stimulation. Expression of Fas, IL1RAcP, GAP43 and 
TMPRSS11D mRNA in PA-SMCs was quantified by TaqMan RT-qPCR (Chapter 
2.11). Fas expression in IPAH patient PA-SMCs was analysed by TaqMan RT-qPCR 
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on RNA previously extracted, prior to me joining the Pulmonary Vascular Research 
group, as described by Hameed et al (2012). 
 
3.3.3 Co-Immunoprecipitation 
Co-immunoprecipitation was used to pull down OPG binding partners and confirm the 
interaction between OPG and the binding partners identified by the Retrogenix cell 
microarray. Co-immunoprecipitation was performed as described in Chapter 2.5.  
 
3.3.4 Immunohistochemistry 
Immunohistochemical analysis of pulmonary artery and right ventricle sections from 
donors with IPAH was performed by Ms Nadine Arnold, Pulmonary Vascular 
Research Group, Department of Cardiovascular Science, University of Sheffield, as 
described in Chapter 2.6. The sections were stained for OPG, Fas and IL1RAcP. 
 
3.3.5 Statistical Analysis 
All data are represented as mean ± SEM. Treatments were compared using Two-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. When 
comparing only two groups, an unpaired T-test was used. P<0.05 was deemed 
statistically significant. The n numbers refer to the number of separate experiments 














3.4.1 Identification of OPG Binding Partners 
As I discussed in the introduction to this chapter, although OPG has been reported to 
bind to several proteins, I believed that OPG might be binding to different proteins 
than those discussed in the introduction to induce PA-SMC proliferation. Therefore, I 
first aimed to identify human membrane proteins to which OPG binds. To do this, an 
unbiased Retogenix cell microarray was performed in order to identify interactions 
between OPG and ~60% of all know human plasma membrane proteins. 
 
Pre-screening of rhOPG and antibody concentrations was performed to determine 
optimum binding conditions of rhOPG and the anti-OPG antibody. Based on the pre-
screen, optimum conditions were determined to be 0.5 μg/ml rhOPG and 0.5 μg/ml 
anti-OPG antibody (Figure 3.1, condition 5). This condition showed successful 
binding of OPG to syndecan-1, with the lowest levels of background detected (2.1 
fold over the glass slide alone), in the absence of non-specific binding to TREM1. The 
other conditions tested generated high background and non-specific binding to 
TREM1 (Figure 3.1, conditions 1 and 4) or specific binding to syndecan-1 but with 
high background (Figure 3.1, condition 2). For the primary and confirmation screens, 













Figure 3.1- Pre-screen to determine background levels and binding. 
Pre-screen of rhOPG and anti-OPG antibody concentrations was conducted to 
determine optimum binding conditions of OPG and the anti-OPG antibody. 1) 2 µg/ml 
OPG and anti-OPG antibody generated binding to both syndecan-1 (positive) and 
TREM1 (non-specific binding to negative control). 2) Binding of OPG to syndecan-1 
was detected in the presence of 0.5 µg/ml OPG and 2 µg/ml anti-OPG antibody, 
however background levels detected were high. 3) Background generated in the 
presence of anti-OPG antibody only. 4) Binding of OPG to syndecan-1 in the 
presence of 2 µg/ml OPG and 0.5 µg/ml anti-OPG antibody was detected, however 
non-specific binding to the negative TREM1 control was detected. 5) 0.5 µg/ml OPG 
and 0.5 µg/ml anti-OPG antibody generated binding to syndecan-1 only with lower 
background levels that condition 2 (2.1 fold over glass slide alone). Based on the pre-
screen, optimum conditions were determined to be 0.5 μg/ml OPG and 0.5 μg/ml anti-
OPG antibody. Successful transfection of both SDC1 and TREM1 membrane proteins 






Results of the primary screen revealed an interaction between OPG and 16 human 




Table 3.1- List of Primary Hits  
In the primary screen, 2505 expression vectors, each encoding one full-length human 
membrane protein, were arrayed across 7 slides. Each slide was arrayed in duplicate 
and the slides were screened with 0.5 µg/ml OPG, followed by addition of 0.5 µg/ml 
anti-OPG primary antibody and secondary AlexaFluor647 rabbit anti-goat secondary 
antibody. A total of 16 hits, duplicate spots identified as a “hit” in one or both of the 
replicate slides, were identified and the intensity of the duplicate spots were quantified 
using the ImageQuant software (GE). 
Hit Number Gene Id Intensity of Duplicate Spots 
1 FCGR1A Weak/medium 
2 SLC13A3 Inverse 
3 TLR7/CDC42 Weak 
4 FGFR1 Weak 
5 GAP43 Very weak 
6 FCGR2B Medium 
7 CXCR7 Inverse 
8 TNFSF11 Strong 
9 TAAR9 Medium 
10 FAS Strong 
11 IL1RAcP Strong 
12 PTPRN/LYD6B Medium 
13 SDC1 Medium 
14 TMPRSS11D Medium 
15 FGF6 Diffuse 




Inverse hits, CXCR7 and SLC13A3, were visible as white spots caused by the 
fluorescence level detected being less than background levels. Binding of OPG to the 
FC-gamma receptors FCGR1A, FCGR2A and FCGR2A was also observed. FGF6 
was also identified as a diffuse hit.  
 
The identity of each vector for the 16 primary hits (Table 3.1) was confirmed by 
sequencing before proceeding to the confirmation screen. As identified in the primary 
screen, binding of OPG to the FC-gamma receptors was found to be present in all 
conditions, even in the negative controls where rhOPG or anti-OPG antibody had not 
been added to the cells (Table 3.2). These “hits” were therefore regarded as non-
specific and thus discounted. The inverse SLC13A3 hit and diffuse FGF6 binding was 
again observed in the confirmation screen (Table 3.2) and these “hits” were also 
discounted. After discounting the non-specific, inverse and diffuse hits, 6 confirmed 
interactions between OPG and syndecan-1 (SDC1), RANKL (TNFSF11), Growth 
Associated Protein 43 (GAP43), Fas, IL1-receptor accessory protein (IL1RAcP) and 
transmembrane protease, serine 11D (TMPRSS11D) (Table 3.2) were identified. 
Images of the spot intensities and binding controls for the 6 confirmed interactions 
described are represented visually in Figure 3.2. Successful transfection of all vectors 
was achieved for the confirmation screen and controls, shown by ZsGreen1 
fluorescence (Figure 3.3). 
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Table 3.2- Results of the Confirmation Screen.  
Each of the 16 hits identified in the primary screen were re-spotted and probed with 0.5 µg/ml OPG and 0.5 µg/ml anti-OPG antibody and 
AlexaFluor647 rabbit anti-goat secondary antibody. No rhOPG (anti-OPG primary antibody and AlexaFluor647 rabbit anti-goat secondary 
antibody) and no anti-OPG primary antibody (rhOPG and AlexaFluor647 rabbit anti-goat secondary antibody) negative controls were also 
included to determine non-specific binding of OPG and the anti-OPG primary antibody to the human membrane proteins. Binding to FC gamma 
receptors was present in all conditions, even in the negative controls where no OPG or anti-OPG primary antibody was added. SLC13A3 was 
identified as an inverse hit (white spots detected where fluorescence levels are less than background levels) and FGF6 was identified as a diffuse 
hit. 6 OPG specific hits were identified as GAP43, TNFSF11, Fas, IL1RAP, SDC1 and TMPRSS11D. Background levels detected in the presence 
of OPG, anti-OPG and secondary antibodies were classified as medium/high and low in the negative controls. 
 82 
 
Figure 3.2- Confirmation Screen Results.  
Left Panel: Binding to FCGR1A, SLC13A3, GAP43, FCGR2B, TNFSF11, Fas, 
IL1RAcP, SDC1, TMPRSS11D and FCGR2A was confirmed and fluorescence 
detected from the AlexaFluor647 secondary antibody is visible as black spots. The 
inverse hit, SLC13A3 is visible as white spots. Centre and right Panels: Binding to 
the FC-gamma receptors, FCGR1A, FCGR2B and FCGR2A, was detected in the 
negative controls: OPG + AlexaFLuor647 secondary (centre panel) and anti-OPG 









Figure 3.3- Retrogenix transfection confirmation (ZsGreen1 fluorescence). 
All vectors of hits identified in the primary screen were successfully transfected into 
HEK293 cells for the confirmation screen (Left panel) and two negative controls: 
OPG + AlexaFluor647 (no anti-OPG, Centre Panel) and Anti-OPG + AlexaFluor647 
(no OPG, Right Panel).  
 
 
The interactions between OPG and sydndecan-1 and RANKL were already known 
prior to the cell microarray. The Retrogenix cell microarray therefore identified 4 












3.4.2 Fas, IL1RAcP and Gap43 RNA Expression in PA-SMCs 
Because the putative OPG binding partners were identified by expressing human 
plasma membrane proteins on HEK293 cells, the next step was to determine whether 
they are expressed in PA-SMCs, the cells that proliferate in vitro following OPG 
stimulation.  
 
TMPRSS11D RNA was not expressed in quiesced or OPG-stimulated PA-SMCs (data 
not shown). Expression of Fas, IL1RAcP and GAP43 RNA was confirmed in 
quiesced and OPG-stimulated PA-SMCs (Figure 3.4). Fas RNA was most abundantly 
expressed in quiesced PA-SMCs (p<0.01) and OPG-stimulated PA-SMCs (p<0.001), 
compared to IL1RAcP and GAP43 RNA expression in quiesced and OPG-stimulated 
PA-SMCs, respectively. Fas expression was also significantly increased in response to 























Figure 3.4- FAS, IL1RAcP and GAP43 RNA expression levels in quiesced and 
OPG-stimulated PA-SMCs.  
Fas, IL1RAcP and GAP43 RNA is expressed in PA-SMCs. However Fas RNA 
expression was significantly higher than IL1RAcP and GAP43 PA-SMCs and Fas 
expression was significantly increased in OPG-simulated PA-SMCs, compared to 
unstimulated PA-SMCs. All data normalised using ΔΔCT with 18S rRNA as the 
endogenous control gene and normalising ΔCT to Fas expression. Bar graphs 
represent mean ± SEM. Ctrl= control, quiesced PA-SMCs. OPG= OPG-stimulated 
(50 ng/ml) PA-SMCs.* p<0.05, **p<0.01, ***p<0.001, n=4.  
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Based on these findings, the interaction between OPG and TMPRSS11D was not 
chosen at this stage for further investigation, because the absence of RNA suggests 
that TMPRSS11D is not expressed in PA-SMCs. Fas RNA expression was not only 
most abundant, but was OPG-responsive in PA-SMCs. Therefore, OPG binding to Fas 
was selected for validation. Although IL1RAcP expression levels were significantly 
lower than Fas, IL1RAcP was also selected for further validation because the IL-1 
signalling is already known to play a role in the pathogenesis of PAH and can increase 
the secretion of OPG (Humbert et al. 1995; Lawrie et al. 2008; Lawrie et al. 2011). 
 
3.4.3 Validating the Interaction of OPG with Endogenous Fas and 
IL1RAcP in PA-SMC Lysates 
Data from the Retrogenix cell microarray suggest that OPG interacts with Fas and 
IL1RAcP when these human membrane proteins are expressed on the surface of 
HEK293 cells. However, I could not conclude from these data that OPG interacts with 
these proteins in PA-SMCs, even though Fas and IL1RAcP RNA was detected in PA-
SMCs. I therefore wanted to determine whether OPG could interact with 
endogenously expressed Fas and IL1RAcP on PA-SMCs.  
 
Using co-immunoprecipitation, I was able to demonstrate that using an anti-Fas 
antibody to immunoprecipitate endogenous Fas also pulled down OPG from HPA-
SMC lysates.  This can be seen by a band in lane 2 at 50 kDa (Figure 3.5). OPG was 
also co-immunoprecipitated from an in vitro mixture of recombinant human Fas and 
recombinant human OPG, shown by a band in lane 3 at 50 kDa (Figure 3.5). 
Furthermore, no bands were detected at 50 kDa in the no antibody negative controls 
(Lanes 3 and 5, Figure 3.5). An anti-IL1RAcP antibody used to immunoprecipitate 
endogenous IL1RAcP from HPA-SMC lysates was also found to pull down OPG 
from HPA-SMC lysates, shown by a band at 50 kDa in lane 6 (Figure 3.5). OPG was 
also co-immunoprecipitated from an in vitro mixture of recombinant human IL1RAcP 
and recombinant human OPG, shown by a band in lane 8 at 50 kDa (Figure 3.5). 
Furthermore, no bands were detected at 50 kDa in the no antibody negative controls 




Figure 3.5- Co-immunoprecipitation of OPG from PA-SMC lysates and 
recombinant human proteins.  
Lanes 2-8: OPG was co-immunoprecipitated from HPA-SMC lysates and recombinant 
human proteins using Fas antibody or IL1RAcP antibody. Lane 1: Novex pre-stained 
protein standards. Lane 2: Fas antibody + HPA-SMC lysate- Fas antibody was found 
to pull down OPG from PA-SMC lysates, shown by a band at 50 kDa. Lane 3: No Fas 
antibody+ HPA-SMC lysate- No bands detected at 50 kDa in the negative control. 
Lane 4: Fas antibody + rhFas + rhOPG- Fas antibody was found to pull down OPG 
from an in vitro mixture of rhFas and rhOPG, shown by a band at 50 kDa. Lane 5: No 
Fas antibody+ rhFas + rhOPG- No bands detected at 50 kDa in the negative control. 
Lane 6: IL1RAcP antibody + HPA-SMC lysate- IL1RAcP antibody was found to pull 
down OPG from PA-SMC lysates, shown by a band at 50 kDa. Lane 7: No IL1RAcP 
antibody + HPA-SMC lysate- No bands detected at 50 kDa in the negative control. 
Lane 8: IL1RAcP antibody + rhIL1RAcP + rhOPG- IL1RAcP antibody was found to 
pull down OPG from an in vitro mixture of rhIL1RAcP and rhOPG, shown by a band 
at 50 kDa. Lane 9: No IL1RAcP antibody+ rhIL1RAcP + rhOPG- No bands detected 
at 50 kDa in the negative control. 
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3.4.4 OPG, Fas and IL1RAcP Expression in Human IPAH Tissues 
After validating the interaction between OPG and Fas and IL1RAcP in PA-SMCs, the 
next aim was to determine whether the binding partners were expressed in human 
tissues and whether this expression was altered in PAH patient tissue. 
 
Immunohistochemical analysis revealed that OPG was barely detectable in the control 
pulmonary artery, however diffuse medial and cellular OPG staining was observed in 
the IPAH pulmonary artery (Figure 3.6 A). Weak immunoreactivity was detected for 
Fas in the control pulmonary artery, however diffuse Fas staining was detected 
throughout the IPAH pulmonary artery (Figure 3.6 A). IL1RAcP immunoreactivity 
was barely detectable in the control pulmonary artery and although an increase in 
immunoreactivity was detected in the IPAH pulmonary artery, levels of IL1RAcP 
staining detected in the pulmonary artery was not as diffuse as OPG or Fas staining 
(Figure 3.6 A).    
 
Interesting, OPG and Fas immunoreactivity was detected in the right ventricle of both 
the control and IPAH sections (Figure 3.6 B). Although IL1RAcP immunoreactivity 
was also increased in right ventricle from patients with IPAH, IL1RAcP staining 
appeared to be less prominent than Fas protein expression in the IPAH sections 
(Figure 3.6 B). This staining shows that the potential OPG binding partners, Fas and 
IL1RAcP are expressed, along with OPG, in the pulmonary artery and right ventricle 
of IPAH patients. However, IL1RAcP immunoreactivity was weaker then both Fas 
and OPG staining in the control and IPAH pulmonary artery and right ventricle 







Figure 3.6- Immunohistochemical staining of Fas, IL1RAcP and OPG in the 
pulmonary artery and right ventricle. 
 Brown Fas, IL1RAcP and OPG staining visible in the pulmonary artery and right 





Because Fas RNA expression in PA-SMCs was the highest out of the four identified 
binding partners, and diffuse Fas immunostaining was observed, along with OPG, in 
the pulmonary artery and right ventricle of IPAH patients, Fas RNA expression was 
also measured in the PA-SMCs from IPAH patients. Fas RNA expression was found 
to be significantly higher in PA-SMCs from IPAH patients, compared to healthy, 
control PA-SMCs (Figure 3.7). Furthermore, previously published data by Condliffe 
et al (2012) has shown a significant increase in OPG mRNA expression in IPAH PA-
SMCs. Taken together, the increase in OPG mRNA and Fas mRNA supports the 
immunohistochemistry data and further shows that OPG and the potential OPG 





Figure 3.7- Fas RNA expression in IPAH patient lungs. 
Fas RNA expression is 3-fold higher in PA-SMCs isolated from IPAH patient lungs 
compared to Fas RNA levels in PA-SMCs isolated from healthy, control patient lungs. 
Bars represent mean ± SEM. Control= healthy PA-SMCs, IPAH= IPAH PA-SMCs. 










The aim of this chapter was to identify the human plasma membrane proteins to which 
OPG binds. Although OPG has previously been shown to bind to several proteins, 
including TRAIL, RANKL, SDC-1 and vWF, I felt that OPG was binding to an 
undescribed cell surface receptor, for reasons discussed in the introduction to this 
chapter. An unbiased cell microarray was therefore conducted to screen OPG binding 
to ~60% of all known human plasma membrane proteins. Four novel interactions 
between OPG and Fas, IL1RAcP, GAP43 and TMPRSS11D were identified by the 
cell microarray. Expression of TMPRSS11D RNA was not detected in PA-SMCs, 
however Fas RNA expression was found to be significantly higher than IL1RAcP and 
GAP43 RNA expression and was significantly increased by OPG stimulation. 
Therefore, the interaction between OPG and Fas was then confirmed in PA-SMCs. 
Although levels of IL1RAcP RNA were lower than Fas levels, the interaction between 
OPG and IL1RAcP was also confirmed in PA-SMCs because IL-1 signalling is 
known to play a role in PAH (Humbert et al. 1995; Lawrie et al. 2008; Lawrie et al. 
2011). Fas protein was identified, along with OPG, in the pulmonary artery and right 
ventricle of IPAH patients, however, only low levels of IL1RAcP was detected. Fas 
RNA levels were also significantly increased in PA-SMCs from IPAH patients. 
 
After reviewing the literature, it seems that Fas and IL1RAcP are the two proteins 
most likely to be acting as receptors for OPG, rather than GAP43 or TMPRSS11D. 
Firstly, GAP43 (neuromodulin, B-50, P-57, F1, pp46) is reported by the literature to 
be a neuron-specific protein, predominantly associated with nerve growth (Denny 
2006; Strittmatter et al. 1991). GAP-43 is synthesized on free ribosomes and is 
transported in vesicles to the plasma membrane (Denny 2006). GAP-43 is highly 
concentrated at the growth cone plasma membrane and is involved in filopodia 
formation, neurotransmitter release, endocytosis and synaptic vesicle recycling at the 
pre-synaptic membrane. Neuronal growth cones deficient in GAP-43 show reduced 
adhesion, spreading and branching (Denny 2006). Although GAP-43 levels decline in 
neurons after mature synapses have formed, GAP-43 persists at the synapses of the 
limbic system and neocortex and is also present in the adult retina and cornea. GAP-
43 appears to be nervous system specific and currently, there are no reports in the 
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literature of a role for GAP-43 outside of the nervous system. Although findings in 
this chapter show for the first time that GAP43 RNA is expressed in PA-SMCs, based 
on the literature, it seems unlikely that GAP43 is the OPG receptor responsible for the 
pathogenic phenotype in PA-SMCs. 
 
Secondly, TMPRSS11D (human airway trypsin-like protease, HAT) is a type-II 
transmembrane trypsin-like serine protease that was identified from the sputum of 
chronic airway disease patients (Yasuoka et al. 1997; C. Liu et al. 2013). Expression 
of TMPRSS11D has been found in cells of the submucosal serous glands located in 
the trachea and bronchi (Yasuoka et al. 1997) and bronchial ciliated endothelial cells 
(Takahashi et al. 2001). Literature suggests TMPRSS11D may function in normal 
airway epithelium (Takahashi et al. 2001) and may play a role in mucous secretion 
(Chokki et al. 2004). Interestingly, OPG levels are increased in the sputum of chronic 
obstructive pulmonary disease patients (To et al. 2011), however interaction between 
OPG and TMPRSS11D in the sputum of healthy individuals or COPD patients has not 
been investigated. Although other serine proteases, such as elastase, have been 
implicated in cardiovascular disease and are involved in pathogenic processes, such as 
atheromatous plaque formation, vascular damage, endothelial cell apoptosis and 
vascular SMC proliferation (Sharony et al. 2010), TMPRSS11D has not been 
implicated in such cardiovascular biological function or pathogenic processes.  
 
Although binding of OPG to GAP43 and TMPRSS11D was not further pursued at this 
stage, the interactions between OPG and these proteins will require further 
investigation in the future to fully understand the implications of these interactions on 
cell function. Although TMPRSS11D RNA expression was not detected in PA-SMCs, 
expression has not been analysed in endothelial cells or fibroblasts, two more cell 
types that play an important role in PAH pathogenesis. The interaction between OPG 
and TMPRSS11D may be important in other lung diseases such as COPD. However, 
the importance of the OPG-TMPRSS11D interaction and expression of TMPRSS11D 
RNA in PA-SMCs this has not been investigated because this is outside the scope of 
this thesis.  
  
The interaction between OPG and Fas and IL1RAcP was successfully confirmed in 
PA-SMCs. IL1RAcP belongs to the interleukin-1 (IL-1) receptor family, a subgroup 
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of the Toll-IL-1-receptors (TIR) (Boraschi & Tagliabue 2013). IL1RAcP is one of the 
ten members of the IL-1 receptor family and is a homologue of IL1R1. IL1RAcP acts 
a co-receptor for other IL-1 receptor family members and does not bind directly to 
ligands (Boraschi & Tagliabue 2013). IL1RAcP binds to IL-1R1 is required for IL-1 
signalling through IL-1R1 (Wesche et al. 1997). 
 
The ligand for the IL-1R1/IL1RAcP complex, IL-1 is a key player in inflammation, 
cytokine production, the immune response and inflammatory disorders (Boraschi & 
Tagliabue 2013; Vicenová et al. 2009). Many cell types constitutively express IL-1α 
and synthesis is stimulated by inflammation (Vicenová et al. 2009). IL-1β however, is 
not produced unless inflammatory signals are received and cleavage to the mature 
form by caspase-1 is carefully regulated. Macrophages are the main IL-1 producing 
cells, however neutrophils, lymphocytes, dendritic cells, keratinocytes, ECs, 
hepatocytes, fibroblasts and muscle cells have also been shown to produce IL-1 
(Vicenová et al. 2009).  
 
IL-1 plays an important role in PAH pathogenesis. Interactions between vascular cells 
and inflammation are important in vascular dysfunction and PAH pathogenesis. 
Inflammatory cytokines, including IL-1 and IL-6, are upregulated in PAH (Dorfmüller 
et al. 2002; Humbert et al. 1995; Sanchez et al. 2007; Perros, Dorfmüller, Souza, 
Durand-Gasselin, Godot, et al. 2007). Voelkel et al (1994) reported that the 
monocrotaline rat model of PAH is protected against disease development when 
treated with IL-1Ra, shown by a reduction in pulmonary artery blood pressure and 
right ventricular hypertrophy (Voelkel et al. 1994). ApoE-/- mice fed on a high fat 
Paigen diet develop PAH, however IL-1-/- mice were protected from PAH. 
Interestingly however, ApoE-/-/IL-1R1-/- mice developed a more severe PAH 
phenotype (Lawrie et al. 2011). It was reported that the ApoE-/-/IL-1R1-/- mice 
expressed a lung-specific alternative IL-1R1 receptor form that may contribute to a 
more severe disease phenotype (Lawrie et al. 2011).  
 
IL1RAcP can also form complexes with ST-2 (suppressor of tumourogenicity) 
(Palmer et al. 2008), to facilitate the binding of the ST-2 ligand, IL-33. ST-2 can exist 
as a membrane bound or soluble form (sST-2) and ST-2 is expressed by endothelial 
cells, myocytes and fibroblasts of the cardiovascular system (Shao et al. 2014). Both 
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ST-2 and its ligand, IL-33, have also been implicated in PAH. Patients with IPAH 
show elevated serum levels of soluble ST2 (sST-2) and elevated sST-2 levels also 
correlate with disease worsening (Zheng et al. 2014; Carlomagno et al. 2013). 
Conversely however, ST2-/- mouse pulmonary fibroblasts were shown to 
hyperproliferate to normoxia and hypoxia (Mahmood et al. 2010). 
 
Although increased ST-2 has been observed in PAH, no difference in IL-33 levels 
were found between patient or control sera (Carlomagno et al. 2013). However, IPAH 
ECs show a reduction in nuclear IL-33 expression and a 50% reduction in IL-33 
mRNA levels have been observed in IPAH lungs (Shao et al. 2014). IL-33 is 
considered to have a beneficial effect and displays anti-hypertrophy, anti-fibrosis 
actions and can reduce cardiac hypertrophy and fibrosis in mice (Carlomagno et al. 
2013; Shao et al. 2014). Furthermore, PAH patients with elevated sST-2 levels show 
an increase in myocardial fibrosis (Carlomagno et al. 2013). Therefore, it has been 
suggested that sST-2 acts as a decoy receptor for IL-33 and blocks the beneficial 
actions of IL-33.  
 
Because of the involvement of IL-1 in PAH, it would seem possible that OPG might 
bind to IL1RAcP protein on PA-SMCs and may be inducing pathogenic changes in 
the cells through this interaction. OPG may also be binding to IL1RAcP to facilitate 
the binding of ST-2 to IL-33, which may also have pathogenic effects on myocardial 
hypertrophy and fibrosis. The possible binding interactions between OPG, IL1RAcP 
and the interleukin receptors and ligand are shown in Figure 3.8. However, due to the 
fact that IL1RAcP is a co-receptor for other IL-1 receptors, I suspect that another 
receptor may be required to induce signalling events in PA-SMCs upon OPG binding 
to IL1RAcP. The possibility of another receptor and the interaction between OPG and 
IL1RAcP will however require further characterisation. Although the interaction 
between OPG and IL1RAcP was confirmed in PA-SMCs, PA-SMC IL1RAcP RNA 
levels and immunoreactivity in the pulmonary artery and right ventricle were lower 
than Fas RNA and immunoreactivity. This was surprising to find, however the low 
levels of IL1RAcP expression in the patient tissue may be due to an issue with the 
time at which the tissues were collected. The tissues that were stained were from 
patients with end-stage disease, by which time IL1RAcP expression may be reduced. 
IL1RAcP expression therefore needs to be assessed in tissues collected at an early 
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Figure 3.8-Schematic showing the interactions between IL1RAcP and OPG and the 
interleukin receptors, ST2 and IL1-R1.  
IL-1 binds to the IL1-R1 receptor and IL-33 binds to the ST-2 receptor. 
 
The fact that both OPG and Fas are so abundantly expressed in the right ventricle and 
pulmonary artery of IPAH patients suggests that Fas may indeed be a receptor for 
OPG that plays a role in disease. Fas (cluster of differentiation 95, CD95, APO-1, 
TNFRSF6) is a 45 kDa, type 1 membrane protein belonging to TNF receptor family 
and plays an important role in cell apoptosis (Serrao et al. 2001; Aggarwal et al. 1995; 
Hamann et al. 2000; Sata et al. 2000; Trauth et al. 1989; Yonehara et al. 1989). Fas 
consists of an N-terminal, containing 3 cysteine-rich domains (CRDs), a 
transmembrane domain and an intracellular region containing a death domain (Brint et 
al. 2013). The death domain (DD) is approximately 80 amino acids long and is 
responsible for transducing the apoptotic signal (Brint et al. 2013). Fas is 
constitutively expressed throughout various tissues of the body, including endothelial 
cells of the biliary tract, intestine, reproductive system, activated fibroblasts and 
osteoclasts (Leithäuser et al. 1993). The natural ligand for the Fas receptor is Fas 
ligand (FasL), a transmembrane protein (Brint et al. 2013), however expression of 
FasL is not ubiquitous and expression is restricted to haematopoetic cells and the 
immune privileged sites of the eye and testes (Brint et al. 2013). 
 
Fas induces apoptosis through either the extrinsic pathway, where pro-caspase-8 and 
the DISC complex act to amplify the signal, or through the intrinsic pathway, where 
mitochondria amplify the apoptotic signal (Scaffidi et al. 1998). Fas induces apoptosis 
of activated mature T cells, virally infected or cancer cells and immune cells which 
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enter immune privileged sites (Ashkenazi & Dixit 1998; Brint et al. 2013).  
 
Fas protein expression has been shown in human alveolar lung basal epithelial (A549) 
cells (Serrao et al. 2001), rabbit alveolar epithelium, macrophages and airway 
epithelium (Matute-Bello et al. 2001). HUVECs have also been shown to express Fas 
mRNA (Sata et al. 2000). The downstream apoptotic mediator of Fas, FADD (Fas-
associated protein with death domain), caspase-1 and caspase-3 are elevated in the 
lungs from patients with idiopathic pulmonary fibrosis (Maeyama et al. 2001). FasL is 
also expressed on HUVECs (Sata et al. 2000) and FasL induces apoptosis of a variety 
of different cell types, including rabbit type II (Matute-Bello et al. 2001) and mouse 
macrophage RAW cells (Lu et al. 2002).  
 
However, more specific to findings in this chapter, Fas mRNA and protein is 
expressed in vascular smooth muscle cells (Sata et al. 2000; Geng et al. 1997). 
Interestingly, Fas expression has been identified in the lipid core and fibrous caps of 
atherosclerotic plaques (Geng et al. 1997). Furthermore, apoptotic SMCs express Fas 
in atherosclerotic plaques (Geng et al. 1997). Although the role of Fas in apoptosis has 
been extensively reported, Fas has also been shown to induce the proliferation of 
normal human foreskin diploid fibroblasts (Aggarwal et al. 1995) and ligation has 
been shown to induce CD3 activated T-cell and naïve T-cell proliferation (Alderson et 
al. 1993). Fas also interacts with LC3B-II and caveolin-1 to mediate a dynamic switch 
between apoptosis and autophagy in lung epithelial cells (Tanaka et al. 2012). This is 
inertesting because autophagy has recently been implicated as an important process in 
PAH pathogenesis (Long et al. 2013; Lee et al. 2011). 
 
Although Fas has not been implicated in PAH, TRAIL, another member of the TNF 
superfamily, is also an important mediator PAH (Hameed et al. 2012). Having 
previously been reported to induce cancer cell apoptosis (Emery et al. 1998), TRAIL 
is now known to induce VSMC and PA-SMC proliferation and migration and TRAIL 
R1 and TRAIL R3 receptors are both significantly upregulated in IPAH PA-SMCs 
(Secchiero et al. 2004; Hameed et al. 2012). Taking into account the fact that Fas is 
expressed in PA-SMCs, both from healthy and IPAH donors, Fas is expressed along 
with OPG in IPAH patient sections and that TRAIL and the TRAIL receptors R1 and 
R3 are important in the pathogenesis of PAH, this all supports the possibility that 
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OPG binding to Fas may be mediating pathogenic changes in PA-SMCs. 
 
To summarise, the aim of this chapter was to identify potential binding partners for 
OPG on PA-SMCs. These data reveal for the first time, four novel interactions 
between OPG and GAP-43, TMPRSS11D, IL1RAcP and Fas receptor (Figure 3.9). 
However, it seems most likely that Fas may be acting as the binding partner for OPG 
in diseased PA-SMCs. The importance of the OPG-Fas interaction in mediating PA-
SMC phenotype will be investigated further in the following chapters. After 
identifying potential OPG binding partners, the proteins through which OPG is 
signalling and the genes that are transcribed as a result of OPG signalling in PA-
SMCs will be investigated in the next chapter. Several known downstream signalling 
proteins of TMPRSS11D, GAP43, IL1RAcP and Fas are also shown in Figure 3.9. In 
the next chapter, I will investigate whether OPG can induce changes in these, and 
many other intracellular proteins, and induce changes in gene expression, by using an 
unbiased screening approach. This will allow me to identify OPG-induced changes in 








Figure 3.9- OPG was found to bind 4 novel binding partners, Fas, IL1RAcP, Gap43 
and TMPRSS11D.  
Several proteins that signal downstream of TMPRSS11D (Orikawa et al. 2012; 
Matsushima et al. 2006), GAP43 (Strittmatter et al. 1991; Denny 2006), IL1RAcP 
(Boraschi & Tagliabue 2013) and Fas (Brint et al. 2013) are also shown, however 





4. IDENTIFICATION OF OPG REGULATED PROTEIN 
AND RNA EXPRESSION IN PULMONARY 
ARTERIAL SMOOTH MUSCLE CELLS 
 
4.1 Introduction 
The results in the previous chapter identified four potential novel binding partners for 
OPG, with Fas being the most likely candidate for the receptor to which OPG is 
binding to induce pathogenic changes in PA-SMCs. The aim of the work presented in 
this chapter was to examine the intracellular mechanisms that are activated as a result 
of OPG binding to the receptor on the cell surface. Firstly, the intermediate protein 
signalling that leads to gene transcription was investigated by assessing changes in the 
expression and activation of proteins in PA-SMCs. Secondly, the changes in gene 
expression induced by OPG in PA-SMCs was assessed. Exploring the changes in gene 
and protein expression and protein activation in OPG-stimulated cells will help build 
our understanding of how OPG is inducing pathogenic changes in PA-SMCs and 
potentially identify any targets that may offer therapeutic potential in the future. 
Furthermore, this will provide evidence as to whether OPG can alter the expression of 
proteins that signal downstream of the binding partners that were identified in Chapter 
3 (Figure 3.9), particularly the IL-1 and Fas-signalling pathways. This will provide 
more evidence as to whether the interactions between OPG and Fas and IL1RAcP are 
driving the phenotypic changes in PA-SMCs. 
 
OPG has been found to induce the phosphorylation of ERK1/2 in HMVEC 
(Kobayashi-Sakamoto et al. 2008) and ERK1/2, Akt and mTOR in endothelial-colony 
forming cells (Benslimane-Ahmim et al. 2011) but there have been no reports about 
changes in protein or gene expression induced by OPG in PA-SMCs. Therefore, an 
unbiased array approach was used, much like the cell microarray used in Chapter 3, to 




The first aim of this chapter was to determine OPG-induced changes in protein 
expression and activation in PA-SMCs and validate selected targets by in-cell western 
and traditional western blotting. The second aim was to identify OPG-induced 




4.3.1 Kinex Antibody Microarray 
In order to identify OPG-induced changes in protein phosphorylation and expression, 
a Kinex antibody microarray (Kinex, Canada) was performed on unstimulated and 
OPG-stimulated HPA-SMC lysates, at 10 minute and 60 minute time points, as 
previously described in chapter 2.7. Uniprot accession codes of proteins deemed 
significantly regulated by OPG (z-ratio of ± 1.5) were then analysed using DAVID 
functional annotation to generate fold enrichment pathway analysis through the Kegg 
Pathway Database. Intersections of ≥2 fold change and p≤0.05 were used for the 
pathway fold enrichment analysis (Chapter 2.7 and 2.8).  
 
4.3.2 In-Cell Western Assay (primary validation of the KAM) 
Results from the Kinex Antibody Microarray were validated using an In-Cell western 
assay, as previously described in chapter 2.9.1. HPA-SMCs (P4-P7) were stimulated 
with rhOPG (50 ng/ml) or 0.2% v/v FBS for 10 and 60 minutes. Cells were fixed and 
permeabilised before incubating with phospho-CDK2, phospho-CDK4, phospho-
HSP27 (S15), phospho-ERK1/2, phospho-PLCγ2 or phospho-AKT primary 
antibodies. Cells were then incubated with secondary antibodies and the nuclear 




4.3.3 Western Blotting (secondary validation of the KAM) 
Western blotting was performed on cell lysates stimulated with OPG (50 ng/ml) or 
0.2% v/v FBS (unstimulated) for 10 minutes and 60 minutes, as described in Chapter 
2.9.2. Membranes were incubated with phospho-CDK4, phospho-ERK1/2, phospho-
HSP27, CDK5, Daxx, phospho-mTOR, Atg13, Atg5, GL and FADD. Following 
secondary antibody incubation, membranes were washed and scanned using the LiCor 
Odyssey Sa system (Chapter 2.9.2).  
 
4.3.4 Agilent 8-plex single colour RNA microarray 
RNA was extracted from HPA-SMCs after 6 hour stimulation with OPG or 0.2% v/v 
FBS (negative). Agilent 8-plex, single colour human gene expression microarrays 
were then performed to analyse gene expression in HPA-SMCs. The data was 
background corrected and Log2 transformed using Bioconductor and Lima programs 
in the programming language R. Output files were then organised by removing 
duplicate probes and using the intersection of Log2 fold change >0.3 and p<0.05. A 
heat map was generated to show OPG-regulated genes that are associated with PAH 
(Appendix 7.5). Agilent Oligo IDs of genes regulated by OPG were then analysed 
using DAVID functional annotation to generate fold enrichment pathway analysis 
through the Kegg Pathway Database (Chapter 2.10).  
 
4.3.5 Real-time TaqMan qPCR Validation 
Taqman validation was performed on the RNA from the nine unstimulated RNA 
samples and nine OPG stimulated RNA samples used for the microarray, and a further 
four unstimulated (0.2% v/v FBS) and four OPG-stimulated HPA-SMC samples 
generated separately from the microarray samples. Taqman data was normalised using 
ΔΔCT, with 18S rRNA as the endogenous control (Chapter 2.11). 
 
4.3.6 Statistical analysis 
All data are represented as mean ± SEM. Treatments were compared using One-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. When 
comparing only two groups, an unpaired T-test was used. P<0.05 was deemed 
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statistically significant. The n numbers refer to the number of separate experiments 
performed and for each experiment performed, each condition was performed in 




4.4.1 Kinex Antibody Microarray 
Out of the 812 antibodies (262 phospho-specific and 550 pan-specific antibodies) 
screened in the Kinex antibody microarray (KAM), OPG was found to significantly 
up-regulate or down-regulate the expression or phosphorylation of 89 proteins (Table 
4.1). Of these 89 proteins, phosphorylation of 12 proteins and expression of 77 
proteins were significantly altered by OPG (Table 4.1). Alterations in protein 
expression and phosphorylation were observed at 10 minutes and 60 minutes, 
however for a number of proteins, these changes were found to persist between 10 
minutes and 60 minutes (Table 4.1). However, 89 proteins was a large number of 
proteins to validate and subsequently investigate in more detail. Therefore, further 
analysis of the protein list was paramount to interpolate the biological meaning of the 
proteins altered by OPG. To do this, the protein list was analysed using DAVID to 
look at the pathway fold enrichment.  
 
OPG was found to alter the expression and phosphorylation of proteins that function 
in a wide variety of signalling pathways, including p53, VEGF, apoptosis, Toll-like 
receptor, MAPK, chemokine signalling and focal adhesion (Figure 4.1), all of which 
are known to be involved in PAH pathogenesis. Interestingly, OPG altered the 
expression and activation of proteins belonging to a variety of cancer pathways, 
including non-small cell lung cancer, chronic myeloid leukaemia, bladder cancer, 
glioma, small cell lung cancer, pancreatic cancer, prostate cancer, endometrial cancer, 
acute myeloid leukaemia, colorectal cancer and melanoma. The fact that OPG altered 
proteins involved in cancer pathways is very interesting because PAH shares 













Figure 4.1- Pathway fold enrichment in OPG-stimulated HPA-SMCs.  
Fold enrichment of different pathways was calculated using DAVID. The fold 
enrichment of a certain pathway demonstrates how many fold were proteins of the 
pathway altered than would be expected by chance. Uniprot accession codes of 
proteins deemed significantly regulated by OPG (z-ratio of ± 1.5) were then analysed 
using DAVID functional annotation to generate fold enrichment pathway analysis 
through the Kegg Pathway Database. Intersections of ≥2 fold change and p≤0.05 
were used for the pathway fold enrichment analysis. 
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However, even after looking at the different pathways in which the proteins altered by 
OPG signalled in, I wanted to futher focus my attention on several proteins that I 
would go on to validate. Therefore, OPG-regulated protein expression at the two 
different time points, proteins that were significantly regulated by OPG at both 10 
minutes and 60 minutes (as shown in Table 4.1) were then presented as a heat map 
(Figure 4.2). This was done to allow for better visual interpretation of the results to 
select the proteins whose expression and phosphorylation was altered by OPG at 
different time points.  
 
Interestingly, OPG was found to increase the expression of cell cycle proteins Abl, c-
myc, chk2 and the cyclin dependent kinases CDK1, CDK2, CDK4, CDK5, CDK6, 
CDK7, CDK8 and CDK9 and alter the expression and phosphorylation of heat shock 
proteins HSP27, HSP70 and HSP90 (Table 4.1 and Figure 4.2). The ability of OPG to 
alter Abl was interesting because Imatinib, a small tyrosine kinase inhibitor used to 
treat the chronic myeloid leukaemia by targeting the BCR-ABL fusion protein 
(Ciarcia et al. 2012), has also been considered as a PH treatment.  
 
Furthermore, OPG was found to increase expression of the IL-1 signalling pathway 
kinase IRAK2 (Interleukin-1 receptor-associated kinase-like 2) and decreased 
expression Fas at 10 minutes and Daxx, a cytoplasmic protein that can interact with 
Fas and mediate Fas signalling, at 10 and 60 minutes. However, Fas expression was 
increased at 60 minutes (Table 4.1 and Figure 4.2). The finding that OPG was able to 
alter the expression of Fas and Daxx was of particular interest after finding that OPG 
was able to interact with Fas (previously discussed in Chapter 3). Interestingly, 
although the Z-score was not deemed significant, OPG was found to reduce the 








Figure 4.2- Heat map of KAM protein expression and phosphorylation.  
Kinex antibody microarray revealed OPG both positively and negatively regulates 
protein phosphorylation and total protein expression. Heat map shows Z-ratio of 





4.4.2 In-Cell Western Validation of OPG-induced Protein 
Expression and Phosphorylation 
To validate the KAM results, several protein targets were selected for validation by 
in-cell western assay. The proteins selected for validation based on KAM results and 
pathway analyses were phospho-CDK2, phospho-HSP27, phospho-PLCγ2, phospho-
Akt and ERK1/2. Targets were selected for validation based on Z-ratio, differential 
time-dependent regulation or involvement in pathways relevant to PAH disease 
pathogenesis and HPA-SMC phenotype. Although results of the KAM revealed a 
change in total CDK4 in response to OPG stimulation, phospho-CDK4, the activate 
form of CDK4, was also selected for analysis by the in-cell western. 
 
Signal quantification of the in-cell western assay revealed rhOPG significantly 
induced the phosphorylation of CDK4, HSP27 and ERK1/2 (Figure 4.3 B, D and F 
respectively). Compared to quiesced HPA-SMCs, rhOPG induced a 67% increase in 
CDK4 phosphorylation at 10 minutes (Figure 4.3 B) and a 90% increase in CDK4 
phosphorylation at 60 minutes (Figure 4.3 B). Signal quantification also revealed 
significant ERK1/2 phosphorylation in OPG-stimulated HPA-SMCs compared to 
quiesced HPA-SMCs. Compared to unstimulated, quiesced cells, OPG induced a 
182% increase in ERK1/2 phosphorylation at 10 minutes (Figure 4.3 F) and a 133% 
increase in ERK1/2 phosphorylation at 60 minutes (Figure 4.3 F). Additionally, 
rhOPG induced a 242% in HSP27 phosphorylation in HPA-SMCs at 10 minutes and a 
311% increase in HSP27 phosphorylation at 60 minutes compared to unstimulated, 
quiesced HPA-SMCs (Figure 4.3 D). OPG had no effect on phosphorylation of 








Figure 4.3- In cell western analysis of OPG-induced protein phosphorylation.  
Graphs A-G show the effect of OPG stimulation at 10 minute and 60 minute time 
points on A) CDK2, B) CDK4, C) Akt, D) HSP27, E) PLCγ2 and F) ERK1/2 in HPA-
SMCs, compared to unstimulated, quiesced control HPA-SMCs. OPG was found to 
significantly increase phosphorylation of B) CDK4, D) HSP27 and F) ERK1/2 at 10 
and 60 minutes compared to unstimulated, control cells.  Representative images are 
shown above the bar graphs. Un= unstimulated (quiesced) HPA-SMCs, 
B=Background wells, 10= 10 minutes, 60= 60 minutes. Error bars represent mean ± 
SEM. N=6 individual experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.4.3 Western blot validation of OPG-induced protein expression 
and phosphorylation 
4.4.3.1 Effect of OPG on ERK1/2 and HSP27 Phosphorylation 
The in-cell western assay is also a relatively high-throughput technique compared to 
traditional western blotting techniques. Therefore, the phosphorylation of proteins 
found to be significantly altered by OPG in the in-cell western assay were examined 
in OPG-stimulated HPA-SMCs using gold standard western blotting. OPG was found 
to induce a significant, almost 3-fold, increase in pERK1/2 at 10 minutes (p<0.0001) 
and a significant 2-fold increase at 60 minutes (p<0.001) in HPA-SMCs, compared to 
unstimulated cells (Figure 4.4 A). OPG however had no statistically significant effect 
on the levels of phospho-HSP27 expression after 10-minute or 60-minute stimulation 
(Figure 4.4 B). However, results show a trend towards increased HSP27 in HPA-
SMCs, which may require further repeats to achieve statistical significance. 
 
These data therefore support data from the in-cell western assay (Figure 4.3) showing 
that OPG significantly induced the phosphorylation of ERK1/2 at 10 and 60 minutes 





Figure 4.4- Western blot analysis of OPG-induced ERK1/2 and HPS27 protein 
phosphorylation in HPA-SMCs. 
Graphs A and B show the effect of OPG stimulation at 10 minute and 60 minute time 
points on A) ERK1/2 and B) HSP27 phosphorylation in HPA-SMCs compared to 
unstimulated, quiesced control cells. A) OPG significantly increased the 
phosphorylation of ERK1/2 at 10 minutes and 60 minutes compared to unstimulated 
cells. Phospho-ERK1/2 levels were normalised to total ERK1/2 loading controls. B) 
OPG did not have any significant effect on the phosphorylation of HSP27 in HPA-
SMCs. Phospho-HSP27 levels were normalised to β-actin loading controls. Relative 
band densities of pERK1/2 and pHSP27 are shown by the bar charts and 
representative western blot images shown above the graph. Un=Unstimulated cells, 
10= 10 minutes, 60= 60 minutes. Bars represent mean ± SEM, n=5-10. ***p<0.001, 
****p<0.0001. 











4.4.3.2 Effect of OPG on CDK4 Phosphorylation and CDK5 Expression 
Levels of CDK4 phopshorylation were also measured by western blotting, however, 
CDK4 phopshorylation was not found to be significantly altered by OPG at 10 
minutes or 60 minutes (Figure 4.5 A). However, results of the KAM revealed that the 
expression of another cyclin dependent kinase, CDK5, was found to be signifcantly 
increased by OPG (Table 4.1, Figure 4.2). CDK5 expression was found to be 
significantly increased by OPG after 60 minutes, compared to 10 minutes stimulation. 
However, when compared to unstimulated HPA-SMCs, there was no signifcant 
change in CDK5 protein levels detected in HPA-SMCs following 10-minute and 60-


























































Figure 4.5- Western blot analysis of OPG-induced CDK4 phosphorylation and 
CDK5 expression in HPA-SMCs.  
Graphs show the effect of OPG stimulation at 10 minute and 60 minute time points on 
A) CDK4 phosphorylation and B) CDK5 expression in HPA-SMCs compared to 
unstimulated cells. A) OPG was found to have no significant effect on CDK4 
phosphorylation at 10 minutes or 60 minutes. Phospho-CDK4 levels were normalised 
to β-actin loading controls. B) OPG significantly increased CDK5 expression at 60 
minutes, compared to 10-minute stimulation (p<0.05). CDK5 levels were normalised 
to β-actin loading controls. Relative band densities of pCDK4 and CDK5 are shown 
by the bar charts and representative western blot images shown above the graph. 
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Un=Unstimulated cells, 10= 10 minutes, 60= 60 minutes. Bars represent mean ± 
SEM, n=4-6. *p<0.05.  
 
So far, this chapter has focused on investigating the effects of OPG stimulation on the 
phosphorylation and expression of different proteins that are involved in anti-
apoptotic (phospho-HSP27, CDK5), pro-proliferative (phospho-ERK1/2) and pro-
survival (phospho-CDK4) pathways. However, my data shows that OPG can to bind 
to the Fas receptor on PA-SMCs (Chapter 3). I therefore wanted to investigate 
whether OPG had any effect on the expression or activation of proteins belonging to 
the Fas signalling pathway.  
 
4.4.3.3 Effect of OPG on Daxx and FADD Expression 
Upon FasL binding, the Fas receptor multimerizes on the cell membrane and 
complexes with another death domain-containing protein, FADD (Fas-associated 
death domain), to signal through the caspases to induce apoptosis (Mollinedo & 
Gajate 2006; Brint et al. 2013; Ouyang et al. 2012). However, Fas-induced apoptosis 
is not exclusively mediated through FADD and the caspases. Another protein, Daxx, 
also associates with Fas to facilitate Fas-induced apoptosis. 
Interestingly, results of the KAM revealed a significant reduction in Daxx expression, 
a protein known to associate with Fas to mediate apoptotic signalling in cells, after 60-
minute stimulation with OPG, which was accompanied by an increase in Fas 
expression at 60 minutes. Western blotting revealed that OPG had no significant effect 
on Daxx expression at 10 minutes or 60 minutes (Figure 4.6). PA-SMCs were also 
stimulated with OPG for 24 hours in an attempt to determine whether OPG could 
induce changes in Daxx protein expression at a later time point. However, even after 




Figure 4.6- Western blot analysis of OPG-induced Daxx expression in HPA-SMCs.  
Graph shows the effect of OPG stimulation at 10 minute, 60 minute and 24-hour time 
points on Daxx expression in HPA-SMCs compared to unstimulated, quiesced control 
cells. OPG had no significant effect on Daxx expression in HPA-SMCs. Daxx levels 
were normalised to the GAPDH loading control. Relative band densities of Daxx are 
shown by the bar charts and representative western blot images shown above the 
graph. Un=Unstimulated cells, 10= 10 minutes, 60= 60 minutes, 24h= 24 hours. 
Error bars represent mean ± SEM, n=3. 
 
However, in addition to the interaction with Daxx, Fas forms a complex with another 
death domain-containing protein, FADD (Fas-associated death domain), to induce 
apoptosis through the intrinsic and extrinsic apoptotic pathways (Mollinedo & Gajate 
2006). I therefore next sought to determine whether OPG could induce changes in 
FADD expression. However, western blotting revealed that OPG has no significant 
effect on FADD expression in PA-SMCs following 10-minute, 60-minute or 24-hour 
stimulation (Figure 4.7). I also analysed the expression of phospho-FADD in OPG-
stimulated cells, however no bands were detected for phospho-FADD (data not 
shown).  
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Figure 4.7- Western blot analysis of OPG-induced FADD expression in HPA-
SMCs. 
Graph shows the effect of OPG stimulation at 10 minute, 60 minute and 24-hour time 
points on FADD expression in HPA-SMCs compared to unstimulated, quiesced 
control cells. OPG had no significant effect on FADD expression in HPA-SMCs. 
FADD levels were normalised to the GAPDH loading control. Relative band densities 
of FADD are shown by the bar charts and representative western blot images shown 
above the graph. Un=Unstimulated cells, 10= 10 minutes, 60= 60 minutes, 24= 24 
hours. Error bars represent mean ± SEM, n=3. 
 
My data show that OPG has no significant effect on the expression of Daxx and 
FADD. Furthermore, phospho-FADD was not detected in PA-SMCs. These data 
suggest that the OPG-Fas interaction may not be signalling directly through 
components the Fas signalling pathway in PA-SMCs. However, cross-talk between 
Fas and the autophagy pathway has recently been reported (Chen et al. 2010; Zhang et 
al. 2011; Tanaka et al. 2012). I therefore decided to investigate whether OPG was 




4.4.3.4 Investigating the Effect of OPG on mTOR Phosphorylation, 
Atg13, Atg7 and GβL Expression in PA-SMCs 
The autophagy pathway is a pro-survival pathway, which may be activated by OPG in 
PA-SMCs via Fas. The autophagy proteins that I selected to investigate the expression 
of are highlighted in Figure 4.8 A (yellow and red stars). I chose to investigate 
whether OPG could significantly change the expression of phospho-mTOR because 
the KAM revealed a reduction in mTOR expression in PA-SMCs following OPG 
stimulation (Figure 4.8 A, red star), although this reduction was not statistically 
significant. However, based on this result, I began to speculate that OPG might be 
inducing changes in the autophagy signalling pathway. Along with phospho-mTOR, 
the autophagy inhibitor, I also chose to examine expression changes of proteins that 
function in different branches of the autophagy pathway that were not analysed by the 
KAM to determine whether OPG stimulation was inducing changes in autophagy 
proteins that form complexes with, or signal downstream, of mTOR (Figure 4.8 A, 
yellow stars).  
 
OPG was found to cause a significant difference in phospho-mTOR between 10 
minutes and 60 minutes stimulation (p<0.05, Figure 4.8 B). However, when compared 
to unstimulated HPA-SMCs, no significant change in phospho-mTOR was detected 
following OPG-stimulation at 10 minutes and 60 minutes (Figure 4.8 B). This 
suggests that OPG stimulation may cause a rapid reduction in mTOR activation to 
prevent autophagy inhibition and allow activation of downstream autophagy 
signalling, a response that recovers by 60 minutes. 
 
After finding that OPG could induce changes in phospho-mTOR, I then went on to 
determine whether OPG could induce changes in the protein GβL, which binds to 
mTOR to activate the kinase activity of mTOR, facilitate complex formation with 
other proteins and mediate the downstream signalling of mTOR (Kim et al. 2003). 
However, OPG was not found to induce any significant changes on GβL expression in 
PA-SMCs following 10-minute, 60-minute or 24-hour stimulation with OPG (Figure 
4.8 E). 
 
In order to determine whether the change observed in mTOR phosphorylation was 
indeed having downstream effects on the autophagy signalling pathway, the 
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expression of two important autophagy proteins, Atg7 and Atg13, was examined in 
OPG-stimulated HPA-SMCs. However, OPG did not induce any significant changes 
in Atg13 or Atg7 expression at 10 minutes, 60 minutes or 24 hours, compared to 




Figure 4.8- Western blot analysis of OPG-induced phospho-mTOR, Atg13 and Atg7 expression in HPA-SMCs.  
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A) Autophagy schematic showing the proteins selected for investigation using western blotting (yellow stars). Expression of mTOR (red star) was 
also shown by the KAM to be reduced by OPG stimulation and although this result was not statistically significant, mTOR was also selected for 
validation by western blotting. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). Bar graphs show the 
effect of OPG stimulation at 10 minute, 60 minute and 24-hour time points on B) phospho-mTOR, C) Atg13, D) Atg7 and E) GβL expression in 
HPA-SMCs compared to unstimulated, quiesced control cells. Relative band densities of phospho-mTOR, Atg13, Atg7 and GβL are shown by the 
bar charts and representative western blot images shown above the graph. Un=Unstimulated cells. Error bars represent mean ± SEM, n=3-6.
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Having failed to see a significant change in the expression of Atg7, I next wanted to 
determine whether OPG could induce changes in the expression of LC3B-II. This was 
because LC3B-II plays an important role in the formation of the autophagosome, a 
double membrane vesicle into which cell oragnelles are packed into for recycling 
during autophagy (Tanaka et al. 2012). LC3B-II is formed from the LC3 precursor, 
which is first processed by Atg4 to form LC3-I and then LC3-I is activated, to form 
LC3B-II by Atg7 and Atg3, through the addition of a phosphatidylethanolamine (PE) 
group (He & Klionsky 2009; Codogno et al. 2012). Therefore, despite not observing 
any changes in Atg7, I sought to establish whether OPG could alter the expression of 
LC3B-II, perhaps through a mechanism that was independent of Atg7. Unfortunately, 
no bands were detected for LC3B-II after analysing OPG-stimulated PA-SMC lysates 
by western blotting (data not shown). 
 
Data presented so far in this chapter suggest that OPG can alter the phosphorylation of 
CDK4, HSP27, ERK1/2 and mTOR and OPG can induce the expression of CDK5 in 
PA-SMCs. However, OPG was found to have no significant effect on the expression 
of Daxx and FADD, proteins belonging to the Fas signalling pathway, or the 
autophagy proteins Atg7, Atg13 and GβL. A summary of the validated changes in 
protein expression and phosphorylation that have been investigated in this chapter 













Table 4.2- Summary of the validated changes in protein expression and 
phosphorylation in PA-SMCs following OPG stimulation.  
Protein Pan-Specific /  
Phospho-specific 
OPG-induced changes in expression 
HSP27 Phospho-specific Significantly increased at 60 minutes (results of ICW). 
CDK4 Phospho-specific Significantly increased at 10 minutes and 60 minutes (results of 
ICW). 
CDK5 Pan-specific Significantly increased at 60 minutes (results of western blotting) 
Daxx Pan-specific No significant change 
FADD Pan-specific No significant change 
mTOR Phospho-specific Significantly increased at 60 minutes (results of western blotting) 
Atg13 Pan-specific No significant change 
Atg7 Pan-specific No significant change 
GβL Pan-specific No significant change 
ERK1/2 Phospho-specific Significantly increased at 10 minutes and 60 minutes (results of 
ICW and western blotting). 
 
After investigating the changes in protein expression and phosphorylation, the next 
aim of this chapter was to examine the changes in gene expression caused by OPG 
stimulation. To do this, an mRNA expression microarray was performed on 
unstimulated and OPG-stimulated cells to compare differences in gene expression 
between the two conditions. 
 
 
4.4.4 Microarray Analysis of OPG-induced Changes in Gene 
Expression in HPA-SMCs 
After conducting a microarray to investigate OPG-regulated changes in gene 
expression in HPA-SMCs, OPG was found to alter the expression of 1732 genes out 
of the 60,000 probes analysed. Such a large gene list is hard to analyse manually, 
therefore, the list was analysed using DAVID in order to identify pathways that the 
genes altered by OPG belonged too. OPG was found to regulate the expression of 
genes involved in several signalling pathways, including p53, ECM receptor 
interaction, TGF-β, focal adhesion, PPAR, the cell cycle and pathways in cancer 
(Figure 4.9). Interestingly, OPG was previously found to alter the expression and 
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phosphorylation of proteins belonging to the p53 pathway, focal adhesion pathway, 
cell cycle and pathways involved in cancer (discussed above), as well as altering the 




Figure 4.9- Pathway fold enrichment of genes in OPG-stimulated HPA-SMCs. 
Fold enrichment of different pathways was calculated using DAVID. The fold 
enrichment of a certain pathway demonstrates how many fold were proteins of the 
pathway altered than would be expected by chance. Agilent IDs of genes deemed 
significantly regulated by OPG (Log2 fold change of >0.4 and P<0.05) were analysed 
using DAVID functional annotation to generate fold enrichment pathway analysis 
through the Kegg Pathway Database. Intersections of ≥2 fold change and p≤0.05 
were used for the pathway fold enrichment analysis. OPG was found to alter the 
expression of genes in a number of different pathways, including the p53 signalling 
pathway, ECM-receptor interaction, focal adhesion, PPAR signalling pathway, cell 
cycle and pathways in cancer. 
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Although the pathway analysis allowed us to see which pathways the genes altered by 
OPG belonged to, such a large number of genes and pathways make it hard to 
pinpoint exactly which changes to gene expression are causing PA-SMCs to acquire a 
pathogenic phenotype. I next wanted to determine whether the gene list contained any 
genes that were already associated with PAH pathogenesis. Consequently, the list of 
1732 genes was compared to a list of genes already known to be involved in the 
pathogenesis of PAH (Appendix 7.5). OPG was found to positively and negatively 
regulate the expression of 57 (40%) genes already associated with the pathogenesis of 
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Figure 4.10- Heat map of PAH-associated genes regulated by OPG.  
When compared to unstimulated PA-SMCs, OPG was found to both positively and 
negatively regulate the expression of genes that have already been associated with 
PAH in PA-SMCs. Each column represents each of the three individual sub-arrays 
used to analyse 3 pooled RNA samples from each condition. Heat map shows Z-score 
ratio. 
 
After these findings that a number of PAH-associated genes were altered by OPG in 
PA-SMCs, several genes were subsequently selected for validation to ensure results of 




4.4.5 TaqMan Validation of the mRNA Microarray 
Ten genes of the 57 were selected for validation based on their known involvement in 
PAH pathogenesis (Appendix 7.5). The TGF signalling pathway is now widely 
acknowledged to play an important role in the pathogenesis of PAH. Mutations in the 
TGF superfamily have been identified as important genetic defects underpinning 
PAH. Mutations in ACVRL1 (ALK-1) have been identified in hereditary 
haemorrhagic telangiectasia (HTT)-associated PAH (Harrison et al. 2003) and 
TGFBR2 mutations have been identified in IPAH vascular lesions (Yeager et al. 
2001). Furthermore, the expression of BMPR1A (Du et al. 2003), TGFBR1 and 
TGFBR2 (Gore et al. 2014; Richter et al. 2004) are altered in IPAH patients. 
Therefore the TGF superfamily members ACVRL1, BMPR1A, TGFBR1 and 
TGFBR2 were selected for validation. TRAIL (Hameed et al. 2012), PDGFRA 
(Perros et al. 2008) and TNC (Jones et al. 1997; Ihida-Stansbury et al. 2006) are all 
known to play an important role in PAH and mRNA and protein expression of these 
pathogenic mediators are also increased within IPAH patients. Furthermore, VEGF 
levels are increased in the serum and SMCs from PAH patients (Selimovic et al. 2009; 
Hirose et al. 2000). Therefore, TRAIL, PDGFRA, TNC and VEGFA expression was 
selected for validation. Cav-1 and VIPR were also selected for validation because 
there is increasing evidence suggesting that an increase in Cav-1 is important for the 
pathogenesis of PAH (Mathew et al. 2004; Mathew 2011) and finally VIP serum 
concentrations are reduced in IPAH patients (Petkov et al. 2003). 
 
OPG was found to significantly increase the expression of TRAIL, PDGFRA, CAV-1, 
TNC and VEGFA in HPA-SMCs compared to unstimulated control cells (Figure 
4.11). These results validate the changes in gene expression observed in the 
microarray. OPG also significantly decreased the expression of VIPR, compared to 
unstimulated HPA-SMCs, and these data also validate the changes in VIPR observed 
by the microarray analysis.  
 
However, OPG had no significant effect on BMPR1A, TGFBR1, TGFBR2 or 
ACVRL1 expression (Figure 4.11). These data do not support the results of the 
microarray, which instead shows a reduction in BMPR1, ACVRL1 and TGFRB1 and 
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Figure 4.11- TaqMan analysis of RNA expression in HPA-SMCs.  
Bar graphs show Taqman RT-qPCR validation of (A) TRAIL, (B) PDGFRA, (C) Cav-1, (D) TNC, (E) VEGFA, (F) VIPR, (G) ACVRL1, (H) 
BMPR1A, (I) TGFBR1 and (J) TGFBR2 RNA expression in OPG- stimulated PA-SMCs. All data are normalised using ΔΔCT with 18S rRNA as 




Following the identification of potential binding partners for OPG in Chapter 3, this 
fourth chapter aimed to explore the intracellular signalling mechanisms through which 
OPG signals to induce pathogenic changes in PA-SMCs. In this chapter, I aimed to 
answer two questions, 1) which intermediate proteins is OPG signalling through to 
induce downstream mRNA transcription? and 2) which genes are transcribed as a 
result of OPG signalling in PA-SMCs? To do this, changes in protein phosphorylation 
and gene and protein expression were examined in OPG-stimulated PA-SMCs. 
 
Results of the Kinex antibody microarray, undertaken to analyse protein 
phosphorylation, revealed that OPG both positively and negatively regulated the 
expression and activation of 89 proteins in PA-SMCs (Table 4.1). Pathway analysis 
revealed fold enrichment of a number of signalling pathways including p53, VEGF, 
apoptosis, Toll-like receptor, MAPK, chemokine signalling and focal adhesion 
(Figure 4.1). Interestingly, OPG was found to alter the expression and activation of 
proteins involved in cancer (Figure 4.1), which shares some similarities with PAH 
pathogenesis, such as abnormal and uncontrolled cell growth, migration and apoptosis 
evasion (Rai et al. 2008). OPG was found to induce the phosphorylation of the cyclin 
dependent kinases CDK4 and CDK5, along with the ERK1/2 and HPS27 and also to 
alter phosphorylation of the autophagy inhibitor mTOR. Microarray analysis revealed 
that OPG altered the expression of 1732 genes in PA-SMCs and pathway analysis 
showed the genes altered belonged 27 different signalling pathways. OPG was found 
to regulate the expression of 57 PAH-associated genes (Figure 4.10), including 
TRAIL, PDGFRA, CAV-1, TNC, VEGF and VIPR (Figure 4.11). These data 
highlight the diverse effects OPG has on gene expression in PA-SMCs and reveal that 
OPG can modulate the expression of genes belonging to many different signalling 
pathways.  
 
My data show OPG interacts with Fas (Chapter 3), so I next looked at whether OPG 
could alter the expression of FADD and Daxx, which are proteins belonging to the Fas 
signalling pathway. Although expression of Daxx was reduced in the KAM, 
expression remained unchanged in the western blot analysis of OPG-stimulated PA-
SMCs. Furthermore, OPG did not induce any significant change in FADD expression 
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in PA-SMCs. This suggests that the signalling mechanisms employed by OPG may 
not be occurring through the Fas signalling pathway. Instead, the data in this chapter 
suggest that OPG activates an atypical network of pro-proliferative, pro-survival and 
anti-apoptotic proteins in PA-SMCs. 
 
4.5.1 The Effects of OPG on PA-SMC Proliferation 
Data in this chapter revealed an increase in the expression of proteins and genes that 
are involved in pro-proliferative pathways. OPG was found to increase CDK4 
phosphorylation in PA-SMCs. CDK4 is a cell cycle protein that, when complexed 
with at least one of the three D-type cyclins, D1, D2 and D3 and phosphorylated in the 
activation loop, can phosphorylate pRb and subsequently allow S-phase gene 
transcription and cell cycle progression (Meloche & Pouysségur 2007; Hirai et al. 
1995; Lukas et al. 1996). CDK4 activity and expression is increased in proliferating 
PA-SMCs (Ibe et al. 2008). Furthermore, CDK4 expression is reduced in HPA-SMCs 
where PDGF-induced proliferation is inhibited (G. Liu et al. 2013). Furthermore, 
ERK1/2 is required for the expression of the CDK4 activator, cyclin-D1 (Lavoie et al. 
1996).  
 
It is well known that ERK1/2 is important in SMC proliferation and migration. In 
proliferating SMCs, including PA-SMCs, ERK1/2 expression and phosphorylation is 
increased (G.-W. Li et al. 2011; Jia et al. 2012; Wilden et al. 1998; Yoshizumi et al. 
1998; Kingsley et al. 2002) and ERK1/2 blockade reduces viability of PA-SMCs 
(Song et al. 2013). Furthermore, ERK1/2 expression is required for PDGF-BB-
induced migration of VSMCs and has been implicated in ET-1 induced PA-SMC 
migration (Kingsley et al. 2002; Meoli & White 2010). Phospho-ERK1/2 also 
mediates TRAIL-induced PA-SMC proliferation and migration (Hameed et al. 2012). 
In my data, not only was OPG found to induce ERK1/2 phosphorylation in PA-SMCs, 
but OPG also increased TRAIL RNA expression in PA-SMCs and TRAIL has also 
been shown to induce PA-SMC proliferation through ERK1/2 phosphorylation 
(Hameed et al., 2012).  
 
TRAIL protein expression, along with OPG expression, has been previously observed 
in concentric and plexiform lesions of IPAH patients and TRAIL RNA expression is 
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elevated in IPAH PA-SMCs (Hameed et al. 2012; Lawrie et al. 2008).  TRAIL can 
also induce the proliferation and migration of VSMCs and PA-SMCs in vitro, a 
process that is mediated by ERK1/2 phosphorylation (Secchiero et al. 2004; Hameed 
et al. 2012). The OPG-induced increase in TRAIL gene expression in PA-SMCs 
suggests that, since TRAIL protein expression correlates with the changes seen in 
mRNA expression (Hameed et al. 2012), TRAIL may also be contributing to PA-
SMC proliferation. I propose that TRAIL-induced PA-SMC proliferation may be 
occurring through an ERK1/2-dependent mechanism. In support of this, the TRAIL 
receptors, TRAIL R1 and R3 are also significantly upregulated in IPAH PA-SMCs 
(Hameed et al. 2012), therefore TRAIL may be causing this increase in phospho-
ERK1/2 by binding to TRAIL R1 and R3. Thus, OPG may be directly activating 
pERK1/2 to induce PA-SMC proliferation, whilst also causing indirect proliferation 
through an increase in TRAIL expression and TRAIL-induced ERK1/2 
phosphorylation.  
 
I therefore propose that OPG is inducing PA-SMC proliferation through the activation 
of CDK4 and ERK1/2 and that the increase in TRAIL RNA expression caused by 
OPG might also be potentiating the pro-proliferative effect TRAIL has on PA-SMCs. 


















Figure 4.12- OPG induces the phosphorylation of CDK4 and ERK1/2 in PA-SMCs.  
Activation of CDK4 and ERK1/2 may subsequently lead to the proliferation of PA-
SMCs as both CDK4 and ERK1/2 activity has been identified in proliferating PA-
SMCs (Ibe et al. 2008; G.-W. Li et al. 2011; Jia et al. 2012; Wilden et al. 1998; 
Yoshizumi et al. 1998; Kingsley et al. 2002). Phospho-ERK1/2 may also activate 
cyclin D (Lavoie et al. 1996), to result in further activation of CDK4 in PA-SMCs. 
OPG induces RNA expression of it’s ligand, TRAIL and TRAIL has also been shown 
to induce PA-SMC proliferation through ERK1/2 (Hameed et al., 2012). 
 
My data also suggest a role for the PDGF signalling pathway in OPG-induced PA-
SMC proliferation as OPG increased PDGFRA mRNA expression. PDGFRA is a 
receptor tyrosine kinase that acts as a receptor, along with PDGFRB, for PDGF. 
PDGF can induce the proliferation and migration of PA-SMCs (Yu et al. 2003) and 
plays an important role in the pathogenesis of PAH, as evidenced by the mechanistic 
action of Imatinib, a drug previously approved for PAH treatment. Imatinib is a 
tyrosine kinase inhibitor that inhibits PDGF-induced PA-SMC proliferation and 
PDGFRA and PDGFRB receptor phosphorylation (Pankey et al. 2013).  
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PDGFRA mRNA expression is elevated in the small PAs from patients with severe 
PAH and protein expression is increased in proliferating SMCs of pulmonary vascular 
lesions (Perros et al. 2008). Interestingly, PDGF has also been shown to induce OPG 
mRNA expression and OPG protein secretion from human aortic SMCs (Zhang et al. 
2002). It would be interesting to investigate whether PDGF induces an increase in 
OPG expression and release from PA-SMCs because if this is the case, there may be a 
feedback loop occurring between OPG and PDGF in PA-SMCs. The role I propose 
the PDGF signalling pathway plays in OPG-induced PA-SMC proliferation is shown 
below in Figure 4.13. 
 
 
Figure 4.13- OPG induces the expression of PDGFRA RNA.  
PDGF has been shown to induce the proliferation of PA-SMCs (Yu et al. 2003) and 
can induce OPG mRNA expression and secretion (Zhang et al. 2002). Therefore, there 
may be the possibility of a positive feedback loop existing between OPG and PDGF in 
PA-SMCs. 
 131 
OPG was found to increase mRNA expression of TNC and Cav-1, both of which have 
been associated with PA-SMC proliferation. TNC is an extracellular matrix 
glycoprotein that can interact with a variety of receptors to induce a variety of 
different signalling pathways. Increased TNC expression is observed animal models 
of PAH (Jones et al. 2002; Jones & Rabinovitch 1996; Ivy et al. 2005), in the 
adventitia and media of PAs and neointima of children with congenital heart disease 
and PAH (Jones et al. 1997) and in the occlusive vascular lesions and wall of 
remodelled PAs of FPAH patients, including those harbouring BMPR2 mutations 
(Ihida-Stansbury et al. 2006). TNC also promotes VSMC growth (Jones & 
Rabinovitch 1996) and co-localises with proliferating SMCs (Jones & Rabinovitch 
1996; Ivy et al. 2005).  
 
Caveolin-1 is an important component of caveolae, membrane invaginations that are 
abundant in cell surface receptors, critical for cellular signalling cascades (Soubrier et 
al. 2013). Although mutations in the CAV1 gene have been identified in PAH patients 
(Austin et al. 2012), discussed in Chapter 2, there are still conflicting reports in the 
literature surrounding the role of Cav-1 in PAH. Cav-1 expression is reduced in the 
hypoxic, MCT and SuHx models of PAH (Zhao et al. 2002; Bauer et al. 2012; Achcar 
et al. 2006) and reduced Cav-1 has been reported in vascular lesions of PAH patients 
(Achcar et al. 2006). However, there are some conflicting reports that show Cav-1 
expression is elevated in the SMC layer of pulmonary vessels from human IPAH lung 
sections (Patel et al. 2007). Additionally, Cav-1 mRNA is increased in PA-SMCs 
from IPAH patients and proliferation of PA-SMCs overexpressing Cav-1 is elevated, 
whereas Cav-1 inhibition in IPAH-PA-SMCs reduced proliferation of these cells 
(Patel et al. 2007). Literature now suggests that compartmentalisation of Cav-1 is 
important in PAH and it is the reduction in PA-EC Cav-1 and increase in PA-SMC 
Cav-1 expression that is important in PAH pathogenesis (Mathew, 2011; Mathew et 
al., 2004; Y. Zhao et al., 2009; Huang et al., 2012), with increased SMC Cav-1 been 
described in animal models and patients with PAH (Mathew, 2011; Huang et al., 
2012). I therefore hypothesise that the increase in Cav-1 and TNC expression that is 





Figure 4.14- Cav-1 and TNC induce PA-SMC growth and proliferation (Jones & 
Rabinovitch 1996; Ivy et al. 2005).  
OPG increased both CAV1 and TNC gene expression in PA-SMCs, therefore, Cav-1 




In addition to the pro-proliferative pathways discussed above, phosphorylation of 
HSP27 suggests that OPG is also activating anti-apoptotic pathways in HPA-SMCs. 
Historically, the induction of evolutionarily conserved heat shock proteins in response 
to stress has been shown to protect cells and this correlates with increased tolerance to 
stressful conditions (Samali & Cotter 1996). HSP27 has a number of protective roles 
in cells in response to heat, oxidative and mechanical stress and when phosphorylated, 
acts as an inhibitor of apoptosis by retaining cytochrome C9 to block the intrinsic 
apoptotic pathway (Ghayour-Mobarhan et al. 2012). Interestingly, dimers of 
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phosphorylated HSP27 have been shown to interact with Daxx to block Fas-induced 
apoptosis (Charette & Landry 2000; Charette et al. 2000). Upon Fas activation, Daxx 
translocates from the nucleus to the cytoplasm where Daxx then activates Ask1 to 
induce apoptosis. However, HSP27 is though to block this translocation, maintaining 
Daxx localisation to the nucleus and blocking apoptosis (Charette & Landry 2000; 
Charette et al. 2000). This suggests that OPG may be blocking Fas-induced apoptosis 
through the Daxx-dependent pathway by inducing the phosphorylation of HSP27. 
This may also explain why no change in Daxx expression was detected if the 
mechanism by which HSP27 blocks Daxx-mediated apoptosis is through inhibiting 
Daxx translocation to the cytoplasm, rather than altering expression of Daxx. 
 
In support of HSP27 being an important mediator, HPS27 expression has been 
observed in the ECs and SMCs of pulmonary arteries of congenital heart disease 
patients with pulmonary hypertension, and HSP27 expression was most prominent in 
the ECs and SMCs of pulmonary arteries that showed medial hypertrophy and 
proliferation (Geiger et al. 2009). Furthermore, HSP27 was detectable in the 
concentric and plexiform lesions of pulmonary arteries (Geiger et al. 2009). 
Interestingly, treating human retinal endothelial cells with a mixture of cytokines, 
interferon-γ, TNFα and IL-1 inhibit HSP27 expression, which correlated with an 
increase in cell apoptosis. Interferon-γ, TNFα and IL-1β are all increased in patients 
with pulmonary hypertension (Humbert et al. 1995; Feinberg et al. 1999; George et al. 
2014). This raises the question as to whether the increase in inflammatory cytokines 
observed in PAH may act to reduce HSP27 expression and contribute the initial 
endothelial cell apoptosis commonly observed in PAH pathogenesis. Conversely, the 
increase in HSP27 observed in plexiform lesions, a hallmark of late stage disease, may 
contribute to the proliferation of endothelial cells in later stages of the disease (Geiger 
et al. 2009). Therefore, the OPG-induced increase in HSP27 observed in SMCs may 
act to promote SMC survival by protecting cells against apoptosis.  
 
OPG was also found to induce the expression of another cyclin-dependent kinase, 
CDK5. Although a member of the cyclin-dependent kinase family, CDK5 plays no 
evident role in the cell cycle (Arif 2012). Expression of CDK5 and its activators were 
originally thought to be restricted to neurons (Xie & Tsai 2004). However, the 
functions of CDK5 are now known to extend beyond the nervous system and there is 
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increasing evidence to support an anti-apoptotic role for CDK5. CDK5 has been 
reported to bind to cyclin-I in mouse podocytes and neurons (Brinkkoetter et al. 
2009). CDK5 inhibition increases the susceptibility of podocytes to apoptosis in vitro 
and inhibition of CDK5 and cyclin-I knockout both cause a reduction in the anti-
apoptotic proteins Bcl-2 and Bcl-XL, as well as a redcution in pERK1/2 (Brinkkoetter 
et al. 2009). CDK5 has also been shown to directly phosphorylate Bcl-2 (Cheung et al. 
2008). These data therefore suggest a pro-survival, anti-apoptotic role for CDK5, and 
its activator cyclin-I. 
 
In support of this, CDK5 has also been implicated in cell proliferation, with CDK5 
expression identified in proliferating bovine aortic endothelial cells and low levels of 
CDK5 have been detected in quiesced cells (Sharma et al. 2004). Interestingly, basic 
fibroblast growth factor (bFGF), shown to be increased in PAH patients and the MCT-
rat model of PAH (Arcot et al. 1995; Benisty et al. 2004), induces CDK5 expression 
and inhibition of CDK5 causes the inhibition of bFGF-induced cell proliferation 
(Sharma et al. 2004). Inhibition of cell proliferation by angiotensin also causes a 
reduction in CDK5 expression (Sharma et al. 2004). I propose that the combination of 
increased HSP27 activation and CDK5 expression might be preventing PA-SMC 
apoptosis, hence promoting PA-SMC survival, as well as inducing PA-SMC 







Figure 4.15- OPG induces the phosphorylation of HSP27.  
Phospho-HSP27 is an inhibitor of apoptosis (Ghayour-Mobarhan et al., 2012) and 
might therefore inhibiting PA-SMC apoptosis. Furthermore, phsopho-HSP27 has 
been shown to block the translocation of Daxx to prevent Fas-induced apoptosis 
(Charette & Landry 2000; Charette et al. 2000) and so might also be preventing Fas-
induced apoptosis of PA-SMCs. 
 
 
OPG was found to induce changes in phosphorylation of the autophagy inhibitor, 
mTOR. Autophagy has also been investigated as a potential mediator in PAH 
pathogenesis, however the exact role autophagy plays in PAH development still 
remains ambiguous. Increased levels of the autophagy marker, LC3B, have been 
reported in the lungs of PH patients and LC3B expression is increased in PA-ECs and 
PA-SMCs exposed to hypoxia, in vitro, suggesting autophagy contributes to PAH 
(Lee et al. 2011). However, LC3B knockout caused an increase in SMC proliferation 
and exaggerated disease in hypoxic mice, which on the contrary, suggests a protective 
role for autophagy in PAH (Lee et al. 2011). Furthermore, similar contradictory 
findings for the role of the autophagy protein, ATG5, have also been reported. ATG5 
expression is increased within the heart of mice after haemodynamic stress, however 
ATG5 knockout actually causes more rapid heart failure in response to haemodynamic 
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stress (Nakai et al. 2007). However, a recent report by Long et al (2013) suggests a 
more definitive and pathogenic role for autophagy in PAH. Increased levels of 
LC3BII and ATG5 are observed in the MCT rat model of PAH and Chloroquine, an 
inhibitor of disease development, was shown to reduce autophagy (Long et al. 2013).  
 
In my data, although OPG was found to cause a significant increase in phospho-
mTOR levels at 60 minutes, compared to 10 minutes of stimulation, there were no 
changes detected in the autophagy proteins |GβL, ATG7 or ATG13. Levels of LC3B 
were also assessed in OPG-stimulated PA-SMC lysates after 10 minutes, 60 minutes 
and 24-hour of stimulation with OPG. No bands were detected by western blotting, 
even after attempting to optimise the western blotting process by using different 
antibody concentrations and amounts of protein loaded onto the gels. This may be due 
cells requiring longer stimulation with OPG, for example 48-hour or 72-hour 
stimulation, before changes in LC3B-II expression are observed. The LC3B-II 
antibody has been used successfully in several research papers (Chertov et al. 2011; 
Gao et al. 2011; Ouyang et al. 2012) and LC3B expression has been described in PA-
SMCs (Lee et al. 2011). Therefore, I propose that the reason LC3B-II was not 
detected might have been due to the duration of OPG stimulation, rather than the 
antibody not successfully detecting LC3B-II or LC3B-II not being expressed in PA-
SMCs. The duration of OPG stimulation may require further optimisation for changes 
in LC3B-II to be detected in PA-SMCs. Therefore, further investigation into changes 
in autophagy protein expression must be conducted in PA-SMCs in order to determine 
whether OPG is signalling through the autophagy pathway. 
 
In addition to the genes mentioned above, OPG was also found to increase the 
expression of VEGFA RNA and to reduce VIPR RNA expression. Opposing findings 
for the role of VEGF in PAH have been reported in the literature. On the one hand, the 
literature has reported increased VEGF mRNA and protein expression, along with 
increased VEGF receptor mRNA expression, in the hypoxic rat model of PAH (Tuder 
et al. 1995). On the other hand, literature has reported a reduction in VEGF expression 
in the MCT-treated rat (Arcot et al. 1993) and the VEGFR2 antagonist, Sugen5416, is 
now used to induce PAH in animal models of PAH, either alone or combined with 
hypoxia (Taraseviciene-Stewart et al. 2001). Curiously, arterial and venous serum 
levels of VEGF are elevated in PAH patients and VEGF mRNA is expressed in 
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proliferative SMCs found in, and surrounding, plexiform lesions (Selimovic et al. 
2009; Hirose et al. 2000). OPG was found to increase the expression of VEGF mRNA 
in PA-SMCs, which mirrors the increase observed in PAH patients. However, the 
effect of increased VEGF mRNA expression on PA-SMC phenotype requires further 
investigation to confirm whether increased VEGF mRNA expression correlates with 
increased VEGF protein expression and determine whether the increase in VEGF 
expression causes PA-SMC proliferation. 
 
VIPR expression was also reduced in PA-SMCs stimulated with OPG. VIP binds to 
the receptors, VIPR (VIPR1, VPAC-1) and VIPR2 (VPAC-2) and acts as a systemic 
vasodilator and causes the relaxation of human pulmonary arteries (Greenberg et al. 
1987). VIP also inhibits the proliferation of human airway and pulmonary arterial 
smooth muscle cells (Maruno et al. 1995; Petkov et al. 2003). VIP serum 
concentrations are reduced in IPAH patients (Petkov et al. 2003), however, VIPR 
levels are elevated in IPAH patient PA-SMCs and animal models of PAH (Vuckovic 
et al. 2009). VIP (aviptadil) inhalation has been trialled as a potential therapy for PH 
and although results showed significant selective pulmonary vasodilation and an 
improvement in stroke volume, results were modest and short-lived (Leuchte et al. 
2008). Although the literature shows an increase in VIPR expression in PAH, PA-
SMCs stimulated with OPG show a reduction in VIPR mRNA expression. Evidently, 
the phenotypic effects of this will require further investigation. 
 
These data reveal for the first time that OPG can modulate the expression and 
activation of proteins that, although signal in different pathways, all may ultimately 
lead to the survival and proliferation of PA-SMCs via a multidirectional, cooperative 
network. This is shown in the proposed schematic (Figure 4.16), detailing the process 
that I reason occurs in PA-SMCs as a result of OPG stimulation in vitro. Although Fas 
was identified as the most likely OPG binding partner in the previous chapter, it still 
remains to be determined whether these intracellular protein changes are occurring as 




Figure 4.16- Proposed schematic for OPG signalling in PA-SMCs.  
This schematic incorporates all the data discussed and the individual schematics 
(Figures 4.12-4.15) discussed throughout this chapter to illustrate the proposed 
signalling mechanisms activated by OPG to induce PA-SMC proliferation in vitro. 
OPG induces the phosphorylation of CDK4 and ERK1/2 and increases the protein 
expression of CDK5 to induce PA-SMC proliferation, as well as inducing HSP27 
phosphorylation and CDK5 expression to block PA-SMC apoptosis. OPG induces the 
expression of the pro-proliferative genes Cav-1, TNC, PDGFRA and TRAIL, which 
may also induce PA-SMC proliferation if the changes in protein levels reflect the 
changes that are occurring at the mRNA level.   
 
 
Although results of the microarray revealed a significant change in BMPR1A, 
ACVRL1, TGFBR1 and TGFBR2 expression in response to OPG, these results were 
not validated and OPG was found to have no effect on the expression of these genes 
when analysed by TaqMan. This may be due to the fact that the microarray data can 
vary due to the large amount of probes used on the array. Differences in probe 
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hybridization efficiency for each probe may mean that cDNA from some genes 
hybridize much more readily than cDNA for other probes (Geeleher et al. 2011). 
Although data are expressed as a ratio between OPG stimulated and unstimulated PA-
SMCs to overcome this, it is important to note that the ratio does not give an absolute 
measure of the amount of mRNA in each PA-SMC sample. Furthermore, probes with 
a sequence that is closely related to other members of the same gene may fail to 
accurately differentiate between closely related members of the same family. This 
may lead to cross hybridization, causing some probes to bind the wrong cDNA from 
closely related gene family members (Geeleher et al. 2011). Therefore, the 
discrepancies in gene expression observed may be a limitation of the microarray. 
 
As further analysis for my findings, it would be important to assess the levels of 
protein for all of the genes altered by OPG in this chapter to determine whether 
changes in mRNA levels reflect the changes at the protein levels. Therefore, all my 
conclusions about the effect changes in mRNA expression have on PA-SMC 
phenotype would need to be confirmed at the protein level. It would also be 
particularly interesting to see if there is any change in gene expression when the OPG-
Fas interaction is blocked, and if this change in gene expression is accompanied by a 
change in OPG-induced PA-SMC proliferation. The effect of OPG-Fas blockade on 




5. INVESTIGATING THE EFFECT OF BLOCKING 




The results presented in this thesis have thus far identified potential OPG binding 
partners on PA-SMCs and have begun to reveal the proteins and genes through which 
OPG may be mediating PA-SMC proliferation. These findings are summarized in 
Figure 4.16. However, it still remains to be determined whether the changes in protein 
activation and expression, along with changes in gene expression, are being mediated 
through interactions between OPG and the identified OPG binding partners. As 
discussed previously, Fas was identified as the most probable binding partner for OPG 
on PA-SMCs (Chapter 3), therefore I next determined whether OPG-induced changes 
in gene expression and PA-SMC proliferation were being mediated through an OPG-





The aim of this chapter was to determine the effect of blocking the OPG-Fas 















5.3.1 Real-time TaqMan qPCR 
Following 30-minute incubation in the presence or absence of Fas neutralising 
antibody, HPA-SMCs were stimulated with 0.2% v/v FBS or rhOPG (50 ng/ml) for 6 
hours. RNA was then extracted using TRIzol reagent and the Zymo Direct-Zol RNA 
extraction kit. Complementary DNA (cDNA) was synthesized by reverse transcription 
and mRNA levels of TRAIL, PDGFRA, CAV1, VEGFA and TNC were quantified by 
TaqMan RT-qPCR (Chapter 2.13). 
 
5.3.2 HPA-SMC Proliferation 
HPA-SMCs were pre-incubated in the presence or absence of Fas neutralising 
antibody (1500 ng/ml), TRAIL neutralising antibody or both Fas and TRAIL antibody 
(1500 ng/ml) for 30 minutes prior to 72-hour stimulation with OPG (30 ng/ml), PDGF 
(20 ng/ml) or 0.2% v/v FBS. Proliferation was then measured using the CellTiter-
Glo® luminescent assay. In order to analyse PA-SMC proliferation, results were 




All data are represented as mean ± SEM. Treatments were compared using Two-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. P<0.05 was 
deemed statistically significant. The n numbers refer to the number of separate 
experiments performed and for each experiment performed, each condition was 










5.4.1 The Effect of Blocking the OPG-Fas Interaction on OPG-
induced PAH-associated Gene Expression 
To determine whether Fas truly was the key receptor driving the OPG-induced 
phenotype, I aimed to determine the effect of Fas blockade on OPG-induced gene 
expression.  
 
In support of my data discussed in the previous results (Chapter 4, Figure 4.11), OPG 
stimulation of PA-SMCs induced a significant increase in TRAIL, PDGFRA, TNC, 
VEGFA and CAV1 expression (Figure 5.1). Interestingly, Fas blockade prior to OPG 
stimulation of PA-SMCs significantly inhibited the OPG-induced expression of 
PDGFRA, Cav-1, TNC and VEGFA expression (Figure 5.1). Although OPG did not 
induce a significant change in BMPR1A expression in PA-SMCs, these data support 
my TaqMan data in Chapter 4. Furthermore, Fas blockade did not have any significant 
effect on BMPR1A expression (Figure 5.1). Surprisingly however, Fas blockade 
induced a further significant increase in TRAIL expression in PA-SMCs following 






































Figure 5.1- The effect of Fas blockade on OPG-induced gene expression in PA-
SMCs.  
Quiesced HPA-SMCs were incubated in the presence or absence of Fas neutralising 
antibody for 30 minutes prior to 6 h stimulation of cells with OPG (50 ng/ml) or 0.2% 
FBS (negative). The effect of Fas blockade on the expression of A) TRAIL, B) 
PDGFRA, C) TNC, D) VEGFA, E) CAV1 and F) BMPR1A RNA was assessed by 
TaqMan RT-qPCR. All data are normalised using ΔΔCT with 18S rRNA as the 
endogenous control gene. Fas mAb= Fas monoclonal antibody, Un = unstimulated 
PA-SMCs incubated with Fas mAb. Ctrl = control OPG-stimulated (50 ng/ml) cells. 
Fas mAb = cells pre-treated with Fas antibody for 30 minutes before stimulation with 
OPG (50 ng/ml).  Error bars represent mean ± SEM. N=4 experiments, each 
experiment with duplicate wells. 
 
 
5.4.2 Investigating the Effect of Blocking the OPG-Fas Interaction 
on OPG-induced PA-SMC Proliferation 
 
After finding that Fas blockade significantly inhibited OPG-induced gene expression 
of PDGFRA, TNC, VEGF and CAV1 in PA-SMCs, I next wanted to examine the 
effect of Fas blockade on OPG-induced PA-SMC proliferation as this is one of the 
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key drivers of PAH pathogenesis and blocking this process may help to stabilise 
disease and prevent disease progression. Investigating the effect of blocking Fas 
would also convince me of whether the OPG-Fas interaction would be important in 
PA-SMC proliferation. 
 
As expected, OPG caused a significant increase (p<0.0001) in cell proliferation, 
compared to unstimulated cells (Figure 5.2). Pre-treatment of cells with the Fas 
neutralising antibody had no significant effect on unstimulated cells or PDGF-induced 
proliferation of PA-SMCs (Figure 5.2). Conversely, pre-treating the cells with the Fas 
antibody prior to OPG stimulation caused a significant reduction of 34% in OPG-
induced proliferation of PA-SMCs (p<0.01), compared to OPG stimulated cells. This 
observation was intriguing as it suggests Fas is a significant contributor to the 
proliferative phenotype. However, these data also suggest that there may be another 












































Figure 5.2- Fas blockade reduces OPG-induced PA-SMC proliferation.  
OPG significantly increased PA-SMC proliferation after 72 hours stimulation, 
compared to unstimulated PA-SMCs. However, pre-incubation with Fas neutralising 
antibody 30 minutes before OPG stimulation caused a significant reduction of 34% in 
OPG-induced PA-SMC proliferation. Fas blockade had no effect on PDGF-induced 
or unstimulated PA-SMC proliferation. Proliferation was normalised to unstimulated 
(0%) and PDGF stimulated (100%) cells. Error bars represent mean ± SEM, n=4. 
**p<0.01, ****p<0.0001. White bars= no antibody. Blue striped bars= Fas antibody 
pre-treatment 30 minutes before stimulation. 
 
After looking back at the changes in gene expression in the presence of Fas blockade, 
the change in TRAIL expression remained puzzling (Figure 5.1 A). Although changes 
in TRAIL RNA expression was not deemed significant, Fas blockade led to a further 
increase in TRAIL expression, rather than a reduction. TRAIL has already been 
shown to induce the proliferation of PA-SMCs in vitro (Hameed et al. 2012) and 
therefore TRAIL could possibly be the mitogen responsible for the remaining PA-
SMC proliferation. This led me to speculate that TRAIL may the additional factor 
responsible for the PA-SMC proliferation.  
 
I therefore investigated at the effect of blocking TRAIL on PA-SMC proliferation. 
TRAIL blockade alone however had no effect on unstimulated cells, PDGF-induced 
or OPG-induced proliferation (Figure 5.3). After observing that TRAIL blockade 
alone did not cause a reduction in OPG, I then looked at the effect of blocking both 
Fas and TRAIL simultaneously to see whether this could inhibit OPG-induced 
 146 
proliferation more so than Fas blockade alone. As shown in Figure 5.3, treatment of 
PA-SMCs with both Fas and TRAIL antibody had no effect on PDGF-induced 
proliferation. However, Fas and TRAIL blockade significantly inhibited OPG-induced 





























Figure 5.3- Simultaneous Fas and TRAIL blockade further inhibits OPG-induced 
PA-SMC proliferation. 
Pre-incubation with both the Fas neutralising antibody and TRAIL antibody had no 
effect on PDGF-induced or unstimulated PA-SMC proliferation. However, OPG-
induced proliferation was significantly reduced by 58% when both Fas and TRAIL 
were blocked by antibody pre-treatment. Pre-incubation with TRAIL antibody 30 
minutes before stimulation (red striped bars) had no effect on OPG-induced, PDGF-
induced or unstimulated cell proliferation. Proliferation was normalised to 
unstimulated (0%) and PDGF stimulated (100%) cells. Error bars represent mean ± 
SEM, n=4. ****p<0.0001. White bars= no antibody. Purple spotted bars= Fas and 








In this chapter, I aimed to answer the last of the four questions set out in the Chapter 2 
of this thesis to identify a mechanism by which OPG induces PA-SMC proliferation. 
The data show that Fas blockade significantly inhibited OPG-induced gene expression 
of PDGFRA, TNC, VEGFA, and CAV1. Furthermore, Fas blockade alone caused a 
significant reduction in OPG-induced PA-SMC proliferation. 
 
Although Fas blockade was found to significantly inhibit OPG-indcued gene 
expression, it would be interesting to access the effect Fas antibody only treatment has 
on gene expression in unstimulated cells. This would ensure that the inhibition of 
OPG-induced gene expression in HPA-SMCs caused by Fas blockade is not due to the 
antibody treatment of cells. After observing that OPG-induced PA-SMC proliferation 
was only partially reduced by Fas blockade, I began to speculate whether there might 
be another factor that was inducing PA-SMC proliferation, in addition to OPG. Fas 
blockade significantly reduced PDGFRA, TNC, VEGFA and Cav-1 expression, Fas 
blockade induced a significant increase in TRAIL expression in OPG-stimulated cells 
pre-treated with a Fas neutralising antibody. The fact that TRAIL is a potent PA-SMC 
mitogen (Hameed et al. 2012) led me to suspect that TRAIL might also be inducing 
PA-SMC proliferation. TRAIL blockade alone had no effect on OPG-induced PA-
SMC proliferation, confirming that OPG was not inducing pathogenic changes in PA-
SMCs by binding to TRAIL. However, blockade of both Fas and TRAIL together 
caused a greater reduction in OPG-induced proliferation. I therefore propose that there 
may be a redundancy mechanism between Fas and TRAIL in PA-SMCs.  
 
There are no reports in the literature of a redundancy mechanism between Fas and 
TRAIL. However, in support of my theory, a recent study has reported a redundancy 
mechanism for TRAIL-resistance. Resistance against TRAIL-induced apoptosis in 
normal, non-transformed human primary fibroblasts and SMCs was caused by cellular 
FLICE-like inhibitory protein (cFLIP), B-cell lymphoma 2 (Bcl-2) and XIAP (van 
Dijk et al. 2013). However, knockdown or inhibition of cFLIP, Bcl-2 or XIAP 
independently was not sufficient to induce sensitivity to TRAIL-induced apoptosis, 
which suggests a redundancy mechanism between these proteins (van Dijk et al. 
2013). These data therefore support my theory that a redundancy mechanism may 
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exist in PA-SMCs. OPG-induced PA-SMC proliferation may be mediated by a 
redundancy mechanism that exists between Fas and TRAIL, and blocking Fas or 
TRAIL alone does not fully inhibit OPG-induced proliferation. 
 
I therefore postulate that in normal PA-SMCs, where there are low levels of OPG, 
Fas, TRAIL and the TRAIL receptors, TRAIL R1 and TRAIL R3, there is a basal 
level of PA-SMC proliferation. Because OPG levels are low, there is only a small 
amount of OPG binding to Fas, hence a low amount of PA-SMC proliferation. This 
allows FasL to bind to Fas and induce PA-SMC apoptosis. In normal PA-SMCs, OPG 
might also be binding to TRAIL to prevent TRAIL binding to TRAIL R1 and TRAIL 
R3 and hence OPG prevents TRAIL-induced PA-SMC proliferation. Therefore, in 
normal, healthy PA-SMCs, there is a balance between PA-SMC proliferation and 
apoptosis maintained by the interaction of OPG with Fas and TRAIL. However, 
during PAH pathogenesis, there is an unknown insult or injury that triggers an 
increase in OPG, TRAIL and TRAIL receptor expression, which has already been 
shown by the literature (Lawrie et al. 2008; Condliffe et al. 2012; Hameed et al. 
2012), and an increase in Fas expression caused by OPG stimulation of PA-SMCs, as 
shown by data in this thesis. I therefore propose that OPG-induced PA-SMC 
proliferation is increased by OPG binding to Fas, which then leaves TRAIL free to 
bind to the TRAIL R1 and TRAIL R3 receptors and subsequently induce PA-SMC 




Figure 5.4- OPG, FAS and TRAIL signalling in normal and diseased PA-SMCs. 
A) In normal PA-SMCs, there is a low level of Fas, OPG and TRAIL expression, 
hence a low level of PA-SMC proliferation. Due to low levels of OPG binding to Fas, 
FasL can still bind to Fas and induce apoptosis of PA-SMCs. Therefore, in normal 
PA-SMCs there is a balance between PA-SMC proliferation and apoptosis. B) 
However, in PAH, an unknown insult or injury causes an increase in OPG expression, 
which subsequently increases Fas expression and OPG binds to Fas to induce PA-
SMC proliferation. An unknown insult/injury also increases TRAIL, TRAIL R1 and 
TRAIL R3 expression and TRAIL induces PA-SMC proliferation.  
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Blockade of TRAIL alone however had no effect on OPG-induced proliferation, 
suggesting that OPG-induced proliferation is not mediated through the OPG-TRAIL 
interaction. Fas blockade significantly reduced OPG-induced proliferation, however 
upon blockade of Fas, there was an increase in TRAIL expression. This TRAIL 
surplus may therefore continue to induce cell proliferation, even though the 
interaction between OPG and Fas is blocked and OPG is free to bind TRAIL. 
Therefore, both Fas and TRAIL blockade is required to inhibit PA-SMC proliferation 




Figure 5.5- TRAIL blockade, Fas blockade and simultaneous TRAIL and Fas blockade in PA-SMCs.  
A) TRAIL blockade alone has no effect on OPG-induced proliferation of PA-SMCs in vitro, however B) Fas blockade prevents OPG binding and 
thus inhibits OPG-induced PA-SMC proliferation. Fas blockade also induces TRAIL expression, which may also potentiate the TRAIL-induced 
proliferation that occurs in PA-SMCs, even when the OPG-Fas interaction is blocked. C) Simultaneous blockade of both Fas and TRAIL is 





These data would therefore be important to consider if the OPG-Fas interaction was to 
be pursued as a therapeutic target. In this case, an antibody against OPG to block 
interaction with Fas may the more suitable that an antibody against Fas, due to the 
effect of blocking Fas on TRAIL expression. However, it would also be beneficial to 
develop an antibody that binds to OPG to block the interaction with Fas, but also still 
allow OPG to bind to TRAIL. This would allow OPG to “mop up” excess TRAIL to 
prevent TRAIL binding to its receptors, TRAIL R1 and TRAIL R3, thus preventing 
TRAIL-induced proliferation. 
 
Although these data have provided evidence that the OPG-Fas interaction is 
responsible for the pathogenic changes in PA-SMCs, further work to investigate the 
effects of Fas blockade on PA-SMC phenotype should be conducted. Firstly, it would 
be interesting to assess the effect of Fas blockade on OPG-induced CDK4, HSP27, 
ERK1/2 and mTOR phosphorylation and CDK5 expression in PA-SMCs at different 
time points, for example, at 10 minutes, 60 minutes and 24 hours. This would provide 
further information about whether the changes in protein expression and activation are 
being mediated through the OPG-Fas interaction. It would also be interesting to 
determine the effect of Fas blockade on OPG-induced migration of PA-SMCs because 
Lawrie et al (2008) have reported that OPG induced the migration, as well as 
proliferation, of PA-SMCs in vitro.  
In conclusion, the data presented in this chapter provide evidence that the interaction 
between the TNF receptor superfamily members, OPG and Fas, is responsible for the 
proliferation and changes in pathogenic gene expression in PA-SMCs induced by 
OPG. Furthermore, these data reveal a possible redundancy between Fas and another 
TNF superfamily member, TRAIL, in the proliferation of PA-SMCs. These data 
suggest that if the Fas blockade was to be considered as a therapeutic target, the need 
to also block TRAIL as well would have to be considered. Finally, these data reveal 
for the first time that blocking the Fas receptor can prevent OPG-induced pathogenic 
changes in PA-SMCs and may be of therapeutic potential in the future. As discussed 
in this chapter, I propose that OPG induces the survival and proliferation of PA-SMCs 
in vitro through the novel interaction with Fas. Furthermore, my data in Chapter 4, 
show that OPG induces changes in protein phosphorylation and expression and gene 
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expression, which may consequently be inducing the survival and proliferation of PA-









6. GENERAL DISCUSSION 
PAH is a devastating lung disease with a high mortality and a poor quality of life. 
PAH is defined as an mPAP of >25 mmHg at rest, however, symptoms often present 
late and are often misdiagnosed. Unfortunately, there is currently no cure for PAH and 
right heart failure is the major cause of mortality (Elliot & Kiely 2006; Kiely et al. 
2013; Pokreisz et al. 2007). The pathogenesis of PAH is an incredibly complex 
process that affects all layers of the pulmonary arteries (Humbert et al. 2004). PAH is 
characterised by progressive pulmonary vascular remodelling, a key component of 
which is the proliferation and migration of pulmonary arterial smooth muscle cells 
(PA-SMCs) (Rabinovitch 2008). OPG has recently been implicated as an important 
pathogenic mediator in PAH and OPG also induces the proliferation and migration of 
PA-SMCs in vitro (Lawrie et al. 2008; Condliffe et al. 2012). Furthermore, recent 
unpublished data from the Pulmonary Vascular Research Group (Department of 
Cardiovascular Science, University of Sheffield) shows that OPG blockade, either by 
genetic deletion or anti-OPG antibody treatment prevents and reverses disease in 
animal models of PAH. OPG is therefore an attractive therapeutic target, but the 
mechanism through which OPG induces PA-SMC proliferation is currently unknown. 
Therefore, the work undertaken in this thesis aimed at identifying the binding partner 
and intracellular signalling mechanism through which OPG induces the proliferation 
of PA-SMCs. 
 
6.1 Summary of Key Findings 
The data presented in this thesis show for the first time that OPG can bind to four 
previously undescribed human membrane proteins: Fas, IL1RAcP, TMPRSS11D and 
GAP43. Although the interaction between Fas and IL1RAcP was confirmed in 
endogenous PA-SMC lysates, Fas mRNA expression levels in PA-SMCs were the 
greatest of the four binding partners identified by the Retrogenix cell microarray, Fas 
mRNA expression was increased upon PA-SMC stimulation with OPG and was 
significantly higher in IPAH PA-SMCs compared to control PA-SMCs. Fas protein 
was also expressed in the pulmonary artery and right ventricle of IPAH patients, along 
with OPG (Chapter 3).  
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After identifying a potential OPG binding partner, I then investigated OPG-induced 
changes in protein and gene expression in PA-SMCs. OPG was found to alter the 
expression and activation of proteins and expression of genes involved in pro-
proliferative pathways (phospho-ERK1/2, TRAIL, PDGFRA, TNC, Cav-1), the cell 
cycle (phospho-CDK4), anti-apoptotic pathways (phospho-HSP27 and CDK5) and 
pro-survival pathways (phospho-mTOR) (Chapter 4).  
 
Finally, in order to determine the importance of the OPG-Fas interaction, I then 
looked at the effect of blocking this interaction on OPG-induced gene expression and 
PA-SMC proliferation. Fas blockade significantly inhibited OPG-induced gene 
expression and PA-SMC proliferation, however simultaneous Fas receptor and 
TRAIL blockade resulted in an even greater inhibition of OPG-induced PA-SMC 
proliferation (Chapter 5).  
 
Although only six proteins from the KAM list of 89 OPG-regulated proteins were 
chosen for validation, the KAM data indicated that a high proportion of proteins 
induced by OPG are involved in the cell cycle. These data suggest that OPG is 
exerting its mitogenic actions by pushing the cell cycle forward in cells by inducing 
the expression of cell cycle proteins, which subsequently promote PA-SMC division 
and hyperplasia. Importantly, the KAM also showed activation of a number of protein 
kinases, such as PKC, P38 MAPK, JNK, MEK, Raf and Abl (Chapter 4), which are 
known for their pro-proliferative actions, and anti-apoptotic proteins, such as the heat 
shock proteins. Activation of both these classes of proteins by OPG would all 
contribute to a pro-survival, pro-proliferative phenotype in PA-SMCs. Furthermore, 
constitutively active protein kinases and the inhibition of apoptosis are 
characteristically observed in neoplastic cells. Interestingly, PAH has been likened to 
cancer, with cells involved in PAH acquiring a hyperproliferative phenotype, which is 




6.2 OPG, PAH and the Cancer Hypothesis 
The idea that PAH shared characteristics with cancer first came from the finding that 
monoclonal endothelial cell proliferation was occurring in the plexiform lesions of 
remodelled pulmonary arteries (Tuder & Graham 2010). VEGF and VEGFR2 
expression is detected in the endothelial cells with plexiform lesions and VEGF and 
its receptors are also expressed on a variety tumour cells, including lung cancer cells 
(Tuder & Graham 2010; Goel & Mercurio 2013). The major similarities between PAH 
and cancer include altered cell crosstalk, proliferation and apoptosis-resistance (Rai et 
al. 2008; Guignabert et al. 2013). In support of this, ex vivo human IPAH PA-SMCs 
and PA-ECs have been shown to maintain their hyperproliferative, anti-apoptotic 
phenotype for longer than normal PA-SMCs and PA-ECs (Guignabert et al. 2013). 
Recent evidence also suggests a pulmonary vascular cells acquire a “Warburg” 
phenotype, that is, they show a shift in energy production from mitochondrial 
oxidative phosphorylation to glycolysis, which is also observed in cancer cells 
(Guignabert et al. 2013). Furthermore, several markers detected in the IPAH lung 
have also been described in cancers, including Cav-1 and the PDGF receptors (Tuder 
& Graham 2010). Data presented in this thesis demonstrate the ability of OPG to alter 
expression of VEGFA, Cav-1 and PDGFRA, suggesting that the mechanism through 
which OPG induces PA-SMC proliferation may be similar to the dysregulated 
mechanisms seen in cancer cell growth and proliferation. 
 
Although PAH shares the above similarities with cancer, there are also differences 
between PAH and cancer and it is clear that PAH is not actually a cancer (Rai et al. 
2008; Guignabert et al. 2013). One important difference between PAH and cancer is 
the phenotype cells acquire during the pathogenesis of each disease (Guignabert et al. 
2013). Cancer cells develop an aggressive, hyperproliferative phenotype and the cells 
continue to proliferate despite restricted space and nutrients. Cancer cells also invade 
and destroy adjacent tissue, as well as metastasising to other locations in the body 
(Guignabert et al. 2013). Although PA-SMCs and PA-ECs acquire a 
hyperproliferative, anti-apoptotic phenotype in PAH, these cells do not have invade 
other tissues or metastasise like cancer cells do (Guignabert et al. 2013).  
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A further difference is that, unlike cancer cells, which generate malignant cells 
through clonal expansion, PAH affects all layers of the vessel wall and affects 
multiple cell types, including SMCs, ECs and fibroblasts, rather than a single 
homogenous cell population (Guignabert et al. 2013). Interestingly, cancer cells show 
alterations in cell proliferation machinery, especially cyclins and cyclin dependent 
kinases that enable cancer cells to proliferate on their own (Guignabert et al. 2013). 
However, although there is currently no evidence in the literature of pulmonary 
vascular cells acquiring the ability to proliferate on their own, my data indicate that 
OPG induces the activation and expression cell cycle proteins, including 
phosphorylation of CDK4. My data therefore suggest that, although PA-SMCs may 
not develop alterations in cell cycle machinery like cancer cells do, OPG may be 
causing cell proliferation and hyperplasia by inducing cell cycle protein activation and 
expression, similar to cancer cells. These data therefore support the theory that PA-
SMCs involved in PAH pathogenesis may acquire a phenotype similar to cancer cells. 
Despite the similarities between PAH and cancer, it is clear that the mechanisms that 
lead to the tumorigenic phenotype in cancer can not fully explain how PAH develops 
due to the differences discussed above. However, the similarities between PAH and 
cancer has identified a group of anti-proliferative, oncological drugs that may also 
prove therapeutically beneficial in PAH (Guignabert et al. 2013). 
 
In addition to the activation of the pro-proliferative pathways, OPG was also found to 
activate anti-apoptotic heat shock proteins. HPS27 expression has been identified in 
the PA-ECs and PA-SMCs of congenital heart disease patients with pulmonary 
hypertension, remodelled pulmonary arteries and plexiform lesions (Geiger et al. 
2009). Dimers of phosphorylated HSP27 have been shown to interact with Daxx to 
prevent its translocation from the nucleus to the cytoplasm, prevent subsequent Ask1 
activation and block Fas-induced apoptosis (Charette & Landry 2000; Charette et al. 
2000). Therefore, OPG may not only be binding to Fas to induce PA-SMC 
proliferation, but may be inhibiting the apoptotic effects of Fas by increasing levels of 
phosphorylated HSP27, which then blocks Fas-induced apoptosis. High levels of 
HSP27 expression are observed in treatment resistant cancers, such as prostrate cancer 
and HSP27 is thought to contribute to apoptosis resistance in cancer cells (Zoubeidi & 
Gleave 2012). The HSP27 specific inhibitor, Apatorsen (OGX-427) is now 
undergoing phase II clinical trials to treat prostate and bladder cancer (Lamoureux et 
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al. 2014). It would therefore be interesting to assess the effect of inhibiting HSP27 on 
disease development and reversal in animal models of PAH to determine the 
therapeutic potential in of HSP27 in PAH. 
 
OPG most significantly altered the expression of Abl in the KAM and this was very 
interesting because this supports the cancer hypothesis. As briefly mentioned in 
Chapter 4, Imatinib, is used to treat the myeloproliferative disorder, chronic myeloid 
leukaemia by competitively binding to and blocking the ATP binding site of the BCR-
ABL fusion protein (Ciarcia et al. 2012). Imatinib has previously been shown to 
inhibit the PDGF receptor and c-Kit in addition to Abl and so was suspected of having 
therapeutic potential for the treatment of PAH (Galiè et al. 2013). Imatinib was 
previously shown to prevent MCT-induced PH and reverse PH in both the MCT rat 
model and hypoxic mouse model of PH (Schermuly et al. 2005; Pankey et al. 2013). 
Imatinib was also shown to inhibit proliferation and induce apoptosis of PDGF-
stimulated IPAH PA-SMCs (Nakamura et al. 2012). However, despite these 
promising data, in a randomized, double blind placebo controlled trial of Imatinib as 
an add-on therapy for the treatment of PAH, a high number of serious adverse effects, 
such as subdermal hematoma, were reported (Hoeper, Barst, et al. 2013). 
Consideration for Imatinib as a treatment for PH has currently been halted (Galiè et al. 
2013). My data suggest that small molecule inhibitors against specific targets, such as 
HSP27 and Abl, might be useful as future PAH therapies. 
  
A number of small molecule inhibitors that therapeutically target ERK1/2 activation 
have been approved to treat cancers. Vemurafenib and Selumetinib inhibit Raf and 
MEK1/2, respectively to block ERK1/2 activation (Sale & Cook 2013). ERK1/2 has 
also, like the proteins discussed above, been shown to be important in the 
pathogenesis of PAH, as well as in cancer. TRAIL-induced PA-SMC proliferation and 
migration is ERK1/2 dependent and recent work looking into the mechanism of the 
PH therapeutic, Sildenafil, revealed that Sildenafil reduced in ERK1/2 activation (Kiss 
et al. 2014). ERK1/2 may therefore be a therapeutic target in itself, and blocking 




6.3 The OPG-Fas Interaction as a Potential Therapeutic 
Target 
As discussed previously in Chapter 5, Fas blockade inhibited OPG-induced PA-SMC 
proliferation. The OPG-Fas interaction may therefore be a potential therapeutic target 
in the treatment of PAH. However, if the OPG-Fas interaction were to be targeted, the 
effect of Fas blockade on TRAIL RNA expression and TRAIL-induced PA-SMC 
proliferation would need to be considered. It appears at this stage that targeting Fas 
would not be beneficial because Fas ligation resulted in an increase in TRAIL RNA 
expression and still did not completely inhibit OPG-induced proliferation, 
simultaneous Fas and TRAIL blockade was required. TRAIL has already been 
implicated as an important pathogenic mediator in PAH (Hameed et al. 2012) and 
considering the possible redundancy mechanism between Fas and TRAIL, Fas 
blockade may result in an undesirable increase in TRAIL expression if therapeutically 
blocked. Therefore, one possible way to target the OPG-Fas interaction would be to 
develop a monoclonal antibody that binds OPG to prevent interaction with Fas and 
inhibit PA-SMC proliferation. 
 
Monoclonal antibodies (mAbs) are highly specific antibodies that recognize only a 
single epitope on any one antigen. This could be highly advantageous if targeting 
OPG because it may allow a mAb to be developed that binds specifically to the 
epitope to which Fas binds OPG, blocking the OPG-Fas interaction, but still leaving 
OPG free to interact with TRAIL. This would allow the role of OPG as a decoy 
receptor for TRAIL to be exploited, allowing OPG to bind excess TRAIL and prevent 
TRAIL-induced PA-SMC proliferation. This would however rely on the OPG binding 
sites for Fas and TRAIL being different and this has yet to be determined, for example 
by identifying the crystal structure of OPG by X-ray crystallography and investigating 
binding of Fas and TRAIL to OPG by surface plasmon resonance.  
 
Although there are currently no mAb therapies that are approved for PAH therapies, 
there are now reports in the literature of mAbs being used to treat PAH that is 
associated with other conditions. The IL-6 mAb Tocilizumab has been successfully 
used to treat a patient with Castleman’s disease-associated PAH who was resistant to 
conventional PH therapies, and a patient with adult onset Still’s disease-associated 
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PAH (Arita et al. 2010; Kadavath et al. 2014). The successful treatment of 
Castleman’s disease-associated PAH in a non-responder to conventional therapies 
provides a possibility that mAbs may offer an alterative therapy to these patients.  
 
6.4 Limitations 
Although the data presented in this thesis begin to reveal a novel receptor and the 
signalling mechanisms through which OPG may be inducing PA-SMC proliferation, 
there are several limitiations to the work undertaken. The KAM was chosen to 
identify potential protein targets because it is a high-throughput, time-effective 
technique allowing hundreds of different proteins to be screened for changes in 
protein expression and phosphorylation in PA-SMCs following OPG stimulation. 
Because it is a high thorough-put technique, results had to be validated to ensure 
accurate interpretation of the results. However, the KAM showed expression and 
phosphorylation of 89 proteins were significantly altered in PA-SMCs following OPG 
stimulation. Only nine proteins were then selected for validation by In-cell western 
blotting or gold standard western blotting. This means that the remaining 80 proteins 
that were not selected for validation may also play an important role in mediating 
OPG-induced PA-SMC proliferation. Therefore, the role of the remaining 80 proteins 
would require further investigation, as discussed below in Chapter 6.5. The KAM also 
used non-denatured protein samples. Native proteins may not be accessible to certain 
antibodies due to the masking of specific epitopes when proteins are in their native 
form. This could be problematic if proteins activated by OPG form complexes, 
masking antibody-specific epitopes. However, despite the limitations, this technique 
allowed identification of potential phosphorylation targets of OPG that were 
previously unidentified and provided a much more time-effective and cost-effective 
way of screening hundreds of targets to identify proteins for validation. 
 
Just as the KAM was used to investigate changes in protein expression and activation, 
the RNA microarray was used as a high-throughput screen to identify changes in RNA 
expression in OPG-stimulated PA-SMCs. Results of the microarray revealed that OPG 
significantly altered the expression of 1732 genes. However, I chose to focus on the 
57 genes already associated with PAH pathogenesis and of these, ten genes were 
selected for validation. By only investigating the effects of OPG on PAH-associated 
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gene expression, this may have excluded genes not associated with PAH, but may still 
play an important role in OPG-induced PA-SMC proliferation. Results of the 
microarray will therefore required further investigation, as discussed in Chapter 6.5. 
 
Finally, although the Retrogenix cell microarray identified four novel binding partners 
for OPG, only the interaction between OPG and Fas and IL1RAcP was validated. 
Furthermore, I only investigated the effect of blocking the OPG-Fas interaction on 
PA-SMC proliferation. I did not follow up the interactions between OPG and GAP43, 
IL1RAcP or TMPRSS11D on PA-SMC phenotype, or the role of these interactions in 
mediating the phenotype of other cell types, such as PA-ECs or fibroblasts. This 
would be important to do in the future work, discussed below, because these novel 
OPG interactions may reveal important roles for OPG in the biology of other cells and 
diseases, such as neurones and neurodegenerative disorders, which are beyond the 
scope of this thesis.  
 
6.5 Future Directions 
The data in this thesis implicate the novel OPG-Fas interaction as central in PA-SMC 
proliferation and show that OPG has the ability to induce changes in both protein 
expression and activation and PAH-associated gene expression in PA-SMCs. 
However, the identification of novel OPG interactions and downstream changes in 
gene and protein expression have created even more research questions that must be 
investigated to determine the importance of these in normal cell biology and in 
disease.  
 
Future research leading on from this thesis could firstly investigate the expression and 
function of Fas in other cell types and animal models of PAH. It would be interesting 
to determine whether Fas protein expression is observed in other cell types important 
in PAH pathogenesis, such as ECs and fibroblasts, and whether this interaction might 
be important in inducing pathogenic changes in these cell types. It would also be 
important to determine whether Fas is expressed, or even correlates, with disease 
development of animal models of PH and if so, whether blocking Fas in vivo could 
prevent or even reverse experimental PH. Results discussed in this thesis provide 
evidence that the OPG-Fas interaction is a potential therapeutic target. Therefore, 
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research following on from this work is now developing human monoclonal 
antibodies against OPG. Future work will look at the effect of blocking OPG in 
animal models of PH to assess the efficacy and pharmokinetics of the antibodies.  
 
However, after identifying that OPG can bind to four novel human membrane 
proteins, it has become evident that knowing how OPG interacts with the binding 
partners, RANKL and TRAIL would be very beneficial to help with the design of 
therapeutics against OPG. Therefore, it would be very beneficial to determine the 
crystal structure of OPG, for example by X-ray crystallography, to model how OPG 
interacts with its binding partners. If OPG is capable with binding each of the binding 
partners at different binding sites, this would be an important consideration when 
screening anti-OPG antibodies for example, and might allow an anti-OPG antibody to 
be designed that blocks the binding site for Fas, but still allows OPG to bind to 
TRAIL and prevent the mitogenic actions of TRAIL in PA-SMCs. 
 
The increase in HSP27 and CDK4 activation offers another line of therapeutics. Small 
molecule inhibitors against HSP27, such as Apatorsen, should be evaluated to see if 
HSP27 blockade could prevent or reverse disease in animal models of PH, because 
HSP27 may also be an important therapeutic target for the treatment of PAH. 
Additional work should also be undertaken to look at the effect of blocking cyclin 
dependant kinases on OPG-induced PA-SMC proliferation. This could be investigated 
in the future by inhibiting CDK activity in vitro, prior to OPG stimulation of PA-
SMCs, using the pan-specific CDK inhibitor, BAY 1000394, which has been shown 
to inhibit proliferation of cancer cell lines (Siemeister et al. 2012) 
 
Further work would also be required to investigate the changes in protein and gene 
expression in more detail. One limitation of this work is that only a selection of 
proteins were selected from the KAM and only PAH-associated genes were chosen 
from the microarray for validation and further investigation. Therefore, future work 
would be needed to thoroughly investigate the changes in protein and gene expression 
in greater detail, especially looking into the consequences of OPG-induced changes in 
genes that have not been implicated in PAH pathogenesis. There may be proteins and 
genes that have not been investigated in this thesis that may play an important role in 
PAH pathogenesis. It would also be interesting to determine whether Abl expression 
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correlates with disease progression or is reduced in animals that have received the 
anti-OPG intervention and prevention, or whether Abl expression is altered in PAH 
patients that are currently, or have previously received Imatinib treatment.  
 
Data presented in this thesis identified that OPG induced an increase in ERK1/2 
expression in PA-SMCs. ERK1/2 action is also required for TRAIL-induced PA-SMC 
proliferation and migration of PA-SMCs (Hameed et al. 2012). These data suggest 
that ERK1/2 is a common mediator in both OPG and TRAIL signalling. A microarray 
has recently been performed by the Pulmonary Vascular Research Group (University 
of Sheffield, UK), comparing TRAIL-stimulated to unstimulated PA-SMCs. Analysis 
of this microarray will provide more information about the district and overlapping 
signalling pathways that OPG and TRAIL employ in PA-SMCs to induce 
proliferation. This may then identify novel therapeutic targets, or biomarkers that help 
clinicians to diagnose PAH earlier. 
 
Finally, the novel OPG interactions with TMPRSS11D, Gap43 and IL1RAcP will also 
require validation and their role in disease will need to be further studied. Firstly, the 
interaction between OPG and GAP43 and TMPRSS11D would need to be confirmed 
by co-immunoprecipitation. GAP43 RNA was detected in PA-SMCs, therefore the 
interaction between OPG and GAP43 would need to be investigated in PA-SMCs. 
TMPRSS11D expression would need to be investigated in other cell types involved in 
PAH pathogenesis to determine whether the interaction with TMPRSS11D may be 
important in the phenotype of ECs or fibroblasts for example. To investigate 
TMPRSS11D expression in different cell types, TaqMan RT-qPCR would determine 
RNA expression, and protein expression would be confirmed by western blotting. 
Expression of all four binding partners would need further examined in both healthy 
and diseased human tissue and animal tissue. The interaction with IL1RAcP would 
also need to be investigated to determine whether OPG can modulate inflammatory 
pathways through interactions with IL1RAcP, ST-2 and IL1-R1.  
 
I believe that the data presented in this thesis begin to reveal a novel signalling 
pathway and cell surface receptor though which OPG induces PA-SMC proliferation. 
These data contribute to furthering our current understanding of the mechanisms that 
lead to the PA-SMC dysfunction and proliferation that is observed PAH. These data 
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provide further evidence that OPG is a critical mediator of PA-SMC phenotype and as 
such represents a potential therapeutic target for PAH. Furthermore, these data also 
suggest that OPG is not simply a decoy receptor for RANKL and TRAIL and through 
binding to previously undescribed cell membrane proteins, OPG might instead play a 









7.1 Product Suppliers 
7.1.1 General Reagents 
Reagent Cat. No Supplier Location 
CHAPS C-5070 Sigma-Aldrich Dorset, UK 
Complete Protease 
Inhibitor Cocktail mini 
11836153001 Roche West Sussex, UK 
Corning® Costar® 96-Well 
Cell Culture Plates 










DTT D0632 Sigma-Aldrich Dorset, UK 












NaCl 10040460 Fisher Scientific Loughborough, 
Leicestershire, 
UK 
PBS BR0014 Oxoid Basingstoke, UK 
SDS L3771 Sigma-Aldrich Dorset, UK 







Sodium Orthovanadate S6508-50G Sigma-Aldrich Dorset, UK 
Sodium Phosphate 342483 Sigma-Aldrich Dorset, UK 
TRIS T/P630/60 Fisher Scientific Loughborough, 
Leicestershire, 
UK 
Triton X-100 T8787 Sigma-Aldrich Dorset, UK 
Tween-20 P1379 Sigma-Aldrich Dorset, UK 
β-Mercaptoethanol (β-
ME) 
M6250 Sigma-Aldrich Dorset, UK 
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7.1.2 Cell Culture Reagents 
Reagent Cat. No Supplier Location 
DMEM BE12-604F Lonza Basal, 
Switzerland 
Penicillin/streptomycin 15240062 Gibco, Life 
Technologies 
Paisley, UK 





























R-002-100 Gibco, Life 
Technologies 
Paisley, UK 
Human Pulmonary Arterial 
Smooth Muscle Cells 
CC-2581 Lonza Basal, 
Switzerland 
 
7.1.3 Co-Immunoprecipitation Reagents 
Reagent Cat. No Supplier Location 
nProteinG sepharose 4 









7.1.4 In-Cell Western Assay Reagents 
Reagent Cat. No Supplier Location 
DRAC5 DR50050 Biostatus Leicestershire, 
UK 




7.1.5 Pierce 660 nm Protein Assay 
Reagent Cat. No Supplier Location 
Bovine Serum Albumin 
Standard 










Pierce 660nm Protein 
Assay Reagent  
 





7.1.6 Primary Antibody Suppliers 




13273 Cell Signaling 
Technology 





8558 Cell Signaling 
Technology 














4695 Cell Signaling 
Technology 




2782 Cell Signaling 
Technology 
Danvers, MA, USA 









Human Fas rabbit 
polyclonal 
antibody 
NBP1-49957 Novus Biologicals Cambridge, UK 
Human GβL 
rabbit monoclonal 
3274 Cell Signaling 
Technology 










3868S Cell Signaling 
Technology 




2983 Cell Signaling 
Technology 
Danvers, MA, USA 
Human OPG goat 
polyclonal 
antibody 





rabbit polyclonal  
antibody 
2561 Cell Signaling 
Technology 





58845 Cell Signaling 
Technology 






4370 Cell Signaling 
Technology 





2404 Cell Signaling 
Technology 






2974 Cell Signaling 
Technology 





3874 Cell Signaling 
Technology 





AF375 R&D Systems Abingdon, UK 
 
7.1.7 Proliferation Assay Reagents 
Reagent Cat. No Supplier Location 
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CellTiter-Glo® 
Luminescent Cell Viability 
Assay 
G7571 Promega Southampton, UK 
 
7.1.8 Recombinant Proteins 
Recombinant Protein Cat. No Supplier Location 
rhFas-FC Chimera 326-FS-050/CF R&D systems Abingdon, UK 
rhIL1RAcP-FC 
Chimera 
676-CP-100 R&D systems Abingdon, UK 
rhOPG 185-OS-025 R&D systems Abingdon, UK 





7.1.9 RNA Extraction and RT-qPCR 
Reagent Cat. No Supplier Location 
DirectZol RNA Extraction 
Kit 
R250 Zymo, Cambridge 
Bioscience 
Cambridge, UK 
Maxwell LEV simply 
RNA tissue kit 




80004 Qiagen Manchester, UK 
RNA-to-cDNA kit 4387406 Invitrogen, Life 
Technologies 
Paisley, UK 











7.1.10 Secondary Antibody Suppliers 
Antibody Cat. No Supplier Location 
IRDye 680LT 
Donkey anti-goat 




926-68020 LiCOR Bad Homburg, 
Germany 
IRDye 800 CW 
Donkey anti-goat 
926-32214 LiCOR Bad Homburg, 
Germany 
IRDye 800 CW 
Donkey anti-
mouse 
926-32212 LiCOR Bad Homburg, 
Germany 
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IRDye 800 CW 
Donkey anti-
rabbit 




7.1.11 TaqMan Probes 
Probe Cat. No Supplier Location 
18s Hs03003631_g1 Invitrogen, Life 
Technologies 
Paisley, UK 
ACVRL1 Hs00953798_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
BMPR1A Hs01034913_g1 Invitrogen, Life 
Technologies 
Paisley, UK 
Cav-1 Hs00971716_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
Fas Hs00236330_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
GAP43 Hs00967138_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
IL1RAP Hs00895050_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
PDGFRA Hs00998018_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
TGFBR1 Hs00610320_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
TGFBR2 Hs00234253_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
TMPRSS11D Hs00975370_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
TNC Hs01115665_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
TNFSF10 (TRAIL) Hs00921974_m1 Invitrogen, Life 
Technologies 
Paisley, UK 
VEGFA Hs00900055_m1 Invitrogen, Life 
Technologies 
Paisley, UK 





7.1.12 Western Blotting Reagents 
Reagent Cat. No Supplier Location 
Chromatography Paper 3030917 Fisher Scientific Loughborough, 
Leicestershire, 
UK 
Halt™ Protease Inhibitor 87786 Pierce, Thermo Rockford, Illinois, 
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Cocktail (100x) Fisher Scientific USA 
LiCOR Odyssey Blocking 
Buffer 
927-40000 LiCOR Bad Homburg, 
Germany 





St Albans, UK 




Novex Sharp Pre-Stained 
Protein Standards 
LC5800 Life Technologies Paisley, UK 
NuPAGE antioxidant NP0005 Life Technologies Paisley, UK 
NuPAGE MOPS SDS 
running buffer (20x) 
NP0001 Life Technologies Paisley, UK 
NuPAGE Novex Bis-Tris 
gels (1.0 mm, 10 wells) 
NP0321BOX Life Technologies Paisley, UK 
NuPAGE sample reducing 
agent (10x) 
NP0009 Life Technologies Paisley, UK 
NuPAGE Transfer Buffer 
(20x) 
NP00061 Life Technologies Paisley, UK 
Protein loading buffer 
(4x) 
928-40004 LiCOR Bad Homburg, 
Germany 
Reblot Mild Antibody 
Stripping Solution 
2502 Millipore Watford, UK 
XCell Surelock Mini Cell 
Electrophoresis System 





7.2 Preparation of Solutions 
7.2.1 General Solutions 
Solution Preparation 
Phosphate Buffered Saline A one times solution of PBS was 
prepared by dissolving one PBS tablet 
(Oxoid, BR0014G) in 100 ml distilled 
water. A 20x PBS solution was prepared 
by dissolving 20 PBS tablets in 100 ml 
distilled water. A one times PBS solution 
was prepared by diluting 25 ml 20x PBS 
in 475 ml distilled water. 
10% w/v SDS A 10% w/v SDS was prepared by adding 
1 g SDS to 10 ml distilled H2O. 
5% v/v SDS Protein samples were dissolved in a 1:2 
dilution of 10% w/v SDS to give a final 
volume of 5% v/v SDS.  For example, 30 
μl sample was dissolved in 30 μl 10% 
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w/v SDS to give a final concentration of 
5% SDS.  
0.1% v/v Tween-20 wash buffer 0.1% v/v Tween-20 wash buffer was 
prepared by adding 500 μl Tween-20 to 
500 ml one times PBS. 
 
7.2.2 Cell Culture Solutions 
Solution Preparation 
Smooth Muscle Basal Medium 
(SmBM) for HPA-SMC 
The SmGm-2 SingleQuots, containing 25 
ml foetal calf serum (FBS), 500 μl 
insulin, 1000 μl hFGF-β, 500 μl 
gentamycin/amphotericin were defrosted 
overnight at 4°C prior to use. All 
SingleQuots and FBS were added to 500 
ml SmBm-2 cell culture media to produce 
a media containing 5% v/v FBS, 0.1% 
v/v insulin, 0.2% v/v hFGF-β and 0.1% 
v/v gentamycin/amphotericin. 1% v/v 
penicillin/streptomycin was also added. 
Growth Arrest Media for HPA-SMC Growth arrest media was prepared to 
synchronize HPA-SMC cell cycles by 
adding 1 ml FBS and 5 ml 100 X 
penicillin/streptomycin (10,000 units/mL 
of penicillin, 10,000 µg/mL of 
streptomycin) to 500 ml DMEM. DMEM 
containing 0.2% v/v FBS. Therefore, a 
0.2% v/v FBS, 1% v/v 
penicillin/streptomycin growth arrest 
media was produced. 
Sodium Orthovanadate Lysis Buffer 1 M Tris-HCl (pH 7.4) was prepared by 
adding 157.6 mg Tris-HCl (molecular 
weight 157.56) to 1 ml distilled water. 
100 mM sodium orthovanadate was 
prepared by adding 18.39 mg/ml sodium 
orthovanadate (molecular weight 
183.908) to 1 ml distilled water and 
heating at 95°C, until clear to dissolve. 
10% w/v SDS was prepared by adding 1 
g SDS to 10 ml distilled water. Lysis 
buffer (10 mM Tris-HCl, 10 mM Sodium 
orthovanadate, 1% v/v SDS) was then 
prepared by adding 10 μl 1 M Tris-HCl, 
10 μl 100 mM sodium orthovanadate and 
100 μl 10% SDS to 780 μl distilled H2O. 
Immediately before use, 10 μl HALT™ 
protease inhibitor was added to 1 ml lysis 
buffer. 
Triton X-100 Lysis Buffer A 1% Triton X-100 lysis buffer (150 mM 
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NaCl, 20 mM Tris, 1% Triton X-100, 
0.1% SDS) was prepared by adding 438.8 
mg NaCl (molecular weight 58.44), 
121.14 mg Tris (molecular weight 
121.12), 500 μl Triton X-100 and 50 mg 
SDS in 50 ml PBS. 
5% Milk Blocking Buffer Low fat Marvel milk powder was 
purchased from the local supermarket. A 
5% w/v milk blocking buffer was 
prepared by adding 5 g low fat milk to 
100 ml one times PBS and mixing gently. 
 
 
7.2.3 Pierce 660 nm Protein Assay Bovine Serum Albumin 
Standards Preparation 
 
Albumin standards were prepared at 2000 μg/ml, 1500 μg/ml, 1000 μg/ml, 750 μg/ml, 
500 μg/ml, 250 μg/ml, 125 μg/ml, 25 μg/ml and 0 μg/ml by diluting one 2000 μg/ml 
bovine serum albumin standard stock ampule as follows: 
 
Vial BSA Standard 
Concentration (μg/ml) 
Volume and Source 
of BSA (μl) 
Volume of distilled 
water 
A 2000 300 of stock 0 
B 1500 375 of stock 125 
C 1000 325 of stock 325 
D 750 175 of vial B 
dilution 
175 
E 500 325 of vial C 
dilution 
325 
F 250 325 of vial E 
dilution 
325 
G 125 325 of vial F 
dilution 
325 
H 25 100 of vial G 
dilution 
400 
I 0 0 400 
 
 
7.2.4 Western Blotting Solutions 
Solution Preparation 
Protein Loading Buffer One times protein loading buffer (Licor) 
was prepared by diluting 1 μl protein 
loading buffer (4x) in 3 μl protein lysate 
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(1:4 dilution). 
NuPAGE Sample Reducing Agent One times sample reducing agent (Life 
Technologies) was prepared by diluting 1 
μl sample reducing agent (10x) in 9 μl 
protein lysate (1:10 dilution). 
NuPAGE MOPS SDS Running Buffer A one times solution of NuPAGE MOPS 
SDS running buffer (Life Technologies) 
was prepared by diluting 25 ml running 
buffer (20x) in 475 ml distilled water. 
NuPAGE Transfer Buffer A one times solution of NuPAGE transfer 
buffer (life Technologies) containing 
10% methanol was prepared by diluting 
25 ml transfer buffer (20x) in 424 ml 
distilled water containing 50 ml methanol 
and 1 ml antioxidant (Life Technologies). 
A one times solution of NuPAGE transfer 
buffer containing 20% methanol was 
prepared by diluting 25 ml transfer buffer 
(20x) in 374 ml distilled water containing 
100 ml methanol and 1 ml antioxidant. 
30 % LiCOR Odyssey Blocking Buffer A 30% solution of LiCOR Odyssey 
blocking buffer was prepared by diluting 
15 ml blocking buffer in 35 ml PBS. 
30 % LiCOR Odyssey Blocking Buffer 
+ 0.1% v/v SDS 
A 30% solution of LiCOR Odyssey 
blocking buffer was prepared by diluting 
15 ml blocking buffer in 35 ml PBS. 500 
μl 10% w/v SDS was then added to 50 ml 
30% v/v Odyssey blocking buffer. 
Re-blot Plus Mild Antibody Stripping 
Solution 
A one times antibody stripping solution 
was prepared by adding 2 ml 10 times 
Re-blot plus mild antibody stripping 
solution (Millipore) to 18 ml PBS. 
 
7.2.5 Co-Immunoprecipitation Solutions 
Solution Preparation 
CHAPS Lysis Buffer 5 M NaCl was prepared by adding 2922 
mg NaCl (molecular weight 58.44) to 10 
ml distilled H2O. 5 M TRIS-HCl pH 7.4 
was prepared by adding 7880 mg TRIS-
HCl (molecular weight 157.6) to 10 ml 
distilled H2O. 10% w/v CHAPS was 
prepared by adding 1 g CHAPS in 10 ml 
distilled H2O. CHAPS lysis buffer (30 
mM TRIS-HCl, 150 mM NaCl, 1% v/v 
CHAPS) was then prepared by adding 
0.75 ml 5 M NaCl, 0.75 ml 5 M TRIS-
HCl and 2.5 ml 10% CHAPS to 21 ml 
ddH2O. 
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nProteinG Sepharose 4 Fast Flow 
beads (50% slurry) 
 
A 50% slurry of nProteinG sepharose 4 
Fast Flow beads was prepared by 
washing the beads 3 times in CHAPS 
lysis buffer, centrifuging at 12,000 x g for 
20 seconds after each wash and 
discarding the supernatant. 250 μl beads 
were then re-suspended in 250 μl CHAPS 
lysis buffer. 
Co-Immunoprecipitation Wash Buffer Co-Immunoprecipitation wash buffer was 
prepared by adding 302.85 mg Tris 
(molecular weight 121.14) to 50 ml PBS 
and mixing gently. 
 
7.2.6 Cell Assay Solutions 
Solution Preparation 
3.7% Formaldehyde Cell Fixing 
Solution 
A 3.7% formaldehyde cell fixing solution 
was prepared by adding 5 ml 37% 
formaldehyde to 45 ml one times PBS 
0.1% Triton X-100 Permeabilization 
Solution 
 
A 0.1% Triton X-100 permeabilization 
solution was prepared by adding 500 μl 
Triton X-100 to 500 ml one times PBS 
and mixing gently. 
0.3% Triton X-100 Permeabilization 
Solution 
 
A 0.1% Triton X-100 permeabilization 
solution was prepared by adding 1500 μl 
Triton X-100 to 500 ml one times PBS 
and mixing gently. 
DRAC5/Sapphire 700 Nuclear Stain 
 
DRAC5 (Biostatus) and Sapphire 700 
(LiCOR) nuclear stain was prepared by 
diluting DRAC5 1:10,000 and sapphire 
700 1:1000 in 30% v/v LiCOR Odyssey 
blocking buffer. 5 ml DRAC/5/Sapphire 
700 nuclear stain solution was prepared 
for each 96 well plate by adding 0.5 μl 
DRAC5 and 10 μl Sapphire 700 to 5 ml 
30% v/v LiCOR Odyssey blocking 




7.2.7 RNA Isolation, Reverse Transcription and TaqMan RT-qPCR 
Solution Preparation 
DirectZol DNase I Cocktail 
 
A DNase I cocktail was prepared by 
reconstituting 250 units lyophilized 
DNase I in 250 μl DNase/RNase-free 
water. 5 μl (5 units) DNase I were then 
 176 
 
7.2.8 Preparation of Recombinant Proteins 
Solution Preparation 
rhOPG 0.1 μg rhOPG was added to the 
appropriate Co-IP reactions by pipetting 
1 μl of the OPG stock (100 μg/ml) into 
250 μl CHAPS solution in the appropriate 
Eppendorfs. 1 μg rhOPG was added to 
the appropriate Co-IP reactions by 
pipetting 10 μl of the OPG stock (100 




50 ng/ml rhOPG solution was prepared 
for cell stimulation by diluting 1μl 100 
μg/ml stock solution in 2000 μl cell 
culture media. 
rhIL1RAcP 0.1 μg rhIL1RAcP was added to the 
appropriate Co-IP reactions by pipetting 
0.5 μl of the IL1RAcP stock (200 μg/ml) 
into 250 μl CHAPS solution in the 
appropriate Eppendorfs. 1 μg rhIL1RAcP 
was added to the appropriate Co-IP 
reactions by pipetting 5 μl of the 
IL1RAcP stock (200 μg/ml) into 250 μl 




rhFAS Receptor 0.1 μg rhFas was added to the appropriate 
Co-IP reactions by pipetting 1 μl of the 
added to 8 μl 10X DNase I reaction 
buffer, 3 μl DNase/RNase-free Water and 
64 μl RNA wash buffer in an RNase-free 
tube and mixed gently. 
RT Buffer (2x) Dilution 
 
Applied Biosystems High Capacity RNA-
to-cDNA™ RT buffer (2x) was diluted 
1:2 by adding 10 μl to 9 μl RNA sample 
and 1 μl Applied Biosystems High 
Capacity RNA-to-cDNA™ enzyme 
(20x). 
Enzyme (20x) Dilution 
 
Applied Biosystems High Capacity RNA-
to-cDNA™ enzyme (20x) was diluted 
1:20 by adding 1 μl to 9 μl RNA sample 
and 10 μl Applied Biosystems High 
Capacity RNA-to-cDNA™ RT buffer 
(2x). 
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Fas stock (100 μg/ml) into 250 μl 
CHAPS solution in the appropriate 
Eppendorfs. 1 μg rhFas was added to the 
appropriate Co-IP reactions by pipetting 
10 μl of the Fas stock (100 μg/ml) into 




rhPDGF-BB 20 ng/ml solution for stimulation was 
prepared by diluting 1 μl 10 μg/ml stock 
solution in 500 μl growth arrest media. 
 
 
7.2.9 Preparation of Primary Antibodies 
Solution Preparation 
Human Atg13 rabbit 
monoclonal antiobdy 
ATG13 antibody was diluted 1:500, by adding 2 µl 
of antibody to 1000 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human Atg7 (D12B11) rabbit 
monoclonal antibody 
ATG7 antibody was diluted 1:500, by adding 2 µl 
of antibody to 1000 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human CDK5 (EP715Y) 
rabbit monoclonal antibody 
CDK5 antibody was diluted 1:500, by adding 1 µl 
of antibody to 500 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human Daxx (7A11) mouse 
monoclonal antibody 
Daxx antibody was diluted 1:1000, by adding 1 µl, 
1:500, by adding 2 µl and 1:250 µl of antibody to 
1000 µl blocking buffer (30% v/v Odyssey 
blocking buffer in 1x PBS) for use in Western 
blotting. 
Human ERK1/2 rabbit 
monoclonal antibody 
ERK1/2 antibody was diluted 1:1000, by adding 1 
µl of antibody to 1000 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human FADD rabbit 
polyclonal antibody 
FADD antibody was diluted 1:500, by adding 1 µl 
of antibody to 500 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human Fas mouse 
monoclonal neutralising 
antibody 
A working solution of Fas neutralising antibody 
(1500 ng/ml) was prepared by diluting the Fas 
antibody stock solution (1 mg/ml) 1:666.67 by 
adding 1.5 µl Fas neutralising antibody to 1000 µl 
growth arrest media. 
Human Fas rabbit polyclonal 
antibody (Co-IP) 
2 μg anti-Fas antibody was added to the 
appropriate Co-IP reactions by pipetting 20 μl of 
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the anti-Fas antibody stock solution (100 μg/ml) 
into the appropriate Eppendorfs. 
Human GβL rabbit 
monoclonal antibody 
GβL antibody was diluted 1:500, by adding 1 µl of 
antibody to 500 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human IL1RAcP mouse 
monoclonal antibody (Co-IP) 
2 μg anti-IL1RAcP antibody was added to the 
appropriate Co-IP reactions by pipetting 10 μl of 
the anti-IL1RAcP antibody stock solution (200 
μg/ml) into the appropriate Eppendorfs. 
Human mTOR (7C10) rabbit 
monoclonal 
MTOR antibody was diluted 1:500, by adding 2 µl 
of antibody to 1000 µl blocking buffer (30% v/v 
Odyssey blocking buffer in 1x PBS) for use in 
Western blotting. 
Human OPG goat polyclonal 
antibody 
OPG antibody 1:1000, by adding 1 µl of antibody 
to 1000 µl blocking buffer (30% v/v Odyssey 




rabbit polyclonal  
antibody 
Phospho-CDK2 antibody was diluted 1:200, by 
adding 1 µl of antibody to 200 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in the in-
cell western assay.    
Human Phospho-CDK4 
(Thr172) rabbit polyclonal 
antibody 
Phospho-CDK4 antibody was diluted 1:200, by 
adding 1 µl of antibody to 200 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in the in-
cell western assay.  
 
Phospho-CDK4 was diluted 1:1000, by adding 1 
µl of antibody to 1000 µl blocking buffer (5% w/v 





Phospho-ERK1/2 antibody was diluted 1:200, by 
adding 1 µl of antibody to 200 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in the in-
cell western assay.  
 
Phospho-ERK1/2 antibody was diluted 1:1000, by 
adding 1 µl of antibody to 1000 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in 
Western blotting. 
Human Phospho-HSP27 
(Ser15) rabbit polyclonal 
antibody 
Phospho-HSP27 antibody was diluted 1:200, by 
adding 1 µl of antibody to 200 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in the in-
cell western assay.   
 
Phospho-HSP27 was diluted 1:1000, by adding 1 
µl of antibody to 1000 µl blocking buffer (5% w/v 
low-fat milk in 1xPBS) for use in Western 
blotting.  
Human Phospho-mTOR Phospho-mTOR antibody was diluted 1:500, by 
 179 
rabbit polyclonal antibody 
(Ser2481) 
adding 2 µl of antibody to 1000 µl blocking buffer 
(30% v/v Odyssey blocking buffer in 1x PBS) for 
use in Western blotting. 
Human Phospho-PLCy2 
(Tyr759) rabbit polyclonal 
antibody 
Phospho-PLCγ2 antibody was diluted 1:200, by 
adding 1 µl of antibody to 200 µl blocking buffer 
(5% w/v low-fat milk in 1xPBS) for use in the in-
cell western assay.    
Human TRAIL goat 
polyclonal neutralising 
antibody 
A working solution of TRAIL neutralising 
antibody (1500 ng/ml) was prepared by diluting 
the TRAIL antibody stock solution (200 µg/ml) 
1:133.3 by adding 7.5 µl TRAIL neutralising 
antibody to 1000 µl growth arrest media. 
 
7.2.10 Preparation of Secondary Antibodies 
Antibody Preparation 
IRDye 680LT Donkey anti-goat IRDye 800 CW Donkey anti-goat was diluted 
1:15,000, by adding 1 µl of antibody to 15,000 
µl blocking buffer ((30% v/v Odyssey blocking 
buffer in 1x PBS, with 0.1% v/v SDS). 
IRDye 680LT Goat anti-mouse IRDye 800 CW Goat anti-mouse was diluted 
1:15,000, by adding 1 µl of antibody to 15,000 
µl blocking buffer ((30% v/v Odyssey blocking 
buffer in 1x PBS, with 0.1% v/v SDS). 
IRDye 800 CW Donkey anti-goat IRDye 800 CW Donkey anti-goat was diluted 
1:15,000, by adding 1 µl of antibody to 15,000 
µl blocking buffer ((30% v/v Odyssey blocking 
buffer in 1x PBS, with 0.1% v/v SDS). 
IRDye 800 CW Donkey anti-
mouse 
IRDye 800 CW Donkey anti-mouse was diluted 
1:15,000, by adding 1 µl of antibody to 15,000 
µl blocking buffer ((30% v/v Odyssey blocking 
buffer in 1x PBS, with 0.1% v/v SDS). 
IRDye 800 CW Donkey anti-
rabbit 
IRDye 800 CW Donkey anti-rabbit was diluted 
1:15,000, by adding 1 µl of antibody to 15,000 
µl blocking buffer ((30% v/v Odyssey blocking 




















7.3 Antibodies screened in the Kinex antibody microarray 
 
Table 7.1- Antibodies (pan-specific and phospho-specific) screened in the Kinex 





















14-3-3 protein zeta (cross-reacts 
with other isoforms) -0.38 0.05 
4E-BP1 S64 
Eukaryotic translation initiation 
factor 4E binding protein 1 
(PHAS1) 0.28 0.30 
4E-BP1 T45 
Eukaryotic translation initiation 
factor 4E binding protein 1 
(PHAS1) 0.59 -0.10 
4E-BP1 T69 
Eukaryotic translation initiation 
factor 4E binding protein 1 





encoded protein-tyrosine kinase -0.21 9.79 
AcCoA 
carboxylas


















Adducin alpha (ADD1)/gamma 




Apoptosis inducing factor 
(programed cell death protein 8 
(PDCD8)) -1.12 -0.18 
AK2 
Pan-
specific Adenylate kinase 2 0.04 1.07 
ALK 
Pan-






Amyotrophic lateral sclerosis 2 
chromosomal region candidate 
gene protein-serine kinase 7 -1.33 0.01 
AMPKa1/2 T183 
5'-AMP-activated protein kinase 




Ankyrin repeat domain protein-




Hsp 70-related heat shock 
protein 1 (osmotic stress protein 




Hsp 70-related heat shock 




specific Arrestin beta 1 -0.21 -0.57 





Apoptosis signal regulating 





Apoptosis signal regulating 
protein-serine kinase -0.42 1.36 
ASK1 
(MAP3K5) S1046 
Apoptosis signal regulating 




Activating transcription factor 2 
(CRE-BP1) 0.01 -0.16 
ATF2 T69/T71 
Activating transcription factor 2 
(CRE-BP1) -0.55 0.78 
ATF2 T69/T71 
Activating transcription factor 2 





Aurora Kinase A 
(serine/threonine protein kinase 





Aurora Kinase A 
(serine/threonine protein kinase 





Aurora Kinase B 
(serine/threonine protein kinase 





Aurora Kinase C 
(serine/threonine-protein kinase 











kinase 1/2 (MKK1/2) + B23 
(nucleophosmin, numatrin, 
nucleolar protein NO38) -0.30 -0.59 
B23 (NPM) T199 
B23 (nucleophosmin, numatrin, 
nucleolar protein NO38) -0.35 -0.20 
B23 (NPM) T199 
B23 (nucleophosmin, numatrin, 
nucleolar protein NO38) -0.08 -0.50 
B23 (NPM) T234/T237 
B23 (nucleophosmin, numatrin, 
nucleolar protein NO38) -0.38 0.86 
Bad S75 
Bcl2-antagonist of cell death 
protein 0.00 0.40 
Bad S99 
Bcl2-antagonist of cell death 










associated X protein -0.57 0.56 
Bcl2 
Pan-
specific B-cell lymphoma protein 2 alpha  0.00 0.00 
Bcl-xL 
Pan-
specific Bcl2-like protein 1 -0.28 -0.05 
Bcl-xS/L 
Pan-




BH3 interacting domain death 
agonist 0.47 1.52 
BLK 
Pan-
specific B lymphoid tyrosine kinase -0.15 0.07 




Bone marrow X protein-tyrosine 
kinase -0.28 0.70 
BMX (Etk) Y40 
Bone marrow X protein-tyrosine 
kinase 0.37 -0.11 
BRCA1 S1497 
Breast cancer type 1 











tyrosine kinase 0.42 1.40 
Btk Y223 
Bruton's agammaglobulinemia 




BUB1 mitotic checkpoint protein-
serine kinase 0.00 -0.28 
Caldesmon S789 Caldesmon 1.53 -0.19 
Calnexin 
Pan-
specific Calnexin 0.24 0.89 
Calnexin 
Pan-
specific Calnexin 0.34 -0.43 
Calnexin 
Pan-
specific Calnexin -0.16 0.51 
Calreticulin 
Pan-















protein-serine kinase 1 delta -0.85 0.71 
CaMK2a T286 
Calcium/calmodulin-dependent 
protein-serine kinase 2 alpha -0.09 -1.00 
CaMK2a T286 
Calcium/calmodulin-dependent 


















































Cellular apoptosis susceptibility 





protein-serine kinase (Lin2 
homolog) 0.01 -0.23 
CASP12 
Pan-




Pro-caspase 1 (Interleukin-1 
beta convertase) alpha/beta 
isoform -1.78 0.85 
CASP2 
Pan-




Pro-caspase 3 (apopain, 




Pro-caspase 4 (ICH2 protease, 




Caspase 5 (ICH3 protease, 




Pro-caspase 6 (apoptotic 




Pro-caspase 7 (ICE-like 
apoptotic protease 3 (ICE-





Pro-caspase 9 (ICE-like 
apoptotic protease 6 (ICE-





protein) beta 1 -0.26 -0.29 
Caveolin 2 
Pan-
specific Caveolin 2 -0.22 -0.66 





antigen CD45 receptor-tyrosine 




Cell division cycle 25B 




Cell division cycle 25C 
phosphatase 0.71 -1.84 
Cdc25C S216 
Cell division cycle 25C 





Cell division cycle 2-like protein-




Cell division cycle 34 (ubiquitin-




Cell division control protein 42 




































kinase 1  1.07 -0.94 
CDK1/2  T14+Y15 
Cyclin-dependent protein-serine 
kinase 1/2 0.05 -0.29 
CDK1/2  Y15 
Cyclin-dependent protein-serine 
kinase 1/2 -0.77 -0.81 
CDK1/2  Y15 
Cyclin-dependent protein-serine 
kinase 1/2 -0.57 2.19 
CDK1/2  Y15 
Cyclin-dependent protein-serine 
kinase 1/2 -2.91 -1.74 
CDK1/2  T161 
Cyclin-dependent protein-serine 

























































































































kinase 9 1.79 -0.89 
CDKL1 
Pan-















kinase 2 1.90 -0.01 
Chk2 T68 
Checkpoint protein-serine 




Cellular inhibitor of apoptosis 
protein 1 (baculoviral IAP 
repeat-containing protein 3, 




Casein protein-serine kinase 1 




Casein protein-serine kinase 1 




Casein kinase I gamma 1 




Casein protein-serine kinase 1 




Casein protein-serine kinase 2 
alpha/ alpha prime 0.51 0.13 
c-Myc T58/S62 Myc proto-oncogene protein -0.05 3.29 
Cofilin 1 
Pan-
specific Cofilin 1 -0.01 -0.78 
Cofilin 1 S3 Cofilin 1 1.02 -0.28 
Cofilin 2 S3 Cofilin 2 1.18 0.14 




Osaka thyroid oncogene protein-




Osaka thyroid oncogene protein-





(prostaglandin G/H synthase 2 











cAMP response element binding 
protein 1 0.58 -0.36 
CREB1 S133 
cAMP response element binding 
protein 1 0.36 1.15 
CREB1 S133 
cAMP response element binding 





Crystallin alpha B (heat-shock 





Crystallin alpha B (heat-shock 





Crystallin alpha B (heat-shock 





Crystallin alpha B (heat-shock 
20 kDa like-protein) 0.12 0.19 
Crystallin 
aB S19 
Crystallin alpha B (heat-shock 
20 kDa like-protein) -0.31 -0.80 
Crystallin 
aB S45 
Crystallin alpha B (heat-shock 




C-terminus of Src tyrosine 




C-terminus of Src tyrosine 
kinase 1.16 -9.53 
Cyclin A 
Pan-
specific Cyclin A1 0.01 -0.71 
Cyclin B1 
Pan-
specific Cyclin B1 1.17 0.46 
Cyclin D1 
Pan-
specific Cyclin D1 (PRAD1) 0.10 -0.79 
Cyclin D1 
Pan-
specific Cyclin D1 (PRAD1) -0.27 -0.13 
Cyclin E 
Pan-
specific Cyclin E1 -0.53 0.40 
Cyclin G1 
Pan-
specific Cyclin G1 -1.61 -2.84 
CytoC 
Pan-
specific Cytochrome C 0.78 -1.76 




Death-associated protein kinase 




Death-associated protein kinase 




Death-associated protein 6 





DNA fragmentation factor alpha 
(ICAD) 35-kDa, 45-kDa subunit -0.73 -0.35 
DGKz 
Pan-









DNA-dependent protein kinase 
catalytic subunit -1.65 -2.16 
Dok2 Y142 Docking protein 2 (mouse) 0.40 -0.42 





inducing protein-serine kinase 2 









Epidermal growth factor 
receptor-tyrosine kinase -0.10 -0.47 
EGFR Y1092 
Epidermal growth factor 
receptor-tyrosine kinase -1.75 -0.61 




Epidermal growth factor 
receptor-tyrosine kinase 0.09 -1.43 
EGFR Y1197 
Epidermal growth factor 
receptor-tyrosine kinase -0.67 -0.12 
EGFR T693 
Epidermal growth factor 
receptor-tyrosine kinase -0.29 -0.64 
eIF2a  S51 
Eukaryotic translation initiation 
factor 2 alpha -0.49 -0.01 
eIF2a  S51 
Eukaryotic translation initiation 




Eukaryotic translation initiation 
factor 4 (mRNA cap binding 
protein) 0.47 -0.11 
eIF4E S209 
Eukaryotic translation initiation 
factor 4 (mRNA cap binding 
protein) -0.19 -0.43 
eIF4E S209 
Eukaryotic translation initiation 
factor 4 (mRNA cap binding 
protein) -0.27 -1.02 
eIF4G S1107 
Eukaryotic translation initiation 




Ephrin type-A receptor 1 protein-





ErbB2 (Neu) receptor-tyrosine 





ErbB2 (Neu) receptor-tyrosine 
kinase 0.29 -0.11 
ErbB2 
(HER2) Y1248 
ErbB2 (Neu) receptor-tyrosine 
kinase -0.10 0.00 
ErbB2 
(HER2)  Y1248 
ErbB2 (Neu) receptor-tyrosine 
kinase 0.36 0.04 
ErbB2 
(HER2) T686 
ErbB2 (Neu) receptor-tyrosine 
kinase -0.12 -1.42 
ErbB2 
(HER2) Y1112 
ErbB2 (Neu) receptor-tyrosine 





serine kinase 1 (p44 MAP 





serine kinase 1 (p44 MAP 





serine kinase 1 (p44 MAP 





serine kinase 1 (p44 MAP 





serine kinase 1 (p44 MAP 





serine kinase 1 (p44 MAP 





serine kinase 2 (p42 MAP 






serine kinase 1 (p44 MAP 






serine kinase 1 (p44 MAP 






serine kinase 1 (p44 MAP 
















serine kinase 5 (Big MAP kinase 





serine kinase 5 (Big MAP kinase 





serine kinase 5 (Big MAP kinase 





serine kinase 5 (Big MAP kinase 





serine kinase 5 (Big MAP kinase 




ER protein 57 kDa (protein 
disulfide isomerase-associated 
3; 58 kDa glucose regulated 




ER protein 72 kDa (protein 
disulfide isomerase-associated 




Focal adhesion protein-tyrosine 
kinase 0.17 0.44 
FAK Y397 
Focal adhesion protein-tyrosine 
kinase 0.11 0.81 
FAK Y576 
Focal adhesion protein-tyrosine 
kinase -0.24 -0.13 
FAK Y576 
Focal adhesion protein-tyrosine 
kinase -0.83 0.49 
FAK S722 
Focal adhesion protein-tyrosine 
kinase -0.29 0.79 
FAK S732 
Focal adhesion protein-tyrosine 
kinase 0.40 -0.08 
FAK S843 
Focal adhesion protein-tyrosine 
kinase 1.23 1.10 
FAK S910 
Focal adhesion protein-tyrosine 




Tumor necrosis factor 
superfamily member 6 (Apo1, 




Tumor necrosis factor ligand, 
member 6 -0.48 -0.37 
Fes 
Pan-




Fibroblast growth factor 




Fibroblast growth factor 
receptor-tyrosine kinase 2 (BEK) 0.23 0.06 
FKBP52 
Pan-
specific FK506-binding protein 4 -1.41 -0.49 
FKHRL1 T32 
Forkhead-like transcription 




Vascular endothelial growth 
factor receptor-protein-tyrosine 




Fos-c FBJ murine osteosarcoma 
oncoprotein-related transcription 
factor -0.69 2.18 
Fos T232 
Fos-c FBJ murine osteosarcoma 
oncoprotein-related transcription 






protein-tyrosine kinase -1.93 1.40 
GAP-43 S41 
 Growth associated protein 43 




Germinal centre protein-serine 
kinase -0.57 0.16 





protein beta (receptor for 




















GroEL homolog (may 
correspond to Hsp60) 0.08 0.58 
Grp75 
Pan-
specific Glucose regulated protein 75 -1.22 -0.23 
Grp78 
Pan-
specific Glucose regulated protein 78 0.23 0.96 
Grp78 
Pan-




Glucose regulated protein 94 




Glucose regulated protein 94 










kinase 3 alpha/beta 0.32 -0.45 
GSK3ab S21/S9 
Glycogen synthase-serine 
























Haploid germ cell-specific 




UV excison repair protein 




Hsp70/Hsc70 interacting protein 
(ST13) -0.01 0.40 
Histone H1  
phospho 
CDK1 sites Histone H1 phosphorylated 1.64 0.17 
Histone 
H2A.X S139 Histone H2A variant X -0.20 -0.35 
Histone 
H2B S14 Histone H2B -0.86 -0.11 
Histone H3 S10 Histone H3.3 0.26 -0.40 
Histone H3 S28 Histone H3.3 1.06 1.67 
Histone H3 T11 Histone H3.3 0.07 -0.07 
Histone H3 T3 Histone H3.3 0.05 0.73 
Histone H3 T3 Histone H3.3 -1.56 0.52 
HO1 
Pan-
specific Heme oxygenase 1 -0.67 1.17 
HO1 
Pan-
specific Heme oxygenase 1 -0.24 2.51 
HO2 
Pan-






protein-serine kinase 1 0.70 -0.78 
Hsc70 
Pan-
specific Heat shock 70 kDa protein 8 -2.11 3.06 
Hsc70 
Pan-
specific Heat shock 70 kDa protein 8 -0.26 0.29 
Hsc70 
Pan-
specific Heat shock 70 kDa protein 8 0.72 1.09 
HSF4 
Pan-
specific Heat shock transcription factor 4 -0.14 -0.91 
Hsp105 
Pan-




Heat shock 27 kDa protein beta 




Heat shock 27 kDa protein beta 
1 (HspB1) 0.16 0.29 
Hsp27 S15 
Heat shock 27 kDa protein beta 
1 (HspB1) 3.48 0.14 
Hsp27 S15 
Heat shock 27 kDa protein beta 
1 (HspB1) 0.37 0.33 
Hsp27 S78 
Heat shock 27 kDa protein beta 
1 (HspB1) 0.55 -1.04 
Hsp27 S82 
Heat shock 27 kDa protein beta 
1 (HspB1) -0.22 0.54 
Hsp27 S82 
Heat shock 27 kDa protein beta 
1 (HspB1) -0.81 -0.28 
Hsp27 S82 
Heat shock 27 kDa protein beta 




DnaJ homolog, subfamily B 




DnaJ homolog, subfamily B 




DnaJ homolog, subfamily B 




Heat shock 47 kDa protein 
(collagen-binding protein 1, 




Heat shock 60 kDa protein 1 




Heat shock 60 kDa protein 1 




Heat shock 60 kDa protein 1 
(chaperonin, CPN60) 0.02 -0.21 
Hsp70 
Pan-
specific Heat shock 70 kDa protein 1 -0.07 -0.03 
Hsp70 
Pan-
specific Heat shock 70 kDa protein 1 -0.48 -0.14 
Hsp70 
Pan-




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 




Heat shock 90 kDa protein 
alpha/beta 0.04 -0.86 






Heat shock 90 kDa protein 
alpha/beta 0.39 0.38 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha 1.85 0.06 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha 0.32 -0.36 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha 0.64 -0.76 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha 0.71 -1.27 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha -0.72 1.10 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha 0.11 0.35 
Hsp90a 
Pan-
specific Heat shock 90 kDa protein alpha -0.12 -0.07 
Hsp90b 
Pan-
specific Heat shock 90 kDa protein beta -1.90 0.53 
HspBP1 
Pan-
specific Hsp70 binding protein 1 0.32 -0.51 




Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member A 0.16 -0.11 
I2PP2A 
Pan-




Intestinal cell protein-serine 
kinase (MAK-related kinase 




Insulin-like growth factor 




Inhibitor of NF-kappa-B alpha 




Inhibitor of NF-kappa-B alpha 




Inhibitor of NF-kappa-B alpha 




Inhibitor of NF-kappa-B alpha 




Inhibitor of NF-kappa-B beta 
(thyroid receptor interacting 




Inhibitor of NF-kappa-B beta 
(thyroid receptor interacting 




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-
serine kinase alpha (CHUK) 0.36 -0.57 
IKKa/b S180/S181 
Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-




Inhibitor of NF-kappa-B protein-
serine kinase beta 1.47 0.92 
IKKg Pan- I-kappa-B kinase gamma/NF- 0.22 -0.71 
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kinase 1 3.54 -0.78 
Integrin a4 S988 Integrin alpha 4 (VLA4) -0.84 -0.28 
Integrin b1  S785 
Integrin beta 1 (fibronectin 
receptor beta subunit, CD29 
antigen) 2.43 0.61 
IR 
Pan-
specific Insulin receptor beta chain 0.68 -0.97 
IR (INSR) Y999 Insulin receptor 0.26 -0.54 





Insulin receptor / Insulin-like 




Interleukin 1 receptor-associated 
kinase 1 (Pelle-like protein 




Interleukin 1 receptor-associated 
kinase 1 (Pelle-like protein 




Interleukin 1 receptor-associated 




Interleukin 1 receptor-associated 




Interleukin 1 receptor-associated 




Interleukin 1 receptor-associated 




Interleukin 1 receptor-associated 





Insulin receptor / Insulin-like 
growth factor 1 receptor beta  1.05 -0.15 
IRS1 Y612 Insulin receptor substrate 1 -0.23 -0.43 
IRS1 Y1179 Insulin receptor substrate 1 2.23 1.95 
IRS1 S312 Insulin receptor substrate 1 1.43 2.63 
IRS1 S639 Insulin receptor substrate 1 1.08 -0.15 
JAK1 
Pan-
specific Janus protein-tyrosine kinase 1 0.74 0.59 
JAK1 
Pan-
specific Janus protein-tyrosine kinase 1 0.54 -0.45 
JAK2 
Pan-
specific Janus protein-tyrosine kinase 2 -0.45 -0.05 
JAK3 
Pan-
specific Janus protein-tyrosine kinase 3 1.32 -0.94 
JIK (TAO3) 
Pan-
specific STE20-like protein-serine kinase 0.11 -0.11 
JNK T183/Y185 
Jun N-terminus protein-serine 
kinase (stress-activated protein 
kinase (SAPK)) 0.10 -0.17 
JNK T183/Y185 
Jun N-terminus protein-serine 
kinase (stress-activated protein 




Jun N-terminus protein-serine 
kinase (stress-activated protein 




Jun N-terminus protein-serine 
kinase (stress-activated protein 




Jun N-terminus protein-serine 
kinases (stress-activated protein 




Jun N-terminus protein-serine 
kinases (stress-activated protein 





Jun N-terminus protein-serine 
kinases (stress-activated protein 




Jun N-terminus protein-serine 
kinases (stress-activated protein 




Jun N-terminus protein-serine 
kinase (stress-activated protein 




Jun N-terminus protein-serine 
kinase (stress-activated protein 





AP1 transcription factor  0.04 -0.88 
Jun S63 
Jun proto-oncogene-encoded 
AP1 transcription factor  -0.19 -0.03 
Jun S73 
Jun proto-oncogene-encoded 
AP1 transcription factor  0.15 -0.19 
Jun S73 
Jun proto-oncogene-encoded 
AP1 transcription factor  0.61 0.69 
Jun S73 
Jun proto-oncogene-encoded 




Cyclin-dependent  kinase 
associated phosphatase (CDK 





ER lumen protein retaining 




Kinase homologous to 
SPS1/STE20 (MAP kinase 
kinase kinase protein-serine 
kinase 5 (MEKKK5) -0.41 0.43 
Kit Y703 
Kit/Steel factor receptor-tyrosine 
kinase -0.34 -0.02 
Kit Y730 
Kit/Steel factor receptor-tyrosine 
kinase -0.06 0.33 
Kit Y936 
Kit/Steel factor receptor-tyrosine 














LCA antigen-related (LAR) 




Large tumor suppressor 1 










tyrosine kinase -0.34 -0.60 
Lck S158 
Lymphocyte-specific protein-
tyrosine kinase 0.04 0.13 
Lck Y192 
Lymphocyte-specific protein-
tyrosine kinase -0.41 -0.11 
Lck Y505 
Lymphocyte-specific protein-
tyrosine kinase -0.15 -0.04 
LIMK1 
Pan-















kinase -1.02 0.19 






Male germ cell-associated 






kinase-activated protein kinase 




kinase-activated protein kinase 




kinase-activated protein kinase 




kinase-activated protein kinase 










regulating protein-serine kinase 




Myeloid cell leukemia 




Myelin expression factor 2 





































































kinase 1/2 (MKK1/2) + B23 
(nucleophosmin, numatrin, 










































































kinase 3 beta isoform (MKK3 


























































































Hepatocyte growth factor (HGF) 
receptor-tyrosine kinase -0.37 -0.26 
Met Y1003 
Hepatocyte growth factor (HGF) 




MAP kinase phosphatase  1 




MAP kinase phosphatase  2 
(VH2) -0.45 -0.72 
MLC(MLR
C2) S19 
Myosin regulatory light chain 2, 
smooth muscle isoform -0.73 -0.68 
MLC(MLR
C2) S19 
Myosin regulatory light chain 2, 











kinase 3 -0.14 0.13 
mMOB1 
Pan-
specific Preimplantation protein 3 0.02 0.37 









serine kinase 1 (calmodulin-





serine kinase 2 (calmodulin-









DNA mismatch repair protein 
mutS homolog2, colon cancer, 
nonpolyposis type 1 -0.51 -0.13 
Msk1 S376 
Mitogen & stress-activated 



































Mammalian target of rapamycin 
(FRAP) -1.08 -1.05 
mTOR 
(FRAP) S2448 
Mammalian target of rapamycin 
(FRAP) -0.80 -0.92 








































NF-kappa-B p50 nuclear 





NF-kappa-B p65 nuclear 
transcription factor -0.32 -0.68 
NIK 
Pan-




Serine/threonine protein kinase 
NLK -0.39 0.45 
NMDAR2B Y1474 
N-methyl-D-aspartate (NMDA) 




Nucleotide diphosphate kinase 7 
(nm23-H7) -0.24 -0.40 
NR1 S896 
N-methyl-D-aspartate (NMDA) 






Nuclear factor erythroid 2-














p18 INK4c cyclin-dependent 




cyclin-dependent kinase inhibitor 




p27 cyclin-dependent kinase 
inhibitor 1B 0.73 -2.47 
p27 Kip1 T187 
p27 cyclin-dependent kinase 




CDK5 regulatory subunit 1, p35, 






































































































Tumor suppressor protein p53 
(antigenNY-CO-13) -1.18 -0.60 
p53 S392 
Tumor suppressor protein p53 
(antigenNY-CO-13) -1.06 -0.19 
p53 S392 
Tumor suppressor protein p53 
(antigenNY-CO-13) -0.37 -0.58 
p53 S392 
Tumor suppressor protein p53 
(antigenNY-CO-13) -0.05 -1.39 
p73 
Pan-




Dual specificity MAP kinase 




Protein kinase C + casein kinase 





p21-activated kinase 1 (alpha) 
(serine/threonine-protein kinase 




p21-activated kinase 1 (alpha) 
(serine/threonine-protein kinase 




p21-activated kinase 1 (alpha) 
(serine/threonine-protein kinase 




p21-activated kinase 1/2/3 
(serine/threonine-protein kinase 




p21-activated kinase 1/2/3 
(serine/threonine-protein kinase 




p21-activated kinase 2 (gamma) 
(serine/threonine-protein kinase 




p21-activated kinase 2(gamma) 
(serine/threonine-protein kinase 




p21-activated kinase 3 (beta) 
(serine/threonine-protein kinase 




p21-activated kinase 5 
(serine/threonine-protein kinase 




p21-activated kinase 6 
(serine/threonine-protein kinase 




Poly [ADP-ribose] polymerase 1 




Poly [ADP-ribose] polymerase 1 
(ADPRT) -0.07 -0.09 
Pax2 S394 Paired box protein 2 -0.47 -0.26 
Paxillin 
Pan-
specific Paxillin 1 -0.19 -0.99 
Paxillin 1 Y31 Paxillin 1 0.24 -0.56 
Paxillin 1 Y118 Paxillin 1 -1.65 -1.90 
Paxillin 1 Y118 Paxillin 1 -0.58 -0.62 
PCNA 
Pan-







kinase -0.01 -0.20 
PDGFRa Y754 
Platelet-derived growth factor 





Platelet-derived growth factor 
receptor kinase alpha/beta -1.13 -0.73 
PDGFRb Y716 
Platelet-derived growth factor 
receptor kinase beta -0.63 -1.31 
PDI 
Pan-










protein-serine kinase 1 -2.01 -0.95 
PDK1 S244 
3-Phosphoinositide-dependent 




diabetes/astrocytes 15 0.78 -0.80 
PERP 
Pan-
specific p53-induced protein PIGPC1 1.69 -1.45 
PI3K Pan- Phosphatidylinositol 3-kinase -0.17 -0.66 
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biphosphate 3-kinase catalytic 



















phosphatase 5-kinase type 2 










kinase catalytic subunit 





kinase catalytic subunit 
alpha/beta 0.65 0.83 
PKA Ca/b T197 
cAMP-dependent protein-serine 
kinase catalytic subunit 
alpha/beta 0.00 -0.52 
PKA Cb S338 
cAMP-dependent protein-serine 





kinase type I-alpha regulatory 





kinase regulatory type 2 subunit 
alpha 0.26 0.29 
PKA R2a S98 
cAMP-dependent protein-serine 
kinase regulatory type 2 subunit 








specific Protein-serine kinase B alpha -0.01 -0.54 
PKBa 
(Akt1) T308 Protein-serine kinase B alpha -0.22 -0.71 
PKBa 
(Akt1) T308 Protein-serine kinase B alpha 0.25 -0.25 
PKBa 
(Akt1) S473 Protein-serine kinase B alpha 0.12 -0.19 
PKBa 
































specific Protein-serine kinase B gamma 0.12 -0.33 
PKC 
Pan-
specific Protein-serine kinase C alpha 0.57 -0.87 





specific Protein-serine kinase C alpha -0.60 -0.43 
PKCa  S657 Protein-serine kinase C alpha -0.45 -0.85 
PKCa/b2 T638/T641 
Protein-serine kinase C alpha, 
beta 2 -1.76 -0.44 
PKCb1 
Pan-
specific Protein-serine kinase C beta 1 -2.03 0.66 
PKCb1 
Pan-
specific Protein-serine kinase C beta 1 0.19 0.03 
PKCb1/2 T500 Protein-serine kinase C beta 1/2 -0.02 0.02 
PKCb2 
Pan-
specific Protein-serine kinase C beta 2 -0.18 0.58 
PKCb2 
Pan-
specific Protein-serine kinase C beta 2 0.87 0.63 
PKCb2 T641 Protein-serine kinase C beta 2 0.17 0.02 
PKCd 
Pan-
specific Protein-serine kinase C delta -0.74 0.38 
PKCd Y313 Protein-serine kinase C delta -0.21 -0.14 
PKCd Y313 Protein-serine kinase C delta -0.02 -0.06 
PKCd T507 Protein-serine kinase C delta -0.21 0.13 
PKCd S664 Protein-serine kinase C delta -0.68 -0.14 
PKCe 
Pan-
specific Protein-serine kinase C epsilon -1.28 0.69 
PKCe 
Pan-
specific Protein-serine kinase C epsilon -1.76 1.80 
PKCe S729 Protein-serine kinase C epsilon 0.09 0.31 
PKCg 
Pan-
specific Protein-serine kinase C gamma 0.35 -2.28 
PKCg T514 Protein-serine kinase C gamma -0.05 -0.08 
PKCg T514 Protein-serine kinase C gamma 0.02 0.41 
PKCg T655 Protein-serine kinase C gamma 0.55 1.16 
PKCg T674 Protein-serine kinase C gamma 0.08 1.31 




Protein-serine kinase C 
lambda/iota 1.11 0.85 
PKCl/i T555 
Protein-serine kinase C 





Protein-serine kinase C mu 





Protein-serine kinase C mu 
(Protein kinase D) -0.35 0.17 
PKCm 
(PKD) S910 
Protein-serine kinase C mu 
(Protein kinase D) -0.29 0.38 
PKCm 
(PKD) S910 
Protein-serine kinase C mu 
(Protein kinase D) -0.11 -0.42 
PKN3 
Pan-
specific Protein-serine kinase C nu 0.56 1.40 
PKCq 
Pan-
specific Protein-serine kinase C theta -0.10 -0.28 
PKCq  T538 Protein-serine kinase C theta -0.56 0.48 
PKCz 
Pan-
specific Protein-serine kinase C zeta -0.47 0.04 
PKCz/l T410/T403 
Protein-serine kinase C 




Protein-serine kinase G1 
(cGMP-dependent protein 




cGMP-dependent protein kinase 




cGMP-dependent protein kinase 
1, beta isozyme -0.20 -0.03 






Double stranded RNA 




Double stranded RNA 
dependent protein-serine kinase 0.05 -0.17 
PKR1 T451 
Double-stranded RNA-
dependent protein-serine kinase -0.26 0.03 
PKR1 T446 
Double-stranded RNA-







phosphodiesterase gamma-2 -0.36 2.71 
Plk1 
Pan-
specific Polo-like protein-serine kinase 1 0.50 0.10 




Polo-like protein kinase 2 




Polo-like protein kinase 2 




Polo-like protein kinase 3 
(cytokine- inducible kinase 




Protein-serine phosphatase 1 - 




Protein-serine phosphatase 1 - 
catalytic subunit  - alpha isoform 0.55 0.67 
PP1/Ca T320 
Protein-serine phosphatase 1 - 




Protein-serine phosphatase 1 - 




Protein-serine phosphatase 1 - 




Protein-serine phosphatase 1 - 
catalytic subunit  - gamma 





Protein-serine phosphatase 2A - 
B regulatory subunit - B56 alpha 




Protein-serine phosphatase 2A - 
A  regulatory subunit - alpha and 




Protein-serine phosphatase 2A - 
A  regulatory subunit - alpha and 




Protein-serine phosphatase 2A - 
B regulatory subunit - beta 




Protein-serine phosphatase 2A - 
B regulatory subunit - gamma 




Protein-serine phosphatase 2A - 




Protein-serine phosphatase 2B - 




Protein-serine phosphatase 2C - 




Protein-serine phosphatase 2C - 




Protein-serine phosphatase 4 - 




Protein-serine phosphatase X - 




Protein-serine phosphatase X - 




Protein-serine phosphatase 5  - 





Protein-serine phosphatase 5  - 




Protein-serine phosphatase 6  - 




Protein-serine phosphatase 6  - 
catalytic subunit (PPVC) -1.43 1.22 
PRAS40 T246 
Proline-rich Akt substrate 40 





Protein kinase C-related protein-





Protein kinase C-related protein-





Protein kinase C-related protein-





Protein kinase C-related protein-




5'-AMP-activated protein kinase 
(AMPK), beta-1 regulatory 




Putative protein-serine kinase 
WNK4 -0.24 0.11 
Progestero
ne 




Protein-serine kinase PRP4 
homolog 0.10 0.19 
PSD-95 
Pan-
specific Disks large homolog 4 0.09 -0.11 
PSTAIRE 
Pan-






and protein phosphatase and 
tensin homolog deleted on 






and protein phosphatase and 
tensin homolog deleted on 






and protein phosphatase and 
tensin homolog deleted on 
chromosome 10 0.09 0.20 
PTP1B 
Pan-










tyrosine phosphatase 1D 





tyrosine phosphatase 1D 










Pyruvate dehydrogenase kinase 
isoform 2 0.07 -0.31 
Pyk2 
Pan-
specific Protein-tyrosine kinase 2 0.46 0.39 
Pyk2 
Pan-
specific Protein-tyrosine kinase 2 -0.11 0.35 
Pyk2  Y579 Protein-tyrosine kinase 2 -0.33 0.35 
Rab5 
Pan-








Ras-related C3 botulinum toxin 
substrate 1 -0.05 -0.19 
Rac1 S71 
Ras-related C3 botulinum toxin 
substrate 1 0.40 0.24 















protein-serine kinase 2.09 2.31 
Raf1 S259 
Raf1 proto-oncogene-encoded 

























protein 1 -0.61 -0.14 
Rb T356 
Retinoblastoma-associated 
protein 1 0.71 0.01 
Rb S612 
Retinoblastoma-associated 
protein 1 -0.47 0.06 
Rb S780 
Retinoblastoma-associated 
protein 1 0.23 -0.27 
Rb S807 
Retinoblastoma-associated 





protein 1 0.58 0.34 
Rb T821 
Retinoblastoma-associated 
protein 1 -0.10 0.09 
Rb T826 
Retinoblastoma-associated 
protein 1 -0.22 0.09 
Rb S608 
Retinoblastoma-associated 
protein 1 -0.43 -0.60 
Rb S795 
Retinoblastoma-associated 
















RhoA protein-serine kinase 





RhoA protein-serine kinase 























Ribosomal S6 protein-serine 




Ribosomal S6 protein-serine 
kinase 1 0.89 0.16 
RSK1 S363 
Ribosomal S6 protein-serine 
kinase 1 0.84 -0.33 
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RSK1/2 S221/S227 
Ribosomal S6 protein-serine 
kinase 1/2 0.22 0.12 
RSK1/2 S363/S369 
Ribosomal S6 protein-serine 
kinase 1/2 -0.18 0.12 
RSK1/2 S380/S386 
Ribosomal S6 protein-serine 
kinase 1/2 -0.08 -0.07 
RSK1/2 S380/S386 
Ribosomal S6 protein-serine 




Ribosomal S6 protein-serine 





Ribosomal S6 protein-serine 




Ribosomal S6 protein-serine 




Ribosomal S6 protein-serine 
kinase 4 (alpha 6)  0.02 -0.66 
RYK 
Pan-
specific RYK tyrosine-protein kinase 0.35 0.97 

















































p70 ribosomal protein-serine S6 
kinase beta 0.09 0.80 
SG2NA 
Pan-















transforming protein 1 0.06 0.04 
SHP2 S576 
Protein-
tyrosine phosphatase 1D 
(SHPTP2, Syp, PTP2C) 0.40 0.80 
SLK 
Pan-






















SMA- and mothers against 
decapentaplegic homolog 2/3 0.70 -0.03 
SMC1 S957 
Structural maintenance of 





Suppressor of cytokine signaling 




Suppressor of cytokine 








Superoxide dismutase [Mn], 




Silencer of death domains (Bcl2 
associated athanogene 4 
(BAG4)) -0.53 -0.19 
SOX9 S181 
SRY (sex determining region Y)-
box 9 (campomelic dysplasia, 
autosomal sex-reversal) -0.22 0.14 
SPHK1 
Pan-
specific Sphingosine kinase 1 0.41 -0.49 
SPHK2 
Pan-




















protein-tyrosine kinase 1.50 -1.28 
Src Y418 
Src proto-oncogene-encoded 
protein-tyrosine kinase -0.38 -0.31 
Src Y529 
Src proto-oncogene-encoded 
protein-tyrosine kinase -0.21 -0.20 
STAT1a/b S727 
Signal transducer and activator 
of transcription 1 alpha/beta -0.13 -0.31 
STAT1a/b Y701 
Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 
of transcription 2 0.35 -0.19 
STAT2 Y690 
Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 
of transcription 3  -0.73 -0.51 
STAT3 S727 
Signal transducer and activator 
of transcription 3 0.20 -0.09 
STAT3 Y705 
Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 
of transcription 5A 0.66 0.23 
STAT5A Y694 
Signal transducer and activator 




Signal transducer and activator 




Signal transducer and activator 




Stress induced phosphoprotein 
1 (Hsc70/Hsp90 organizing 
protein (Hop)) 0.13 -0.37 





specific Striatin 0.11 0.09 
Syk 
Pan-
specific Spleen protein-tyrosine kinase 0.39 -0.10 
Synapsin 1 S9 Synapsin 1 isoform Ia 0.25 0.61 

























serine kinase 1 1.15 0.72 
Tau S515 
Microtubule-associated protein 





tau 0.02 0.02 
Tau S712 
Microtubule-associated protein 
tau 1.02 -0.20 
Tau S712 
Microtubule-associated protein 
tau 0.06 -0.65 
Tau S716 
Microtubule-associated protein 
tau -1.03 1.09 
Tau S720 
Microtubule-associated protein 
tau -0.02 -0.30 
Tau S518 
Microtubule-associated protein 
tau 0.32 0.34 
Tau S738 
Microtubule-associated protein 
tau 0.10 -0.27 
Tau T547 
Microtubule-associated protein 






























Tumor necrosis factor receptor 
type 1 associated DEATH 




Tumor necrosis factor-related 




Nerve growth factor (NGF) 





tyrosine kinase 0.09 -1.35 
TTK 
Pan-




Protein-tyrosine kinase 2 (Jak-




Protein-tyrosine kinase 2 (Jak-






kinase of discoidin domain 
receptor family, member 2 







kinase of discoidin domain 
receptor family, member 2 
precursor  -0.05 0.07 
Tyrosine 
Hydroxylas
e S71 Tyrosine hydroxylase isoform a  -0.08 0.29 
Tyrosine 
Hydroxylas
e S19 Tyrosine hydroxylase isoform a -0.16 0.11 
Ubiquitin 
Pan-
specific Ubiquitin -0.24 0.17 
VEGFR2 
(KDR) Y1054 
Vascular endothelial growth 
factor receptor-tyrosine kinase 2 
(Flk1) -0.58 -0.33 
VEGFR2 
(KDR) Y1214 
Vascular endothelial growth 
factor receptor-tyrosine kinase 2 




Dual specificity protein 
phosphatase 3 -0.11 -0.14 




Vaccinia related protein-serine 
kinase 1 0.06 0.40 
Wee1 
Pan-
specific Wee1 protein-tyrosine kinase -1.04 -0.50 
WIP1 
Pan-





















Zeta-chain (TCR) associated 




Zeta-chain (TCR) associated 
protein-tyrosine kinase, 70 kDa -0.21 1.04 
ZAP70 Y292 
Zeta-chain (TCR) associated 




Zeta-chain (TCR) associated 
protein-tyrosine kinase, 70 kDa -0.13 -0.43 
ZAP70/Syk Y319/Y352 
Zeta-chain (TCR) associated 
protein-tyrosine kinase, 70 
kDa/Spleen protein-tyrosine 




ZIP kinase (death associated 
protein-serine kinase 3 




ZIP kinase (death associated 
protein-serine kinase 3 





7.4 Bioanalyser Results 
Table 7.2- RNA Integrity Numbers (RIN) following Bioanalyser analysis of RNA 
extracted from unstimulated and OPG-stimulated HPA-SMC lysates.  












7.5 PAH-associated genes 
Table 7.3 - List of PAH-associated genes used to focus the results of the RNA 
microarray in Chapter 4. 







(Alastalo et al. 2011; Jongmin 
Kim et al. 2013) 




(Achcar et al. 2006) 
 
Activin A Receptor type II-
like 1  
ACVRL1  




(Song et al. 2008) 
 
Angiopoietin-1    ANGPT1   
(Kugathasan et al. 2005) 
 
Angiopoietin-2  ANGPT2   
(Gill & Brindle 2005) 
 
Angiopoietin-3   ANGPT3   
(Gill & Brindle 2005) 
 
Angiopoietin-4   ANGPT4   




 APLNR  
(Alastalo et al. 2011; Jongmin 




APOE   
(Hansmann et al. 2008) 
Rho Guanine Nucleotide 
Exchange Factor 12 
ARHGEF12  
(McMurtry et al. 2010) 
B-cell Lymphoma 2  BCL2  





















Protein-6     
BMP6  










(Archer et al. 2010) 
 
Bone Morphogenetic 
Protein Receptor, type IA  
BMPR1A  
(Richter et al. 2004) 
 
Bone Morphogenetic 
Protein Receptor, type 1B  
BMPR1B  
(Richter et al. 2004; 
Simonneau et al. 2009) 
 
Bone Morphogenetic 
Protein Receptor, type II  
BMPR2  
(Deng et al. 2000; Perkett et al. 
1990; Machado et al. 2001) 
CACNA1C calcium 
channel, voltage-dependent, 
L type, alpha 1C subunit  
CACNA1c  
(Sitbon et al. 2005) 
 
Chemokine (C-C motif) 
Ligand 2  
CCL2  
(Ikeda et al. 2002) 
Chemokine (C-C motif) 
Ligand 3 
CCL3   
(Hassoun et al. 2009) 
Chemokine (C-C motif) 
Ligand 5 (RANTES)  
CCL5   




CDKN1B   
(Yu et al. 2005) 
 
Cofilin-1 (non-muscle)  CFL1  
(Foletta et al. 2003) 
 
Cofilin-2 (muscle)  CFL2  
(Foletta et al. 2003) 
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Chemokine (C-X3-C motif) 
Ligand 1   
CX3CL1   
(Perros, Dorfmüller, Souza, 
Durand-Gasselin, Godot, et al. 
2007) 
Chemokine (C-X3-C motif) 
Receptor 1  
CX3CR1   
(Perros, Dorfmüller, Souza, 
Durand-Gasselin, Godot, et al. 
2007) 
Stromal Cell Derived 
Factor -1  
CXCL12   
(Nemenoff et al. 2008) 
 
Dynein, Light Chain, 





(Machado et al. 2003) 
 
Endothelin-1  EDN1   
(Stelzner et al. 1992) 
 
Endothelin-2 EDN2   
(Stelzner et al. 1992) 
 
Endothelin-3   EDN3   
(Stelzner et al. 1992) 
 
Endothelin Receptor A  EDNRA   
(Trow & Taichman 2009) 
Epidermal Growth Factor EGF   
(Dahal et al. 2010) 
 
Epidermal Growth Factor 
Receptor 
EGFR  
(Dahal et al. 2010) 
 
Endothelin Receptor B  ENDRB  
(Trow & Taichman 2009) 
 
Endoglin  ENG  
(Simonneau et al. 2009; 
Chaouat et al. 2004) 
HIF-2alpha    EPAS1  
(Brusselmans et al. 2003) 
FK506 binding protein 12 FKBP12  
(Spiekerkoetter et al. 2013) 
 
FK506 binding protein 1A FKBP1A  
(Kwapiszewska et al. 2005) 
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FK506 binding protein 1B FKBP1B  
(Spiekerkoetter et al. 2013) 
 
FK506 binding protein 2 FKBP2  
(Spiekerkoetter et al. 2013) 
 
Guanosine triphosphate 
cyclohydrolase 1  
GCH1   
(Fagan et al. 2000) 
Guanine Nucleotide 
Binding Protein (G 
protein), beta Polypeptide 
2-Like 1 (RACK1)  
GNB2L1  






(Cahill et al. 2012) 
 Soluble Guanylate Cyclase 
1, alpha 2 subunit 
GUCY1A2  
(Schermuly et al. 2008) 
 
Soluble Guanylate Cyclase 
1, alpha 3 subunit  
 
GUCY1A3   
(Schermuly et al. 2008) 
Soluble Guanylate Cyclase 
1, beta 2 subunit  
GUCY1B2   
(Schermuly et al. 2008) 
 
Soluble Guanylate Cyclase 
1, beta 3 subunit  
GUCY1B3   
(Schermuly et al. 2008) 
 
Hepatitis C Virus HCV   
(Cool et al. 2011) 
 
Human Herpes Virus-8   HHV8   
(Cool et al. 2011) 
HIF-1alpha  HIF1A  
(Fijalkowska et al. 2010) 
Major Histocompatibility 
Complex, class I, B Major  
HLA-B   
(Johnson et al. 2008) 
Histocompatibility 
Complex, class II, DRβ5 
HLA-DRB5  







(Girgis et al. 2007) 
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Heme Oxygenase 
(decycling) 1  
HMOX1  
(Achcar et al. 2006) 
Serotonin Receptor 1B  HTR1B   
(Keegan et al. 2001) 
Serotonin Receptor 2B  HTR2B  
(Launay et al. 2002) 
Intracellular Adhesion 
Molecule 1  
ICAM1   








(Hecker et al. 2010) 
Interleukin-18 IL18  
(Soon et al. 2010) 
Interleukin-  IL1A   
(Beasley & Cooper 1999) 
Interleukin-1β 56 IL1B   
(Itoh et al. 2003) 
Interleukin-6    IL6    
(Furuya et al. 2010) 
Potassium Voltage-Gated 
Channel, Shaker-related 
Subfamily, member 2 
(Kv1.5)  
KCNA5  
(Bonnet et al. 2006) 
Kv Channel Interacting 
Protein 2   
KCNIP2  
(Archer et al. 2010) 
 
 Potassium Channel, 
Subfamily K, Member 3 
 KCNK3  
(Ma et al. 2013) 
 
Kinase Insert Domain 
Receptor  
KDR   
(Mata-Greenwood et al. 2003) 
 
Microtubule-associated 
protein-1 light chain-3B 
LC3B  
(Lee et al. 2011) 
 
LIM motif containing 
Protein Kinase 1  
LIMK1  
(Foletta et al. 2003) 
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PTGIR Low Density 
Lipoprotein Receptor-
related Protein 1  
LRP1   
(Hansmann et al. 2008) 
 Leukotriene B4  LTB4  
(Tian et al. 2013) 
 
Matrix Metallopeptidase 1  MMP1   
(Hassoun 2005) 








MMP9   
(Hassoun 2005) 
Negative Regulatory Factor 
(HIV)  
Nef   
(Cool et al. 2011) 
Nuclear Factor of Activated 
T-cells, Cytoplasmic, 
Calcineurin-Dependent 2    
NFATC2   
(Bonnet et al. 2006) 
Nuclear Factor of Activated 
T-cells, Cytoplasmic, 
Calcineurin-Dependent 3  
NFATc3  
(de Frutos et al. 2007) 
Nuclear factor-kappa B NFKB  
(Sawada et al. 2007) 
 
Nitric Oxide Synthase 1   NOS1   
(Giaid & Saleh 1995) 
Nitric Oxide Synthase 2  NOS2   
(Kawaguchi et al. 2006) 
 
Nitric Oxide Synthase 3  NOS3   
(Giaid & Saleh 1995) 
Osteopontin  OPN  
(Lorenzen et al. 2011) 
Phosphodiesterase 1A  PDE1A   
(Schermuly et al. 2007) 
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Phosphodiesterase 1C  PDE1C   
(Schermuly et al. 2007) 
Phosphodiesterase 3A  PDE3A   
(Murray et al. 2002) 
Phosphodiesterase 5A  PDE5A   
(Murray et al. 2002) 
Platelet-derived Growth 
Factor alpha  
PDGFA   
(Grimminger & Schermuly 
2010)  
Platelet-derived Growth 
Factor beta  
PDGFB   
(Grimminger & Schermuly 
2010) 
Platelet-derived Growth 
Factor Receptor, alpha  
PDGFRA   
(Grimminger & Schermuly 
2010) 
Platelet-derived Growth 
Factor Receptor, beta 
PDGFRB  
(Grimminger & Schermuly 
2010) 
Pyruvate Dehydrogenate 
Kinase 1  
PDK1   
(Archer et al. 2010) 
 
Pyruvate Dehydrogenate 
Kinase 2   
PDK2   
(Archer et al. 2010) 
 
Pyruvate Dehydrogenate 
Kinase 3   
PDK3   
(Archer et al. 2010) 
 
Pyruvate Dehydrogenate 
Kinase 4   
PDK4   




PPARG   
(Hansmann et al. 2008; Sutliff 
et al. 2010) 
Prostacyclin Receptor  PRGIR  
(Christman et al. 1992) 
Phosphatase and Tensin 
Homolog  
PTEN  
(Nemenoff et al. 2008) 
Prostacyclin Synthase  PTGIS   
(Christman et al. 1992) 
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Resistin-like beta  RETNLB  
(Angelini et al. 2009) 
Ras Homologue Gene 
Family member A   
RHOA   
(McMurtry et al. 2010) 
Ras Homologue Gene 
Family member B  
RHOB   
(McMurtry et al. 2010) 
Rho-associated, Coiled-Coil 
containing Protein Kinase 1  
ROCK1   
(McMurtry et al. 2010) 
Rho-associated, Coiled-Coil 
containing Protein Kinase 2  
ROCK2   
(McMurtry et al. 2010) 
Selectin P  SELP   
(Sakamaki et al. 2000) 
 
Serotonin Transporter 4  SLC6A4  
(MacLean 2007) 
SMAD 1  SMAD1  
(Morrell 2010) 
 
SMAD 2  SMAD2  
(Morrell 2010) 
 
SMAD 3  SMAD3  
(Morrell 2010) 
 
SMAD 4  SMAD4  
(Morrell 2010) 
 
SMAD 5  SMAD5  
(Morrell 2010) 
 
SMAD 6  SMAD6  
(Morrell 2010) 
 
  SMAD 7  SMAD7  
(Morrell 2010) 
 
SMAD 8  SMAD8  
(Morrell 2010) 
 
SMAD 9    SMAD9  
(Morrell 2010) 
 
SMAD specific E3 
ubiquitin protein ligase 1 
SMURF1  
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 (Murakami et al. 2010) 
Superoxide Dismutase 2  SOD2   
(Archer et al. 2010) 
 
Src  SRC  
(Tuder et al. 2001) 
 
Signal Transducer and 
Activator of Transcription 
STAT1  
(Cool et al. 2011) 
Trans-activator of 
Transcription (HIV)  
Tat   
(Cool et al. 2011) 
Thromboxane A2 Receptor  TBXA2R  
(Christman et al. 1992) 
Endothelium-Specific 
Receptor Tyrosine Kinase, 
type 2  
TEK/TIE2  
(Yamamoto et al. 2008) 
Transforming Growth 
Factor-β, type 1 
TGFB1  
(Deng et al. 2000; Perkett et al. 
1990; Machado et al. 2001) 
 
Transforming Growth 
Factor-β, induced  
TGFBI  
(Richter et al. 2004) 
Transforming Growth 
Factor-β Receptor type 1  
TGFBR1  
(Deng et al. 2000; Perkett et al. 
1990; Machado et al. 2001) 
 
Transforming Growth 
Factor-β Receptor type 2  
TGFBR2  
(Perkett et al. 1990) 
Tenascin-C  TNC  
(Jones et al. 1997) 





(Lawrie et al. 2008) 







(Lawrie et al. 2008) 







(Hameed et al. 2012) 
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Tumor necrosis factor 





(Lawrie et al. 2008) 
Transient Receptor 
Potential Cation Channel, 
Subfamily C, member 1  
TRPC1  
(Zhang et al. 2007) 
Transient Receptor 
Potential Cation Channel, 
Subfamily C, member 3  
TRPC3  
(Zhang et al. 2007) 
Transient Receptor 
Potential Cation Channel, 







(Hamid & Newman 2009) 
Vascular Cell Adhesion 
Molecule 1   
VCAM1   
(Pendergrass et al. 2010) 
Vascular Endothelial 
Growth Factor A  
VEGFA   
(Schermuly et al. 2008; Tuder 
et al. 2001; Mata-Greenwood 
et al. 2003) 
 
Von Hippel Lindau  VHL  






Peptide Receptor 1  
VPAC1   
(Said 2008) 
Vasoactive Intestinal 







X-linked Inhibitor of 
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